0001615774-17-004407.txt : 20170814 0001615774-17-004407.hdr.sgml : 20170814 20170814171844 ACCESSION NUMBER: 0001615774-17-004407 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170814 DATE AS OF CHANGE: 20170814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATOSSA GENETICS INC CENTRAL INDEX KEY: 0001488039 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 264753208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35610 FILM NUMBER: 171031606 BUSINESS ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 BUSINESS PHONE: 206.588.0256 MAIL ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 10-Q 1 s106997_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 001-35610

ATOSSA GENETICS INC.

(Exact name of registrant as specified in its charter)

Delaware		26-4753208
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

107 Spring Street		98104
Seattle, WA		(Zip Code)
(Address of principal executive offices)

Registrant’s telephone number, including area code: (206) 325-6086

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s common stock, $0.015 par value per share, outstanding at August 14, 2017 was 11,701,075.

ATOSSA GENETICS INC.

FORM 10-Q

QUARTERLY REPORT

INDEX

PART I. FINANCIAL INFORMATION		3

ITEM 1.	Condensed Consolidated Financial Statements – Unaudited	3

	Condensed Consolidated Balance Sheets as of June 30, 2017 and December 31, 2016	3

	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2017 and 2016	4

	Condensed Consolidated Statement of Stockholders’ Equity for the six months ended June 30, 2017	5

	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2017 and 2016	6

	Notes to Consolidated Financial Statements	7

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

ITEM 3	Quantitative and Qualitative Disclosures about Market Risk	26

ITEM 4.	Controls and Procedures	26

PART II. OTHER INFORMATION		26

ITEM 1.	Legal Proceedings	26

ITEM 1A.	Risk Factors	27

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27

ITEM 3.	Defaults upon Senior Securities	28

ITEM 4.	Mine Safety Disclosures	28

ITEM 5.	Other Information	28

ITEM 6.	Exhibits	28

SIGNATURES		29

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

	June 30,			December 31,
	2017			2016
Assets
Current assets
Cash and cash equivalents	$	3,690,023		$	3,027,962
Restricted cash		55,000			55,000
Prepaid expenses		228,370			171,601
Other accounts receivable		2,736
Total current assets		3,976,129			3,254,563

Furniture and equipment, net		18,989			55,119
Intangible assets, net		585,683			640,440
Other assets		128,577			194,250
Total assets	$	4,709,378		$	4,144,372

Liabilities and Stockholders’ Equity

Current liabilities
Accounts payable	$	495,811		$	254,320
Accrued expenses		44,017			16,964
Payroll liabilities		482,420			769,899
Common stock warrant liability		864,371
Other current liabilities		19,157			6,083
Total current liabilities		1,905,776			1,047,266

Commitments and contingencies (note 13)

Stockholders’ equity
Preferred stock - $.001 par value; 10,000,000 shares authorized, consisting of:
Series A convertible preferred stock- $.001 par value; 4,000 and 0 shares authorized, and 839 and 0 shares issued and outstanding, as of June 30, 2017 and December 31, 2016, respectively		1
Additional paid in capital- Series A convertible preferred stock		774,977
Common stock - $.015 par value; 75,000,000 shares authorized, 10,032,410 and 3,786,913 shares issued and outstanding, as of June 30, 2017 and December 31, 2016, respectively		150,486			56,804
Additional paid-in capital		63,126,929			60,344,050
Accumulated deficit		(61,248,791	)		(57,303,748	)
Total stockholders’ equity		2,803,602			3,097,106

Total liabilities and stockholders’ equity	$	4,709,378		$	4,144,372

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	For the Three Months Ended June 30,						For The Six Months Ended June 30,

		2017			2016			2017			2016
Operating expenses:
Research and development	$	824,094		$	168,992		$	1,368,396		$	318,963
General and administrative		1,072,169			1,553,391			2,214,712			3,730,960
Total operating expenses		1,896,263			1,722,383			3,583,108			4,049,923
Operating loss		(1,896,263	)		(1,722,383	)		(3,583,108	)		(4,049,923	)
Change in fair value of common stock warrants		(152,447	)					(152,447	)
Warrant financing expense		(192,817	)					(192,817	)
Other income (expense), net		38						(16,671	)
Loss before income taxes		(2,241,489	)		(1,722,383	)		(3,945,043	)		(4,049,923	)
Income taxes
Net loss	$	(2,241,489	)	$	(1,722,383	)	$	(3,945,043	)	$	(4,049,923	)
Deemed dividends attributable to Series A Preferred Stock		(2,568,132	)					(2,568,132	)
Net loss applicable to common stockholders	$	(4,809,621	)	$	(1,722,383	)	$	(6,513,175	)	$	(4,049,923	)
Loss per common share - basic and diluted	$	(0.64	)	$	(0.67	)	$	(1.15	)	$	(1.63	)
Weighted average shares outstanding, basic and diluted		7,476,046			2,587,871			5,641,671			2,485,853

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

	Series A Convertible Preferred Stock									Common Stock				Additional						Total
							Additional							Paid-in			Accumulated			Stockholders’
	Shares			Amount			Paid-in Capital			Shares		Amount		Capital			Deficit			Equity
Balance at December 31, 2016		—		$	—		$	—			3,786,913	$	56,804	$	60,344,050		$	(57,303,748	)	$	3,097,106

Issuance of common stock in Class A units, net of issuance costs of $65,816											1,194,000		17,910		811,774						829,684
Allocation of Class A unit proceeds to warrant liability															(328,350)						(328,350)
Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231		3,502			4			3,234,769													3,234,773
Allocation of Series A convertible preferred stock to warrants and beneficial conversion feature								(2,568,132)							1,284,066						(1,284,066)
Deemed Dividends on Series A Convertible Preferred Stock								2,568,132							(2,568,132	)
Conversion of Series A Convertible Preferred Stock to common stock		(2,663	)		(3	)		(2,459,792	)		3,550,664		53,260		2,406,535
Reclassification of warrant liability upon net cashless exercise of common stock warrants											1,490,833		22,362		878,126						900,488
Issuance of common stock upon warrant exercise for cash											10,000		150		2,450						2,600

Amortization of commitment shares															(39,705	)					(39,705	)
Compensation cost for stock options granted to executives and employees															336,115						336,115
Net loss																		(3,945,043	)		(3,945,043	)
Balance at June 30, 2017		839		$	1		$	774,977			10,032,410	$	150,486	$	63,126,929		$	(61,248,791	)	$	2,803,602

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Six Months Ended June 30,
	2017			2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(3,945,043	)	$	(4,049,923	)
Compensation cost for stock options granted		336,115			392,664
Loss on disposal of intangible asset		17,695			163,333
Depreciation and amortization		73,193			152,574
Change in fair value of common stock warrants		152,447
Warrant financing expense		192,817
Changes in operating assets and liabilities:
Change in restricted cash					220,000
Prepaid expenses		(56,769	)		(15,836	)
Other assets		25,831			110,527
Accounts payable		241,491			(531,657	)
Payroll liabilities		(287,479	)		(666,368	)
Accrued expenses		27,053			(387,903	)
Other current liabilities		13,074			(41,473	)
Net cash used in operating activities		(3,209,575	)		(4,654,062	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture and equipment					(4,941	)
Net cash used in investing activities					(4,941	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Class A and Class B Units, net of issuance costs		3,871,636
Proceeds from issuance of common stock, net of issuance costs					2,133,974
Net cash provided by financing activities		3,871,636			2,133,974

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		662,061			(2,525,029	)
CASH AND CASH EQUIVALENTS, BEGINNING BALANCE		3,027,962			3,715,895
CASH AND CASH EQUIVALENTS, ENDING BALANCE	$	3,690,023		$	1,190,866

SUPPLEMENTAL DISCLOSURES:
Interest paid	$			$	383
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for cashless exercise of common stock warrants	$	900,488
Amount receivable for warrant exercise		2,600
Allocation of Class A and Class B Unit proceeds to warrant liability		1,612,416
Common stock issued as commitment fee under stock purchase agreement					198,523
Amortization of commitment shares	$	39,705		$	6,617

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1: NATURE OF OPERATIONS

Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31. The Company is focused on development of its pharmaceutical programs.

NOTE 2: GOING CONCERN

The Company’s consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the six months ended June 30 2017, the Company recorded a net loss of approximately $3.9 million and used approximately $3.2 million of cash in operating activities. As of June 30, 2017, the Company had approximately $3.7 million in cash and cash equivalents and working capital of approximately $2.1 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such capital will be obtained on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.

Management’s plan to continue as a going concern is as follows. In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plans to obtain such resources for the Company include obtaining capital from the sale of its equity securities and short-term borrowings from banks, stockholders or other related party(ies), if needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

We expect that our existing resources will be sufficient to fund our planned operations for the next four to six months; however, additional capital resources will be needed to fund operations for the next twelve months.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraphs and eventually to secure other sources of financing and attain profitable operations.

NOTE 3: SUMMARY OF ACCOUNTING POLICIES

Basis of Presentation:

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2016.

In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.

On August 26, 2016, the Company completed a 1-for-15 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 15 shares of issued and outstanding common stock were combined into one issued and outstanding share of Common Stock, and the par value per share was changed to $.015 per share. No fractional shares were issued because of the Reverse Stock Split and any fractional shares that would otherwise have resulted from the Reverse Stock Split were paid in cash. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on August 26, 2016. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split.

Use of Estimates:

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Financial Instruments with Characteristics of Both Liabilities and Equity:

During the three months ended June 30, 2017, the Company issued certain financial instruments, including warrants to purchase common stock, which have characteristics of both liability and equity. Financial instruments such as warrants that are classified as liabilities are fair valued upon issuance and are remeasured at fair value at subsequent reporting periods with the resulting change in fair value recorded in “change in fair value of common stock warrants”. The fair value of warrants is estimated using valuation models that require the input of subjective assumptions including stock price volatility, expected life, and the probability of future equity issuances and their impact to the price protection feature.

Recently Issued Accounting Pronouncements:

In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing U.S. GAAP. The new standard takes effect in 2019 for public business entities. The Company has not adopted the provisions of ASU No. 2016-02. The Company is currently evaluating the impact of adopting ASU 2016-02 on its consolidated financial statements.

In April 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation simplifying the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities and classification on the statements of cash flows. Under the new standard, all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) should be recognized as income tax expense or benefit on the statements of income. We adopted ASU No. 2016-09 effective January 1, 2017. As a result of the adoption of this guidance, we made an accounting policy election to recognize the effect of forfeitures in compensation cost when they occur. There was an immaterial impact on results of operations and financial position and no impact on cash flows at adoption.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The ASU is effective retrospectively for reporting periods beginning after December 15, 2017, with early adoption permitted. The Company has not yet adopted the provisions of ASU No. 2016-18 and does not expect it will have a material impact on the financial statements upon adoption.

In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company has not yet determined when it will adopt the provisions of this Update and has not yet determined the impact on its consolidated financial statements upon adoption.

NOTE 4: PREPAID EXPENSES

Prepaid expenses consisted of the following:

	June 30, 2017		December 31, 2016
Prepaid insurance		156,532		121,333
Trade show				20,000
Retainer and security deposits		29,968		14,218
Financial exchange fees		21,000
Other		20,870		16,050
Total prepaid expenses	$	228,370	$	171,601

NOTE 5: FURNITURE AND EQUIPMENT

Furniture and equipment consisted of the following:

	June 30, 2017			December 31, 2016
Furniture and equipment	$	170,916		$	210,528
Less: Accumulated depreciation		(151,927	)		(155,409	)
Total furniture and equipment, net	$	18,989		$	55,119

Depreciation expense for the three months ended June 30, 2017 and 2016 was $8,773 and $32,734, respectively, and $18,434, and $62,353, for the six months ended June 30, 2017 and 2016, respectively.

NOTE 6: INTANGIBLE ASSETS

Intangible assets consisted of the following:

	June 30, 2017			December 31, 2016
Patents	$	639,000		$	639,000
Software		113,540			113,540
Total intangible assets		752,540			752,540
Less: Accumulated amortization		(166,857	)		(112,100	)
Total intangible assets, net	$	585,683		$	640,440

Software amounted to $113,540 as of June 30, 2017 and December 31, 2016. The amortization period for the purchased software is 3 years. Amortization expense related to software for the three months ended June 30, 2017 and 2016 was $6,759 and $7,857, respectively, and was $19,614 and $15,714, for the six months ended June 30 2017 and 2016, respectively.

Patents amounted to $639,000 as of June 30, 2017 and December 31, 2016, and mainly consisted of patents acquired from Acueity on September 30, 2012 in an asset purchase transaction. Patent assets are amortized based on their determined useful life, and tested annually for impairment. The amortization period is from 7 to 12 years. Amortization expense related to patents was $17,571 and $37,254 for the three months ended June 30, 2017 and 2016, respectively and was $35,142 and $74,508 for the six months ended June 30, 2017 and 2016, respectively.

Future estimated amortization expenses as of June 30, 2017 for the five succeeding years is as follows:

For the years ending December 31,	Amounts
2017 (includes the remainder of the year)	$	48,282
2018		73,433
2019		70,285
2020		70,285
2021		70,285
Thereafter		253,113
	$	585,683

NOTE 7: PAYROLL LIABILITIES

Payroll liabilities consisted of the following:

	June 30, 2017		December 31, 2016
Accrued bonus payable	$	280,008	$	609,337
Accrued vacation		134,865		94,514
Accrued payroll liabilities		67,547		66,048
Total payroll liabilities	$	482,420	$	769,899

NOTE 8: STOCKHOLDERS’ EQUITY

The Company is authorized to issue a total of 85,000,000 shares of stock consisting of 75,000,000 shares of common stock, par value $0.015 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750,000 shares of Series A Junior Participating Preferred Stock, par value $0.001 per share, and 4,000 shares of Series A Convertible Preferred Stock, par value $0.001 per share through the filings of certificates of designation with the Delaware Secretary of State.

On May 19, 2014, the Company adopted a stockholder rights agreement which provides that all stockholders of record on May 26, 2014 received a non-taxable distribution of one preferred stock purchase right for each share of the Company’s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if one of the following occurs: (1) a person becomes an “Acquiring Person” by acquiring beneficial ownership of 15% or more of the Company’s common stock (or, in the case of a person who beneficially owned 15% or more of the Company’s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing 2.0% of the Company’s common stock then outstanding (excluding compensatory arrangements)), or (2) a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company’s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is $15.00, so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive $30.00 worth of the Company’s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.

2016 Issuances of Additional Shares to Aspire Capital

On November 11, 2015, we terminated our prior agreement with Aspire Capital Fund, LLC (“Aspire Capital”) and entered into a new common stock purchase agreement. Concurrently with entering into the new purchase agreement, we also entered into a registration rights agreement with Aspire Capital in which we agreed to register 405,747 shares of our common stock.

During the first quarter of 2016, we sold a total of 405,747 shares of common stock to Aspire Capital under the stock purchase agreement dated November 11, 2015 with aggregate gross proceeds to the Company of $2,177,083, or net proceeds of $2,133,973 after deducting costs of the offering.

On May 25, 2016, the Company terminated the November 11, 2015 stock purchase agreement with Aspire Capital and entered into a new common stock purchase agreement with Aspire Capital which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0 million of shares of our common stock over the 30-month term of the purchase agreement, subject to the terms and conditions set forth therein. Concurrently with entering into the purchase agreement, the Company also entered into a registration rights agreement with Aspire Capital, in which the Company agreed to file one or more registration statements, as permissible and necessary to register under the Securities Act of 1933, registering the sale of the shares of our common stock that have been and may be issued to Aspire Capital under the purchase agreement. As part of the stock purchase agreement we issued 49,736 common shares as a commitment fee. The value of the common shares issued as a commitment fee of $198,523 has been reflected as an addition to common stock of $746 and $197,777 in additional paid in capital which will be amortized over the life of the stock purchase agreement. As of the date of filing this Quarterly Report with the SEC no shares of stock have been sold to Aspire Capital under the May 25, 2016 purchase agreement. In connection with our public offering that closed on April 3, 2017, we agreed not to utilize the financing arrangement with Aspire Capital until June 30, 2017 and on June 30, 2017 in connection with the temporary modification of our common stock warrants to allow for the net exercise of those warrants we agreed to extend this stand still for an additional 45 days.

2016 Public Offering of Common Stock

In August 2016, the Company completed an underwritten public offering of 1,150,000 shares of common stock at a price per share of $2.50, with gross proceeds of $2,875,000 to the Company, or net proceeds of $2,561,896 after deducting underwriter discounts, commissions, non-accountable expense allowance and expense reimbursement.

2017 Public Offering of Class A and Class B Units Consisting of Common Stock, Series A Convertible Preferred Stock and Warrants

On March 28, 2017, the Company entered into an underwriting agreement with Aegis Capital Corp. relating to a public offering which closed on April 3, 2017. The offering generated gross proceeds to the Company of approximately $4.4 million and net proceeds of approximately $3.9 million after deducting underwriting discounts and commissions and other offering expenses paid by the Company.

The offering included 664,000 Class A Units at a public offering price of $0.75 per Class A Unit, which consisted of 664,000 shares of common stock and warrants to purchase 664,000 shares of common stock. The offering also included 3,502 Class B Units at a public offering price of $1,000 per Class B Unit, which consisted of 3,502 shares of Series A Convertible Preferred Stock convertible into a total of 4,669,333 shares of common stock and warrants to purchase 4,669,333 shares of common stock. In addition, the underwriter exercised the over-allotment to purchase an additional 530,000 shares of common stock and warrants to purchase 530,000 shares of common stock, which are included in the gross proceeds of $4.4 million. The warrants had a per share exercise price of $0.9375, are exercisable immediately and will expire five years from the date of issuance.

Series A Convertible Preferred Stock

The terms and provisions of our Series A Convertible Preferred Stock (the “Series A Preferred”) are as follows:

Rank. The Series A Preferred ranks on parity to our Common Stock.

Conversion. Each share of the Series A Preferred is convertible into 1,333.33 shares of our Common Stock (subject to adjustment as provided in the related certificate of designation of preferences, rights and limitations). Holders of Series A Preferred are prohibited from converting Series A Preferred into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our Common Stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to us.

Liquidation Preference. In the event of our liquidation, dissolution or winding-up, holders of Series A Preferred will receive the same amount that a holder of Common Stock would receive if the Series A Preferred were fully converted into shares of our Common Stock at the conversion price (disregarding for such purposes any conversion limitations) which amounts shall be paid pari passu with all holders of Common Stock.

Voting Rights. Shares of Series A Preferred will generally have no voting rights, except as required by law. However, as long as any shares of Series A Preferred are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred, (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders, (c) increase the number of authorized shares of Series A Preferred, or (d) enter into any agreement with respect to any of the foregoing.

Dividends. Shares of Series A Preferred will not be entitled to receive any dividends, unless and until specifically declared by our board of directors. The holders of the Series A Preferred will participate, on an as-if-converted-to-common stock basis, in any dividends to the holders of common stock.

Redemption. We are not obligated to redeem or repurchase any shares of Series A Preferred. Shares of Series A Preferred are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.

2017 Warrants

The terms and conditions of the warrants included in the 2017 public offering are as follows:

Exercisability. The warrants are exercisable at any time after April 3, 2017 and expire 5 years from issuance. The warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and, at any time a registration statement registering the issuance of the shares of common stock underlying the warrants under the Securities Act is effective and available for the issuance of such shares, or an exemption from registration under the Securities Act is available for the issuance of such shares, by payment in full in immediately available funds for the number of shares of Common Stock purchased upon such exercise. If a registration statement registering the issuance of the shares of Common Stock underlying the warrants under the Securities Act is not then effective or available, the holder may only exercise the Warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of Common Stock determined according to the formula set forth in the Warrant. No fractional shares of common stock will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.

Exercise Limitation. A holder will not have the right to exercise any portion of the Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days’ prior notice from the holder to us.

Exercise Price. The exercise price of the warrants was initially $0.9375, which was reduced to $0.26 on June 30, 2017. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock. The exercise price may also be adjusted downwards if we issue additional Common Stock (or equivalents) at a price below the exercise price of the Warrants while the Warrants remain outstanding.

Transferability. Subject to applicable laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent. There is currently no trading market for the warrants and a trading market may not develop.

Fundamental Transactions. In the event of a fundamental transaction, as described in the warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the holders of the warrants will be entitled to receive, upon any subsequent exercise of the warrants and for each share of our Common Stock that would have been issuable upon such exercise immediately prior to the occurrence of a fundamental transaction, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable as a result of such fundamental transaction by a holder of the number of shares of Common Stock for which the warrants are exercisable immediately prior to such fundamental transaction. The holder of the Warrant may also require us or any successor entity to purchase the Warrant from the holder by paying to the holder an amount of cash equal to the Black Scholes value of the remaining unexercised portion of the Warrant on the date of or within 30 days after consummation of the fundamental transaction.

Rights as a Stockholder. Except as otherwise provided in the warrants or by virtue of such holder’s ownership of shares of our Common Stock, the holder of a Warrant does not have the rights or privileges of a holder of our Common Stock, including any voting rights, until the holder exercises the Warrant.

Accounting Treatment

The Company allocated the proceeds from the sale of the Class A and Class B units to the separate securities issued. The Company determined that, on the date of issuance, the warrants were not considered indexed to its own stock because the underlying instruments were not “fixed-for-fixed” due to the price protection and fundamental transaction provisions and, therefore, the warrants should be accounted for as liabilities. At the end of each reporting period, the changes in fair value of the warrants during the period are recorded in non-operating income (expense) in the consolidated statement of operations.

The Company allocated the amount representing the fair value of the warrants at the date of issuance separately to the warrant liability and recorded the remaining proceeds as common stock, in the case of the Class A units, or as Series A convertible preferred stock, in the case of the Class B units. Due to the allocation of a portion of the proceeds to the warrants, the Series A convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of $1,284,066 based on the intrinsic value of the beneficial conversion feature. The discount on the Series A convertible preferred stock of $1,284,066 caused by allocation of the proceeds to the warrant was recorded as a deemed dividend upon issuance of the Series A convertible preferred stock. As a result, total deemed dividends of $2,568,132 was recorded upon issuance of the Series A convertible preferred stock, which is reflected as an addition to net loss in the consolidated statement of operations to arrive at net loss applicable to common shareholders.

Net Exercise of 2017 Warrants

On June 29, 2017, the Company offered to modify the rights of the holders of the warrants issued in the public offering the Company completed on April 3, 2017. The temporary modification included (a) lowering the exercise price of the warrants to $0.26 per share, (b) setting the applicable volume-weighted average price (VWAP) at $0.52 per share, and (c) allowing for temporary cashless exercise of the warrants for all holders that accepted the temporary modification before 8:00 a.m. Eastern daylight time on June 30, 2017. Holders of warrants to purchase a total of approximately 3.0 million shares of Common Stock accepted the offer resulting in the cancellation of those warrants and the issuance by the Company of a total of approximately1.5 million shares of Common Stock (including shares held in abeyance). The shares of Common Stock are registered under the Securities Act of 1933, as amended. If delivery of the shares of Common Stock pursuant to the foregoing would result in the holder exceeding the 4.99% “Beneficial Ownership Limitation” (as defined in the warrant) then the shares in excess of such 4.99% will be held in abeyance by the Company pending further instruction from the holder. In connection with the temporary modification, the Company agreed to extend the “Lock-up Period” of the underwriting agreement between the Company and Aegis Capital Corp., dated March 28, 2017, by 45 days and the Company agreed not to enter into any further amendments to the warrants during such extended Lock-up Period without the prior written consent of each holder. Upon exercise of these warrants, the amount of the warrant liability at the date of exercise was reclassified from warrant liability to additional paid-in capital.

The following table summarizes the 2017 liability warrant activity:

	Shares			Weighted Average Exercise Price
Outstanding as of December 31, 2016
Warrants granted		5,863,332		$	0.9375
Warrants exercised		(2,991,666	)		0.26
Warrants cancelled
Outstanding as of June 30, 2017		2,871,666		$	0.26

The Company estimated the fair value of the warrants using the Monte Carlo simulation (MCS) model, which is a type of income approach, where the current value of an asset is expressed as the sum of probable future cash flows across various scenarios and time frames discounted for risk and time. The significant assumptions include timing of future rounds of financing, timing and success rates of oncology clinical trials, and the probability of a merger and acquisition adjusted for a lack of marketability discount. The MCS model also includes a full term and an early conversion scenario that are each weighted at 50% in the final concluded fair value.

Inputs used in the valuation of the warrants at the issuance date of April 3, 2017 and June 30, 2017 were as follows:

Initial valuation
Common stock price	$	0.75
Exercise price	$	0.9375
Expected Volatility		50	%
Dividend Yield		0	%
Risk-Free Interest Rate		0.79% - 1.88	%
Expected Term (years)		0.24 - 5

June 30, 2017 valuation
Common stock price	$	0.50
Exercise price	$	0.26
Expected Volatility		50	%
Dividend Yield		0	%
Risk-Free Interest Rate		0.79% - 1.88	%
Expected Term (years)		0.08-4.76

Outstanding Warrants

As of June 30, 2017, warrants to purchase 3,273,894 shares of common stock were outstanding including:

	Outstanding Warrants to Purchase Shares		Exercise Price		Expiration Date

2011 private placement		283,470	$	18.75 - 24.00	May 8, 2018
Acueity warrants		21,667		75.00	September 30, 2017
2014 public offering		77,790		45.00	January 29, 2019
Placement agent fees for Company’s offerings		16,135		31.80 - 186.45	March - November, 2018
Outside consulting		3,166		63.60	January 14, 2018
2017 public offering		2,871,666		0.26	April 3, 2022
		3,273,894

Conversion of Series A Convertible Preferred Stock

During the three months ended June 30, 2017, certain holders of the Series A Convertible Preferred Stock exercised their conversion option and converted an aggregate of 2,663 shares of Series A Convertible Preferred Stock into 3,550,664 shares of the Company’s common stock based on the conversion ratio of 1,333.33 shares of Series A Convertible Preferred Stock to common stock.

NOTE 9: FAIR VALUE OF FINANCIAL INSTRUMENTS

Pursuant to the accounting guidance for fair value measurement and its subsequent updates, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. The accounting guidance establishes a hierarchy for inputs used in measuring fair value that minimizes the use of unobservable inputs by requiring the use of observable market data when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on active market data. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.

The fair value hierarchy is broken down into the three input levels summarized below:

● Level 1 —Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. Treasuries and trading securities with quoted prices on active markets.

● Level 2 —Valuations based on inputs other than the quoted prices in active markets that are observable either directly or indirectly in active markets. Examples of assets and liabilities utilizing Level 2 inputs are U.S. government agency bonds, corporate bonds, commercial paper, certificates of deposit and over-the- counter derivatives.

● Level 3 —Valuations based on unobservable inputs in which there are little or no market data, which require the Company to develop its own assumptions.

The following tables present the Company’s fair value hierarchy for all its financial assets, in thousands, by major security type measured at fair value on a recurring basis as of June 30, 2017:

	June, 30 2017
	Estimated Fair Value		Level 1	Level 2	Level 3
Assets:
	$		$	$	$
Liabilities:
Common Stock Warrant Liability	$	864,371			$	864,371

There were no financial assets outstanding that were required to be measured at fair value at December 31, 2016.

Warrants containing provisions that could require the Company to settle the warrants in cash in an event outside the Company’s control or that have price protection rights are accounted for as liabilities, with changes in the fair values included in net loss for the respective periods. Because some of the inputs to the valuation model are either not observable or are not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy.

The following table summarizes the changes in the Company’s Level 3 warrant liability for the six months ended June 30, 2017:

	June 30, 2017
Warrant liability
Beginning balance	$
Issuances of warrants		1,612,417
Warrant exercises		(900,493	)
Change in fair value		152,447
Ending balance		864,371

There were no transfers between Level 1, Level 2 or Level 3 for the three and six months ended June 30, 2017 and year ended December 31, 2016.

NOTE 10: NET LOSS PER SHARE

The Company accounts for and discloses net loss per common share in accordance with FASB Accounting Standards Codification (“ASC”) Topic 260, Earnings Per Share. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the conversion of Series A preferred stock, and potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.

The following table summarizes the Company’s calculation of net loss per common share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Net Loss Per share
Numerator

Net loss	$	2,241,489	$	1,722,383	$	3,945,043	$	4,049,920
Deemed dividend attributable to preferred stock	$	2,568,132			$	2,568,132
Net loss attributable to common shareholders	$	4,809,621	$	1,722,383	$	6,513,175	$	4,049,920
Denominator
Weighted average common shares outstanding		7,476,046		2,587,871		5,641,671		2,485,853
Basic and diluted net loss per share	$	0.64	$	0.67	$	1.15	$	1.63

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the three months and six months ended June 30, 2017 and 2016 because the effect of them would be anti-dilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Options to purchase common stock		1,121,567		394,090		754,093		394,090
Series A convertible preferred stock		2,184,356				1,098,212
Warrants to purchase common stock		6,139,797		402,228		3,286,862		402,228
Total		9,445,720		796,318		5,139,167		796,318

NOTE 11: INCOME TAXES

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of June 30, 2017 and December 31, 2016 due to the Company’s continuing operating losses.

NOTE 12: CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At June 30, 2017 and December 31, 2016, the Company had $3,440,023 and $2,777,962 in excess of the FDIC insured limit, respectively.

NOTE 13: COMMITMENTS AND CONTINGENCIES

Lease Commitments

The future minimum lease payments due subsequent to June 30, 2017 under all non-cancelable operating and capital leases for the next five years are as follows:

Year Ending December 31,	Operating Leases Amount
2017 (remainder of year)	$	4,930
Total minimum lease payments	$	4,930

The total rent expense for the three and six months ended June 30, 2017 and June 30, 2016 was $7,395 and $18,540, respectively and $78,600 and $157,200, respectively. Rent expense was included in general and administrative expenses for both years.

Litigation and Contingencies

On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al., No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of the Company’s directors and officers and the underwriters of the Company’s November 2012 initial public offering. The complaint alleges that all defendants violated Sections 11 and 12(a)(2), and that the Company and certain of its directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. This action seeks, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount.

On February 14, 2014, the Court appointed plaintiffs Miko Levi, Bandar Almosa and Gregory Harrison (collectively, the “Levi Group”) as lead plaintiffs, and approved their selection of co-lead counsel and liaison counsel. The Court also amended the caption of the case to read In re Atossa Genetics, Inc. Securities Litigation No. 2:13-cv-01836-RSM. An amended complaint was filed on April 15, 2014. The Company and other defendants filed motions to dismiss the amended complaint on May 30, 2014. The plaintiffs filed briefs in opposition to these motions on July 11, 2014. The Company replied to the opposition brief on August 11, 2014. On October 6, 2014 the Court granted defendants’ motion dismissing all claims against Atossa and all other defendants. The Court’s order provided plaintiffs with a deadline of October 26, 2014 to file a motion for leave to amend their complaint and the plaintiffs did not file such a motion by that date. On October 30, 2014, the Court entered a final order of dismissal. On November 3, 2014, plaintiffs filed a notice of appeal with the Court and have appealed the Court’s dismissal order to the U.S. Court of Appeals for the Ninth Circuit. The appeal was fully-briefed and oral arguments were held on May 18, 2017. We are currently awaiting a decision from the Court.

The Company believes this lawsuit is without merit and plans to defend itself vigorously; however, failure by the Company to obtain a favorable resolution of the claims set forth in the complaint could have a material adverse effect on the Company’s business, results of operations and financial condition. Currently, the amount of such material adverse effect cannot be reasonably estimated, and no provision or liability has been recorded for these claims as of June 30, 2017. The costs associated with defending and resolving the lawsuit and ultimate outcome cannot be predicted. These matters are subject to inherent uncertainties and the actual cost, as well as the distraction from the conduct of the Company’s business, will depend upon many unknown factors and management’s view of these may change in the future.

NOTE 14: STOCK BASED COMPENSATION

Stock Options and Incentive Plan

On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan, or the 2010 Plan, to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stockholder approval. An aggregate of 66,667 shares were initially reserved for issuance in connection with awards granted under the 2010 Plan and on May 18, 2016, an additional 133,333 shares were reserved for issuance under the 2010 Plan. On May 9, 2017, the stockholders approved an additional 1,500,000 shares for issuance under the 2010 Plan.

The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:

January 1,	Number of shares
2012		30,018
2013		34,452
2014		49,532
2015		65,557
2016		220,419
2017		151,477
Total additional shares		551,455

The Company granted 1,716,323 options to purchase shares of common stock during the six months ended June 30, 2017. No options were exercised during the three or six months ended June 30, 2017. There are 100,456 shares available for grant under the 2010 Plan as of June 30, 2017.

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock based compensation expense of $181,408 and $200,187 for the three months ended June 30, 2017 and 2016, respectively and $336,115 and $392,664 for the six months ended June 30, 2017 and 2016, respectively. The fair value of stock options granted for the six months ended June 30, 2017 and 2016 was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	Period ended June 30,
	2017		2016

Risk free interest rate		1.86% - 2.04%		1.48% - 1.55%
Expected term		5.32- 6.36 years		5.58 - 6.06 years

Dividend yield		- %		- %
Expected volatility		112.86% - 114.19%		115.52% - 115.58%

Options issued and outstanding as of June 30, 2017 and their activities during the six months then ended are as follows:

	Number of Underlying Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2017		378,924		$	26.25			$
Granted		1,716,323			.47
Forfeited		(3,167	)		15.00
Expired		(19,081	)		25.05
Outstanding as of June 30, 2017		2,072,999			4.10		9.25	$	51,512
Exercisable as of June 30, 2017		229,158			31.65		7.44	$
Vested and expected to vest		2,072,999		$	4.10		9.26	$	51,512

At June 30, 2017, there were 1,840,530 unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately $1,427,000. This expense is expected to be recognized over a weighted-average period of 2.10 years.

NOTE 15: SUBSEQUENT EVENTS

Subsequent to June 30, 2017 and throughout August 11, 2017 an additional 1,656,666 common stock warrants have been exercised at $0.26 per warrant for cash proceeds of $434,733. As of August 14, 2017 there are 1,215,000 common stock warrants still outstanding.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of the financial condition and results of operations should be read in conjunction with the financial statements and the related notes included elsewhere in this report. This discussion contains forward-looking statements, which are based on assumptions about the future of the Company’s business. The actual results could differ materially from those contained in the forward-looking statements. Please read “Forward-Looking Statements” included below for additional information regarding forward-looking statements.

Forward-Looking Statements

This report contains, in addition to historical information, certain information, assumptions and discussions that may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have made these statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties, which could cause actual results to differ materially from those projected or anticipated. Although we believe our assumptions underlying our forward-looking statements are reasonable as of the date of this report, we cannot assure you that the forward-looking statements set out in this report will prove to be accurate. We typically identify these forward-looking statements by the use of forward-looking words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or the negative version of those words or other comparable words. Forward-looking statements contained in this report include, but are not limited to, statements about:

	●	whether we can obtain approval from the U.S. Food and Drug Administration, or FDA, and foreign regulatory bodies, to sell, market and distribute our therapeutics and devices under development;

	●	our ability to successfully complete clinical trials of our pharmaceutical candidates under development, including endoxifen and our intraductal microcatheters to administer therapeutics, including our study using fulvestrant;

	●	the success, cost and timing of our product and drug development activities and clinical trials, including whether the ongoing clinical study using our intraductal microcatheters to administer fulvestrant will enroll a sufficient number of subjects or be completed in a timely fashion or at all;

	●	our ability to contract with third-party suppliers, manufacturers and service providers, including clinical research organizations, and their ability to perform adequately;

	●	our ability to successfully develop and commercialize new therapeutics currently in development or that we might identify in the future and in the time frames currently expected;

	●	our ability to successfully defend ongoing litigation, including the November 3, 2014 appeal of a dismissal of a securities class action law suit filed against us, and other similar complaints that may be brought in the future, in a timely manner and within the coverage, scope and limits of our insurance policies;

	●	our ability to establish and maintain intellectual property rights covering our products;

	●	our expectations regarding, and our ability to satisfy, federal, state and foreign regulatory requirements;

	●	the accuracy of our estimates of the size and characteristics of the markets that our products and services may address;

●

our expectations as to future financial performance, expense levels and capital sources;

	●	our ability to attract and retain key personnel; and

●

our ability to raise capital, including our ability to sell shares of common stock to Aspire Capital under the terms of the May 25, 2016 common stock purchase agreement with Aspire Capital.

These and other forward-looking statements made in this report are presented as of the date on which the statements are made. We have included important factors in the cautionary statements included in this report, particularly in the section titled “ITEM 1A. RISK FACTORS,” that we believe could cause actual results or events to differ materially from the anticipated results as set forth in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any new information, future events or circumstances that may affect our business after the date of this report. Except as required by law, we do not intend to update any forward-looking statements after the date on which the statement is made, whether as a result of new information, future events or circumstances or otherwise.

Company Overview

We are a clinical-stage pharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. We currently have three programs underway: two using our proprietary endoxifen (oral and topical formulations) and the other using our patented microcatheter technology. Our proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. Our patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients.

Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. Tamoxifen has been widely used for over 30 years to both treat and prevent breast cancer. Additional research has shown that it is the metabolites of tamoxifen, of which endoxifen is the most active that have potential therapeutic value.

We are developing both oral and a topical formulation of endoxifen, which are now in a Phase 1 dose-finding clinical study being conducted by a leading Clinical Research Organization in Australia. The study is a placebo-controlled, repeat dose study of 48 healthy female volunteers. The primary end point is to assess the pharmacokinetics of both formulations of endoxifen over 28 days. The secondary endpoint is to assess safety and tolerability. We have completed enrollment in both the oral and topical arms of this study. Subject to positive results from this study, we plan to advance to one or more Phase 2 clinical studies in the second half of 2017.

Our common stock is currently quoted on The NASDAQ Capital Market under the symbol “ATOS.”

Summary of Our Programs

Oral Endoxifen. We believe that up to 50% of the one million patients taking tamoxifen in the United States each year are refractory, meaning that they have inadequate endoxifen levels (for any number of reasons including low levels of a liver enzyme) and they have an increased risk for breast cancer recurrence. Subject to favorable results from our Phase 1 study, we are planning to begin a Phase 2 study of oral endoxifen in the second half of 2017 for these patients who are refractory to tamoxifen. We are also evaluating oral endoxifen in the neo-adjuvant setting, meaning it would be used, to treat breast cancer before surgery to remove the cancerous tumor.

Topical Endoxifen. Our topical formulation is being developed for women with a condition called high breast density, which has been shown in studies to result in a higher risk of developing breast cancer. Subject to favorable results from our Phase 1 study, we are planning to begin a Phase 2 study of topical endoxifen for women with high breast density. The goal of this program is to reduce high breast density, which should result in the lowering of the risk of breast cancer. Topical endoxifen is also being evaluated for its potential in other breast conditions.

Microcatheter Technology. Our third program uses our patented microcatheter technology to deliver drugs through the nipple directly to the site of the cancer. The goals of this delivery method are to increase the amount of the drug getting to the targeted area while reducing the side effects caused by delivering the drug through the blood stream.

We believe our patented intraductal microcatheter technology may be useful in delivering a number of drugs directly to the breast tissue. The initial drug we are studying using our microcatheters is fulvestrant. Fulvestrant is FDA-approved for metastatic breast cancer. It is administered as a monthly intramuscular injection of two injections, typically into the buttocks. In 2012, a published study documented that the single dose cost of intramuscular fulvestrant was approximately $12,000.

We own one issued patent and several pending applications directed to the treatment of breast conditions, including cancer, by the intraductal administration of therapeutics, including fulvestrant.

We are currently conducting a Phase 2 study using our microcatheter technology to deliver fulvestrant at Montefiore Medical Center. This trial is a Phase 2 study in women with ductal carcinoma in situ (DCIS) or Stage 1 or 2 breast cancer (invasive ductal carcinoma) scheduled for mastectomy or lumpectomy within 30 to 45 days. This study is assessing the safety, tolerability, cellular activity and distribution of fulvestrant when delivered directly into breast milk ducts of these patients compared to those who receive the same drug by injection. Of the 30 patients required for full enrollment, six will receive the standard intramuscular injection of fulvestrant and 24 will receive fulvestrant with our microcatheter device.

The primary endpoint of the clinical trial is to compare the safety, tolerability and distribution of fulvestrant between the two routes of administration (intramuscular injection or through our microcatheters). The secondary endpoint of the study is to determine if there are changes in the expression of Ki67 as well as estrogen and progesterone receptors between a pre-fulvestrant biopsy and post-fulvestrant surgical specimens. Digital breast imaging before and after drug administration in both groups will also be performed to determine the effect of fulvestrant on any lesions as well as breast density of the participant. We cannot provide an estimate of the date by which enrollment will be completed in this study.

Our key objectives are to advance our programs through Phase 2 trials and then evaluate further development independently or with partners.

Research and Development Phase

We are in the research and development phase and are not currently marketing any products or services. We do not anticipate generating revenue unless and until we develop and launch our pharmaceutical programs.

Critical Accounting Policies and Estimates

In our Annual Report on Form 10-K/A for the year ended December 31, 2016, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no changes to these policies since December 31, 2016, other than discussed in the following paragraph. Readers are encouraged to review these disclosures in conjunction with the review of this report.

Financial Instruments with Characteristics of Both Liabilities and Equity

During the three months ended June 30, 2017, the Company issued certain financial instruments, including warrants to purchase common stock, which have characteristics of both liability and equity. Financial instruments such as warrants that are classified as liabilities are fair valued upon issuance and are remeasured at fair value at subsequent reporting periods with the resulting change in fair value recorded in other income/(expense). The fair value of warrants is estimated using valuation models that require the input of subjective assumptions including stock price volatility, expected life, and the probability of future equity issuances and their impact to the price protection feature.

Results of Operations

Three and Six Months Ended June 30, 2017 and 2016

Operating Expenses: Total operating expenses were approximately $1.9 million, and $3.6 million for the three and six months ended June 30, 2017, respectively, consisting of general and administrative (G&A) expenses of approximately $1.1 million and $2.2 million, respectively, and research and development (R&D) expenses of approximately $0.8 million and $1.4 million, respectively. Total operating expenses were approximately $1.7 million and $4.0 million for the three and six months ended June 30, 2016, respectively, consisting of G&A expense of approximately $1.6 million and $3.7 million, respectively and R&D expenses of $0.2 million and $0.3 million, respectively.

Total operating expenses for the three and six months ended June 30, 2017 as compared to the same periods of 2016 increased approximately $0.2 million or 11.8% and decreased $0.4 million or 10.0%, respectively.

General and Administrative Expenses: G&A expenses for the three months ended June 30, 2017 were approximately $1,072,000, a decrease of $481,000 or 31.0%, from approximately $1.553,000, for the same period in 2016. G&A expenses for the six months ended June 30, 2017 were approximately $2,215,000, a decrease of $1,516,000 or 40.5%, from approximately $3,731,000 for the same period in 2016. G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The decrease in G&A expenses is mainly attributed to a reduction in payroll expenses resulting from a decrease in headcount, rent, and exit costs incurred in 2016 that were not incurred in 2017.

Research and Development Expenses: R&D expenses for the three and six months ended June 30, 2017 were approximately $824,000, and $1,368,000, respectively, an increase of approximately $655,000, or 387.6% and $1,049,000 or 328.87% from the three months and six months ended June 30, 2016, respectively. The increase in R&D expenses is attributed to salaries, manufacturing and clinical trial expenses associated with our endoxifen program for which manufacturing commenced at the beginning of 2017 and the clinical studies commenced in the second quarter of 2017. We expect our R&D expenses to increase throughout 2017 as we continue the clinical trial of fulvestrant administered via our microcatheters and as we continue the development of endoxifen and potentially other indications and pharmaceuticals.

Liquidity and Capital Resources

We have a history of operating losses as we have focused our efforts on raising capital and building our products and services in our pipeline. The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the six months ended June 30, 2017, the Company recorded a net loss of approximately $3.9 million, and used approximately $3.2 million of cash in operating activities. As of June 30, 2017, the Company had approximately $3.7 million in cash and cash equivalents and working capital of approximately $2.1 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail is commercial activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.

We expect that our existing resources will be sufficient to fund our planned operations for the next four to six months, however, additional capital resources will be needed to fund operations for the next twelve months.

Our ability to continue as a going concern is dependent on our obtaining additional adequate capital to fund additional operating losses until we become profitable. If we are unable to obtain adequate capital, we could be forced to cease operations.

Cash Flows

As of June 30, 2017 the Company had cash and cash equivalents of $3.7 million.

Net Cash Flows from Operating Activities: Net cash used in operating activities was approximately $3.2 million for the six months ended June 30, 2017, compared with approximately $4.7 million for the six months ended June 30, 2016. The decrease in the 2017 period as compared to 2016 results primarily from reductions in compensation from reduced headcount, reduced occupancy expenses, reduced consulting fees, and from severance payments in 2016 that were not incurred in 2017.

Net Cash Flows from Investing Activities: There was no net cash used in investing activities for the six months ended June 30, 2017, compared with approximately $5,000 for six months ended June 30, 2016. The decrease in 2017 was attributable to the reduction in purchases of fixed asset equipment in 2017 as compared to 2016.

Net Cash Flows from Financing Activities: Net cash provided by financing activities generated proceeds of $3.9 million for the six months ended June 30, 2017, as compared with $2.1 million for the six months ended June 30, 2016. The increase is mainly attributed to our completed public offering in the second quarter of 2017 as compared to a lower level of sales of our stock to Aspire in the second quarter of 2016.

Funding Requirements

We expect to incur ongoing operating losses for the foreseeable future as we continue to develop our planned therapeutic programs including related clinical studies and other programs in the pipeline. We expect that our existing resources will be sufficient to fund our planned operations for at least the next four to six months. In addition to our cash and cash equivalents at June 30, 2017 of approximately $3.7 million, we will be seeking to raise capital through sales of securities to third parties and existing stockholders to fund operations later in the year. If we are unable to raise additional capital when needed, however, we could be forced to curtail or cease operations. Our future capital uses and requirements depend on the time and expenses needed to begin and continue clinical trials for our new drug developments.

Additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities or by selling debt securities, if convertible, further dilution to our existing stockholders would result. To the extent our capital resources are insufficient to meet our future capital requirements, we will need to finance our future cash needs through public or private equity offerings, collaboration agreements, debt financings or licensing arrangements.

If adequate funds are not available, we may be required to terminate, significantly modify or delay our development programs, reduce our planned commercialization efforts, or obtain funds through collaborators that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. Further, we may elect to raise additional funds even before we need them if we believe the conditions for raising capital are favorable.

Off-Balance Sheet Arrangements

We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.

Recent Accounting Pronouncements

In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Updated (“ASU”) No. 2016-02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The Lessor accounting remains largely consistent with existing U.S. GAAP. The new standard takes effect in 2019 for public business entities. The Company has not adopted the provisions of ASU No. 2016-02. We are currently evaluating the impact of our pending adoption of ASU 2016-02 on our consolidated financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2017. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer concluded that, as of June 30, 2017, the Company’s disclosure controls and procedures were not effective at the reasonable assurance level.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended June 30, 2017 that has materially affected, or is reasonably likely to materially affect our disclosure controls and procedures.

For the year ended December 31, 2016, we identified a material weakness in that we did not design and maintain effective controls over the preparation of the 2016 impairment analysis of the Acueity patents, primarily because we did not include potential income taxes in the discounted cash flow model we used to estimate the fair value of the Acueity patents at December 31, 2016. This resulted in an initial overstatement of the fair value of the Acueity patents at December 31, 2016 in the amount of $366,000 and an initial understatement of the 2016 impairment charge and net loss by the same amount. We corrected our estimate and the related accounts prior to the issuance of the consolidated financial statements contained in our Annual Report on Form 10-K/A. Management’s remediation plan, which we are in the process of implementing, is to use appropriate valuation methodologies in future analyses that may be required to determine the fair value of these intangible assets and to seek the assistance of outside valuation resources, if necessary, in performing such analyses.

For the year ended December 31, 2016, we also identified a material weakness in that we did not design and maintain effective controls over the calculation of the weighted average number of shares outstanding and basic and diluted loss per share for the year ended December 31, 2016 because the calculation of weighted average shares outstanding did not include the shares of common stock we issued in August 2016. The preparation and review of the weighted average share calculation was not performed at an appropriately detailed level to prevent or detect this error, which led to a material error in our calculation of the weighted average number of shares outstanding and the net loss per share for the year ended December 31, 2016. During the first and second quarter of 2017, we began implementing a remediation plan to enhance the procedures performed to document our preparation of and to independently review the calculation of weighted average shares outstanding and income (loss) per share. Our enhanced review procedures and documentation standards were in place during the first and second quarter of 2017. The material weakness cannot be considered remediated until the control has operated for a sufficient period of time and until management has concluded that the control is operating effectively.

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al., No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering. The complaint alleges that all defendants violated Sections 11 and 12(a)(2), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. This action seeks, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount.

On February 14, 2014, the Court appointed plaintiffs Miko Levi, Bandar Almosa and Gregory Harrison (collectively, the “Levi Group”) as lead plaintiffs, and approved their selection of co-lead counsel and liaison counsel. The Court also amended the caption of the case to read In re Atossa Genetics, Inc. Securities Litigation No. 2:13-cv-01836-RSM. An amended complaint was filed on April 15, 2014. The Company and other defendants filed motions to dismiss the amended complaint on May 30, 2014. On October 6, 2014 the Court granted defendants’ motion dismissing all claims against Atossa and all other defendants. On October 30, 2014, the Court entered a final order of dismissal. On November 3, 2014, plaintiffs filed a notice of appeal with the Court and have appealed the Court’s dismissal order to the U.S. Court of Appeals for the Ninth Circuit. The appeal was fully briefed and oral argument took place on May 18, 2017. We are currently awaiting a decision from the Court.

We believe this complaint is without merit and plan to defend ourselves vigorously; however failure to obtain a favorable resolution of the claims set forth in the complaint could have a material adverse effect on our business, results of operations and financial condition. Currently, the amount of such material adverse effect cannot be reasonably estimated, and no provision or liability has been recorded for these claims as of June 30, 2017. The costs associated with defending and resolving the complaint and ultimate outcome cannot be predicted. These matters are subject to inherent uncertainties and the actual cost, as well as the distraction from the conduct of our business, will depend upon many unknown factors and management’s view of these may change in the future.

ITEM 1A. RISK FACTORS

RISK FACTORS

A purchase of our shares of Common Stock is an investment in our securities and involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information contained in this report, before purchasing our securities. If any of the following risks actually occur, our business, financial condition and results of operations would likely suffer. In that case, the market price of the Common Stock could decline, and you may lose part or all of your investment in our company. Additional risks of which we are not presently aware or that we currently believe are immaterial may also harm our business and results of operations.

There have been no material changes to the risk factors described in our Annual Report on Form 10-K/A, as filed with the SEC on March 21, 2017 except as follows:

Our shares of Common Stock are listed on The NASDAQ Capital Market, but we cannot guarantee that we will be able to satisfy the continued listing standards going forward.

Although our shares of Common Stock are listed on The NASDAQ Capital Market, we cannot ensure that we will be able to satisfy the continued listing standards of The NASDAQ Capital Market going forward. If we cannot satisfy the continued listing standards going forward, NASDAQ may commence delisting procedures against us, which could result in our stock being removed from listing on The NASDAQ Capital Market. On September 28, 2015, we received a letter from NASDAQ stating that the Company was not in compliance with NASDAQ Listing Rule 5550(a)(2), because the Company’s Common Stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. We regained compliance with the $1.00 minimum bid price requirement in September 2016 after effectuating a reverse stock split. On May 11, 2017, we received a letter from NASDAQ stating we are not in compliance with Rule 5550(a)(2) because our common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. We have until November 7, 2017 to either regain compliance, or request additional time to regain compliance.

If our stock price does not satisfy the $1.00 minimum bid price requirement or we otherwise fail to satisfy other continued listing requirements, we may be delisted from NASDAQ, which could adversely affect our stock price, liquidity, and our ability to raise funding.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

ITEM 6. EXHIBITS

(a)

Exhibits

		Incorporated by Reference Herein
Exhibit No.	Description	Form	Date
3.1	Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock	Form 10-Q	May 11, 2017

10.1	Underwriting Agreement between Atossa Genetics Inc. and Aegis Capital Corp. as representative of the several underwriters, dated March 28, 2017	Current Report on Form 8-K, as Exhibit 1.1	April 4, 2017

10.2	2010 Stock Option and Incentive Plan, as amended	Form 10-Q	May 11, 2017

31.1	Certification pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 of Steven C. Quay	Filed herewith

31.2	Certification pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 of Kyle Guse	Filed herewith

32.1	Certification pursuant to 18 U.S.C. Section 1350 of Steven C. Quay	Filed herewith

32.2	Certification pursuant to 18 U.S.C. Section 1350 of Kyle Guse	Filed herewith

101	Interactive Data Files pursuant to Rule 405 of Regulation S-T	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 14, 2017

/s/ Steven C. Quay
President and Chief Executive Officer
(On behalf of the Registrant)

/s/ Kyle Guse
Kyle Guse
Chief Financial Officer, General Counsel and Secretary
(As Principal Financial and Accounting Officer)

EX-31.1 2 s106997_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steven C. Quay, certify that:

1. I have reviewed this Report of Atossa Genetics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Date: August 14, 2017

	/s/ Steven C. Quay
	Steven C. Quay
	Chief Executive Officer and President
	(Principal executive officer)

EX-31.2 3 s106997_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kyle Guse, certify that:

1. I have reviewed this Report of Atossa Genetics Inc.;

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Date: August 14, 2017

	/s/ Kyle Guse
	Kyle Guse
	Chief Financial Officer, General Counsel and Secretary
	(Principal financial and accounting officer)

EX-32.1 4 s106997_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atossa Genetics Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven C. Quay, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Date: August 14, 2017

	/s/ Steven C. Quay
	Steven C. Quay
	Chief Executive Officer and President
	(Principal executive officer)

EX-32.2 5 s106997_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atossa Genetics Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kyle Guse, Chief Financial Officer, General Counsel and Secretary of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Date: August 14, 2017

	/s/ Kyle Guse
	Kyle Guse
	Chief Financial Officer, General Counsel and Secretary
	(Principal financial and accounting officer)

EX-101.INS 6 atos-20170630.xml XBRL INSTANCE FILE 0001488039 2017-01-01 2017-06-30 0001488039 2017-06-30 0001488039 2016-12-31 0001488039 2016-01-01 2016-06-30 0001488039 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0001488039 us-gaap:CommonStockMember 2016-12-31 0001488039 us-gaap:CommonStockMember 2017-06-30 0001488039 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0001488039 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001488039 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001488039 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0001488039 us-gaap:RetainedEarningsMember 2016-12-31 0001488039 us-gaap:RetainedEarningsMember 2017-06-30 0001488039 atos:ReverseStockSplitMember 2016-08-25 2016-08-26 0001488039 atos:ReverseStockSplitMember 2017-05-31 0001488039 atos:ReverseStockSplitMember 2016-08-26 0001488039 us-gaap:PatentsMember 2017-06-30 0001488039 us-gaap:ComputerSoftwareIntangibleAssetMember 2017-06-30 0001488039 us-gaap:PatentsMember 2016-12-31 0001488039 us-gaap:ComputerSoftwareIntangibleAssetMember 2016-12-31 0001488039 us-gaap:ComputerSoftwareIntangibleAssetMember 2017-01-01 2017-06-30 0001488039 us-gaap:ComputerSoftwareIntangibleAssetMember 2016-01-01 2016-06-30 0001488039 us-gaap:PatentsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001488039 us-gaap:PatentsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0001488039 us-gaap:PatentsMember 2017-01-01 2017-06-30 0001488039 us-gaap:PatentsMember 2016-01-01 2016-06-30 0001488039 atos:TwoThousandAndElevenPrivatePlacementMember 2017-01-01 2017-06-30 0001488039 atos:AcueityWarrantsMember 2017-01-01 2017-06-30 0001488039 atos:TwoThousandAndFourteenPublicOfferingMember 2017-01-01 2017-06-30 0001488039 atos:PlacementAgentFeeMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001488039 atos:PlacementAgentFeeMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0001488039 atos:OutsideConsultingFirmMember 2017-01-01 2017-06-30 0001488039 atos:TwoThousandAndElevenPrivatePlacementMember 2017-06-30 0001488039 atos:AcueityWarrantsMember 2017-06-30 0001488039 atos:TwoThousandAndFourteenPublicOfferingMember 2017-06-30 0001488039 atos:PlacementAgentFeeMember 2017-06-30 0001488039 atos:OutsideConsultingFirmMember 2017-06-30 0001488039 atos:TwoThousandAndElevenPrivatePlacementMember us-gaap:MinimumMember 2017-06-30 0001488039 atos:TwoThousandAndElevenPrivatePlacementMember us-gaap:MaximumMember 2017-06-30 0001488039 atos:PlacementAgentFeeMember us-gaap:MinimumMember 2017-06-30 0001488039 atos:PlacementAgentFeeMember us-gaap:MaximumMember 2017-06-30 0001488039 us-gaap:SeriesAPreferredStockMember 2017-06-30 0001488039 us-gaap:BeneficialOwnerMember 2014-05-19 0001488039 atos:AspireCapitalFundLlcMember atos:NewCommonStockPurchaseAgreementMember 2015-11-11 0001488039 atos:AspireCapitalFundLlcMember atos:NewCommonStockPurchaseAgreementMember 2016-05-25 0001488039 atos:AspireCapitalFundLlcMember atos:StockPurchaseAgreementMember 2016-05-24 2016-05-25 0001488039 atos:AspireCapitalFundLlcMember atos:StockPurchaseAgreementMember us-gaap:AdditionalPaidInCapitalMember 2016-05-24 2016-05-25 0001488039 atos:IPO2Member 2016-08-01 2016-08-31 0001488039 atos:IPO2Member 2016-08-31 0001488039 us-gaap:StockOptionMember 2017-01-01 2017-06-30 0001488039 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001488039 us-gaap:StockOptionMember 2016-01-01 2016-06-30 0001488039 us-gaap:WarrantMember 2016-01-01 2016-06-30 0001488039 atos:Plan2012Member 2017-01-01 2017-06-30 0001488039 atos:Plan2013Member 2017-01-01 2017-06-30 0001488039 atos:Plan2014Member 2017-01-01 2017-06-30 0001488039 atos:Plan2015Member 2017-01-01 2017-06-30 0001488039 atos:Plan2016Member 2017-01-01 2017-06-30 0001488039 atos:StockOptionAndIncentivePlan2010Member 2010-09-28 0001488039 atos:StockOptionAndIncentivePlan2010Member 2016-05-18 0001488039 atos:StockOptionAndIncentivePlan2010Member 2017-06-30 0001488039 2015-12-31 0001488039 2016-06-30 0001488039 2017-08-14 0001488039 atos:Plan2017Member 2017-01-01 2017-06-30 0001488039 us-gaap:IPOMember atos:UnderwritingAgreementMember atos:AegisCapitalCorpMember 2017-04-02 2017-04-03 0001488039 us-gaap:IPOMember atos:UnderwritingAgreementMember atos:AegisCapitalCorpMember atos:ClassAUnitsMember 2017-04-02 2017-04-03 0001488039 us-gaap:IPOMember atos:UnderwritingAgreementMember atos:AegisCapitalCorpMember atos:ClassAUnitsMember 2017-04-03 0001488039 us-gaap:IPOMember atos:UnderwritingAgreementMember atos:AegisCapitalCorpMember atos:CommonStockAndWarrantsMember atos:ClassAUnitsMember 2017-04-02 2017-04-03 0001488039 us-gaap:IPOMember atos:UnderwritingAgreementMember atos:AegisCapitalCorpMember atos:ClassBUnitsMember 2017-04-02 2017-04-03 0001488039 us-gaap:IPOMember atos:UnderwritingAgreementMember atos:AegisCapitalCorpMember atos:SeriesAConvertiblePreferredStockConvertibleMember 2017-04-02 2017-04-03 0001488039 us-gaap:IPOMember atos:UnderwritingAgreementMember atos:AegisCapitalCorpMember atos:SeriesAConvertiblePreferredStockConvertibleMember atos:CommonStockAndWarrantsMember 2017-04-02 2017-04-03 0001488039 us-gaap:OverAllotmentOptionMember atos:UnderwritingAgreementMember atos:AegisCapitalCorpMember atos:CommonStockAndWarrantsMember 2017-04-02 2017-04-03 0001488039 us-gaap:OverAllotmentOptionMember atos:UnderwritingAgreementMember atos:AegisCapitalCorpMember atos:CommonStockAndWarrantsMember 2017-04-03 0001488039 atos:ScientificAdvisorMember 2017-01-01 2017-06-30 0001488039 us-gaap:IPOMember atos:UnderwritingAgreementMember atos:AegisCapitalCorpMember 2017-03-27 2017-03-28 0001488039 us-gaap:ComputerSoftwareIntangibleAssetMember 2016-01-01 2016-12-31 0001488039 2017-04-01 2017-06-30 0001488039 2016-04-01 2016-06-30 0001488039 us-gaap:ComputerSoftwareIntangibleAssetMember 2017-04-01 2017-06-30 0001488039 us-gaap:ComputerSoftwareIntangibleAssetMember 2016-04-01 2016-06-30 0001488039 us-gaap:PatentsMember 2017-04-01 2017-06-30 0001488039 us-gaap:PatentsMember 2016-04-01 2016-06-30 0001488039 us-gaap:PatentsMember 2016-01-01 2016-12-31 0001488039 us-gaap:IPOMember 2017-06-30 0001488039 us-gaap:IPOMember 2017-01-01 2017-06-30 0001488039 us-gaap:StockOptionMember 2017-04-01 2017-06-30 0001488039 us-gaap:WarrantMember 2017-04-01 2017-06-30 0001488039 us-gaap:StockOptionMember 2016-04-01 2016-06-30 0001488039 us-gaap:WarrantMember 2016-04-01 2016-06-30 0001488039 atos:StockOptionAndIncentivePlan2010Member 2017-05-09 0001488039 us-gaap:PreferredStockMember 2017-01-01 2017-06-30 0001488039 us-gaap:PreferredStockMember 2016-12-31 0001488039 us-gaap:PreferredStockMember 2017-06-30 0001488039 us-gaap:SubsequentEventMember 2017-08-10 2017-08-11 0001488039 us-gaap:SubsequentEventMember 2017-08-11 0001488039 atos:StockOptionAndIncentivePlanMember 2017-01-01 2017-06-30 0001488039 atos:StockOptionAndIncentivePlanMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001488039 atos:StockOptionAndIncentivePlanMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0001488039 atos:StockOptionAndIncentivePlanMember 2016-01-01 2016-06-30 0001488039 atos:StockOptionAndIncentivePlanMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0001488039 atos:StockOptionAndIncentivePlanMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0001488039 atos:SeriesAConvertiblePreferredStockConvertibleMember 2017-01-01 2017-06-30 0001488039 atos:SeriesAConvertiblePreferredStockConvertibleMember 2016-01-01 2016-06-30 0001488039 atos:SeriesAConvertiblePreferredStockConvertibleMember 2016-04-01 2016-06-30 0001488039 atos:SeriesAConvertiblePreferredStockConvertibleMember 2017-04-01 2017-06-30 0001488039 atos:SeriesAConvertiblePreferredStockConvertibleMember 2017-06-30 0001488039 us-gaap:OverAllotmentOptionMember atos:UnderwritingAgreementMember atos:AegisCapitalCorpMember atos:CommonStockAndWarrantsMember 2017-06-30 0001488039 atos:Warrant2017Member 2017-06-29 0001488039 atos:Warrant2017Member 2017-06-28 2017-06-29 0001488039 atos:Warrant2017Member 2017-01-01 2017-06-30 0001488039 atos:Warrant2017Member 2017-06-30 0001488039 atos:AspireCapitalFundLlcMember atos:StockPurchaseAgreementMember 2016-01-01 2016-03-31 0001488039 atos:SeriesAConvertiblePreferredStockConvertibleMember 2016-12-31 0001488039 atos:AdditionalPaidInCapital1Member 2017-01-01 2017-06-30 0001488039 atos:AdditionalPaidInCapital1Member 2016-12-31 0001488039 atos:AdditionalPaidInCapital1Member 2017-06-30 0001488039 us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001488039 us-gaap:FairValueInputsLevel3Member 2017-06-30 0001488039 atos:Warrant2017Member 2017-04-02 2017-04-03 0001488039 atos:Warrant2017Member 2017-04-03 0001488039 atos:Warrant2017Member us-gaap:MinimumMember 2017-04-02 2017-04-03 0001488039 atos:Warrant2017Member us-gaap:MaximumMember 2017-04-02 2017-04-03 0001488039 atos:Warrant2017Member us-gaap:MinimumMember 2017-01-01 2017-06-30 0001488039 atos:Warrant2017Member us-gaap:MaximumMember 2017-01-01 2017-06-30 0001488039 us-gaap:SubsequentEventMember 2017-08-14 0001488039 us-gaap:CommonStockMember 2017-04-01 2017-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ATOSSA GENETICS INC 0001488039 10-Q 2017-06-30 false --12-31 No No Yes Smaller Reporting Company Q2 2017 ATOS 11701075.

3200000

3690023

3027962

3715895

1190866

2100000

4400000

3900000

The Company completed a 1-for-15 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 15 shares of issued and outstanding common stock were combined into one issued and outstanding share of Common Stock, and the par value per share was changed to $.015 per share.

0.015

228370

171601

20870

16050

21000

29968

14218

20000

156532

121333

18989

55119

151927

155409

170916

210528

752540

639000

113540

639000

113540

585683

640440

166857

112100

253113

70285

73433

48282

482420

769899

67547

66048

134865

94514

280008

609337

18434

62353

8773

32734

113540

639000

113540

639000

P3Y

P7Y

P12Y

19614

15714

35142

74508

6759

7857

17571

37254

3273894

283470

21667

77790

16135

3166

2871666

1215000

0.26

75.00

45.00

63.60

18.75

24.00

31.80

186.45

15.00

0.9375

0.26

0.9375

2018-05-08 2017-09-30 2019-01-29 2018-03-31 2018-11-30 2018-01-14 2022-04-03 85000000

75000000

10000000

750000

4000

0.001

0.15

0.0200 30.00

2.50

0.75

0.52

0.50

0.75

1194000

1150000

664000

4669333

530000

3000000

405747

829684

17910

811774

2875000

2133974

2561896

2177083

405747 10000000

49736

746

197777

198523

5139167

796318

754093

3286862

394090

402228

9445720

796318

1121567

6139797

394090

402228

1098212

2184356

250000

3440023

2777962

4930

18540

157200

7395

78600

551455

30018

34452

49532

65557

220419

151477

2072999

378924

1716323

3167

19081

229158

2072999

4.10

26.25

0.47

15.00

25.05

31.65

P9Y3M

P7Y5M8D

51512

4.10

P9Y3M4D

51512

336115

392664

181408

200187

66667

133333

1500000

100456

P2Y1M6D

1840530

1427000

10032410

3786913

10032410

839

664000

1000

3502

4669333

530000

P5Y P5Y

4709378

4144372

2803602

3097106

56804

150486

60344050

63126929

-57303748

-61248791

774977

-61248791

-57303748

150486

56804

1905776

1047266

19157

6083

44017

16964

495811

254320

4709378

4144372

128577

194250

3976129

3254563

55000

2736

864371 864371 864371

63126929

60344050

10032410

3786913

-3945043

-4049923

-3945043

-2241489

-1722383

39705

6617

198523

383

662061

-2525029

3871636

2133974

-4941

4941

-3209575

-4654062

13074

-41473

27053

-387903

-287479

-666368

241491

-531657

-25831

-110527

56769

15836

73193

152574

-17695

-163333

336115

392664

NOTE 1: NATURE OF OPERATIONS   Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31. The Company is focused on development of its pharmaceutical programs.

3234773 4 3234769

53260

2406535

-3

-2459792

3550664

-2663

2663

3550664

2600 150 2450 -797595 -22362 -775233 -39705 -39705

336115

900488 2600

0.0186

0.0204

0.0148

0.0155

0.0079

0.0188

0.0079

0.0188

1.1286

1.1419

1.1552

1.1558

0.50

1333.33

1500000

Each share of the Series A Preferred is convertible into 1,333.33 shares of our Common Stock (subject to adjustment as provided in the related certificate of designation of preferences, rights and limitations). Holders of Series A Preferred are prohibited from converting Series A Preferred into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our Common Stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to us.

The shares of Common Stock are registered under the Securities Act of 1933, as amended. If delivery of the shares of Common Stock pursuant to the foregoing would result in the holder exceeding the 4.99% “Beneficial Ownership Limitation” (as defined in the warrant) then the shares in excess of such 4.99% will be held in abeyance by the Company pending further instruction from the holder. A holder will not have the right to exercise any portion of the Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days’ prior notice from the holder to us.

P5Y3M25D

P6Y4M10D

P5Y6M29D

P622D

P0Y2M26D

P5Y

P0Y0M29D

P4Y9M4D

0.00

2133973

839

NOTE 2: GOING CONCERN   The Company’s consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the six months ended June 30 2017, the Company recorded a net loss of approximately $3.9 million and used approximately $3.2 million of cash in operating activities. As of June 30, 2017, the Company had approximately $3.7 million in cash and cash equivalents and working capital of approximately $2.1 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such capital will be obtained on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.   Management’s plan to continue as a going concern is as follows. In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plans to obtain such resources for the Company include obtaining capital from the sale of its equity securities and short-term borrowings from banks, stockholders or other related party(ies), if needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.   We expect that our existing resources will be sufficient to fund our planned operations for the next four to six months; however, additional capital resources will be needed to fund operations for the next twelve months.   The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraphs and eventually to secure other sources of financing and attain profitable operations.

NOTE 4: PREPAID EXPENSES   Prepaid expenses consisted of the following:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">June 30, 2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">December 31, 2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 74%">Prepaid insurance</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">156,532</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">121,333</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Trade show</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Retainer and security deposits</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">29,968  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,218</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Financial exchange fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">21,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">20,870</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">16,050</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">228,370 </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">171,601</td></tr> </table>

NOTE 5: FURNITURE AND EQUIPMENT   Furniture and equipment consisted of the following:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">June 30, 2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">December 31, 2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; width: 74%">Furniture and equipment</td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%">170,916</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%">210,528</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(151,927</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(155,409</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total furniture and equipment, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">18,989</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">55,119</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   Depreciation expense for the three months ended June 30, 2017 and 2016 was $8,773 and $32,734, respectively, and $18,434, and $62,353, for the six months ended June 30, 2017 and 2016, respectively.

NOTE 7: PAYROLL LIABILITIES   Payroll liabilities consisted of the following:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">June 30, 2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">December 31, 2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 74%">Accrued bonus payable</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">280,008</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">609,337</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Accrued vacation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">134,865</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">94,514</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Accrued payroll liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">67,547</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">66,048</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total payroll liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">482,420</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">769,899</td></tr> </table>

NOTE 11: INCOME TAXES   Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.    As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of June 30, 2017 and December 31, 2016 due to the Company’s continuing operating losses.

NOTE 12: CONCENTRATION OF CREDIT RISK   Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At June 30, 2017 and December 31, 2016, the Company had $3,440,023 and $2,777,962 in excess of the FDIC insured limit, respectively.

Use of Estimates:   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Prepaid expenses consisted of the following:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">June 30, 2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">December 31, 2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 74%">Prepaid insurance</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">156,532</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">121,333</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Trade show</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Retainer and security deposits</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">29,968  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,218</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Financial exchange fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">21,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">20,870</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">16,050</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">228,370 </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">171,601</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

Furniture and equipment consisted of the following:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">June 30, 2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">December 31, 2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; width: 74%">Furniture and equipment</td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%">170,916</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%">210,528</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(151,927</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(155,409</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total furniture and equipment, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">18,989</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">55,119</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

Intangible assets consisted of the following:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">June 30, 2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">December 31, 2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 74%">Patents</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">639,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">639,000</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Software</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">113,540</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">113,540</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Total intangible assets</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">752,540</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">752,540</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(166,857</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(112,100</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">585,683</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">640,440</td></tr> </table>

Future estimated amortization expenses as of June 30, 2017 for the five succeeding years is as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: left; font-weight: bold">For the years ending December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Amounts</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 86%">2017 (includes the remainder of the year)</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">48,282</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">2018</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">73,433</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">2019</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">70,285</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">70,285</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">2021</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">70,285</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">253,113</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">585,683</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

Payroll liabilities consisted of the following:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">June 30, 2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">December 31, 2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 74%">Accrued bonus payable</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">280,008</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">609,337</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Accrued vacation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">134,865</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">94,514</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Accrued payroll liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">67,547</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">66,048</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total payroll liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">482,420</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">769,899</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the three months and six months ended June 30, 2017 and 2016 because the effect of them would be anti-dilutive:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Three Months Ended   June 30,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Six Months Ended June 30,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 48%">Options to purchase common stock</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">1,121,567</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">394,090</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">754,093</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">394,090</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Series A convertible preferred stock</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,184,356</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,098,212</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,139,797</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">402,228</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,286,862</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">402,228</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">9,445,720</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">796,318</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">5,139,167</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">796,318</td></tr> </table>

The future minimum lease payments due subsequent to June 30, 2017 under all non-cancelable operating and capital leases for the next five years are as follows:   <table cellspacing="0" cellpadding="0" align="center" style="width: 90%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font-weight: bold">Year Ending December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Operating Leases Amount</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt; width: 87%">2017 (remainder of year)</td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%">4,930</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total minimum lease payments</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4,930</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:   <table cellspacing="0" cellpadding="0" align="center" style="width: 90%; border-collapse: collapse; font-size: 11pt"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">January 1,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of shares</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td style="padding-left: 0.125in; width: 86%">2012</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 10%">30,018</td> <td style="width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 0.125in">2013</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">34,452</td> <td> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td style="padding-left: 0.125in">2014</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">49,532</td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 0.125in">2015</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">65,557</td> <td> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td style="padding-left: 0.125in">2016</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">220,419</td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 0.125in">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">151,477</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td style="padding-left: 0.125in">Total additional shares</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">551,455</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The fair value of stock options granted for the six months ended June 30, 2017 and 2016 was calculated using the Black-Scholes option-pricing model applying the following assumptions:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 11pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Period ended June 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2" nowrap="nowrap" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" nowrap="nowrap" style="text-align: right"> </td> <td> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td style="width: 64%">Risk free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 15%">1.86% - 2.04%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 15%">1.48% - 1.55%</td> <td style="width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Expected term</td> <td> </td> <td> </td> <td style="text-align: right">5.32- 6.36 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.58 - 6.06 years</td> <td> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">- % </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">- % </td> <td> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">112.86% - 114.19%</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">115.52% - 115.58%</td> <td> </td></tr> </table>

Options issued and outstanding as of June 30, 2017 and their activities during the six months then ended are as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Number of Underlying Shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Weighted- Average Exercise Price Per Share</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Weighted- Average Contractual Life Remaining in Years</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Aggregate Intrinsic Value</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 48%">Outstanding as of January 1, 2017</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">378,924</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">26.25</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%"></td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.25in">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,716,323</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">.47</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.25in">Forfeited</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,167</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(19,081</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">25.05</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Outstanding as of June 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">2,072,999</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">4.10</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.25</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">51,512</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Exercisable as of June 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">229,158</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">31.65</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.44</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right"></td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Vested and expected to vest</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">2,072,999</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.10</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.26</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">51,512</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

3502 10000 -1490833

5641671

2485853

7476046

2587871

-1.15

-1.63

-0.64

-0.67

-3945043

-4049923

-2241489

-1722383

-16671

152447 152447

-3583108

-4049923

-1896263

-1722383

3583108

4049923

1896263

1722383

2214712

3730960

1072169

1553391

1368396

318963

824094

168992

192817 192817

2568132

-6513175

-4049923

-4809621

-1722383

65816

267231 2568132 -2568132 2568132

NOTE 15: SUBSEQUENT EVENTS   Subsequent to June 30, 2017 and throughout August 11, 2017 an additional 1,656,666 common stock warrants have been exercised at $0.26 per warrant for cash proceeds of $434,733. As of August 14, 2017 there are 1,215,000 common stock warrants still outstanding.

Inputs used in the valuation of the warrants at the issuance date of April 3, 2017 and June 30, 2017 were as follows:   <table cellspacing="0" cellpadding="0" style="width: 70%; border-collapse: collapse; font-size: 10pt"> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Initial valuation</td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="width: 85%">Common stock price</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">0.75</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Exercise price</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.9375</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected Volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">50</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Dividend Yield</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0</td> <td style="text-align: left">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Risk-Free Interest Rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.79% - 1.88</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Expected Term (years)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.24 - 5</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>June 30, 2017 valuation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Common stock price</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.50</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Exercise price</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.26</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected Volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">50</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Dividend Yield</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0</td> <td style="text-align: left">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Risk-Free Interest Rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.79% - 1.88</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Expected Term (years)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.08-4.76</td> <td style="text-align: left"> </td></tr> </table> -900493 1612415 1600000

1800000

2871666

1656666

-220000

NOTE 6: INTANGIBLE ASSETS   Intangible assets consisted of the following:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">June 30, 2017</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">December 31, 2016</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%">Patents</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">639,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">639,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Software</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">113,540</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">113,540</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total intangible assets</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">752,540</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">752,540</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left">Less: Accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(166,857</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(112,100</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Total intangible assets, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">585,683</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">640,440</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Software amounted to $113,540 as of June 30, 2017 and December 31, 2016. The amortization period for the purchased software is 3 years. Amortization expense related to software for the three months ended June 30, 2017 and 2016 was $6,759 and $7,857, respectively, and was $19,614 and $15,714, for the six months ended June 30 2017 and 2016, respectively.   Patents amounted to $639,000 as of June 30, 2017 and December 31, 2016, and mainly consisted of patents acquired from Acueity on September 30, 2012 in an asset purchase transaction. Patent assets are amortized based on their determined useful life, and tested annually for impairment. The amortization period is from 7 to 12 years. Amortization expense related to patents was $17,571 and $37,254 for the three months ended June 30, 2017 and 2016, respectively and was $35,142 and $74,508 for the six months ended June 30, 2017 and 2016, respectively.   Future estimated amortization expenses as of June 30, 2017 for the five succeeding years is as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: left">For the years ending December 31,</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Amounts</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 86%; text-align: left">2017 (includes the remainder of the year)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">48,282</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">2018</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">73,433</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2019</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">70,285</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">70,285</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">70,285</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">253,113</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">585,683</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

As of June 30, 2017, warrants to purchase 3,273,894 shares of common stock were outstanding including:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 11pt"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding Warrants to Purchase Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td style="width: 43%">2011 private placement</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 15%">283,470</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 15%">18.75 - 24.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 20%">May 8, 2018</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Acueity warrants</td> <td> </td> <td> </td> <td style="text-align: right">21,667</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">75.00</td> <td> </td> <td> </td> <td style="text-align: right">September 30, 2017</td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td>2014 public offering</td> <td> </td> <td> </td> <td style="text-align: right">77,790</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">45.00</td> <td> </td> <td> </td> <td style="text-align: right">January 29, 2019</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Placement agent fees for Company’s offerings</td> <td> </td> <td> </td> <td style="text-align: right">16,135</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">31.80 - 186.45</td> <td> </td> <td> </td> <td style="text-align: right">March - November, 2018</td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td>Outside consulting</td> <td> </td> <td> </td> <td style="text-align: right">3,166</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">63.60</td> <td> </td> <td> </td> <td style="text-align: right">January 14, 2018</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">2017 public offering</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,871,666</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">0.26</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">April 3, 2022</td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3,273,894</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table summarizes the 2017 liability warrant activity:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td>Outstanding as of December 31, 2016</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="width: 74%">Warrants granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 10%">5,863,332</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 10%">0.9375</td> <td style="width: 1%"> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td>Warrants exercised</td> <td> </td> <td> </td> <td style="text-align: right">(2,991,666</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">0.26</td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Warrants cancelled</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td style="padding-bottom: 1pt">Outstanding as of June 30, 2017</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,871,666</td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.26</td></tr> </table>

5863332 -2991666 0.9375 0.26

NOTE 9: FAIR VALUE OF FINANCIAL INSTRUMENTS   Pursuant to the accounting guidance for fair value measurement and its subsequent updates, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. The accounting guidance establishes a hierarchy for inputs used in measuring fair value that minimizes the use of unobservable inputs by requiring the use of observable market data when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on active market data. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.   The fair value hierarchy is broken down into the three input levels summarized below:   ● Level 1 —Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. Treasuries and trading securities with quoted prices on active markets.   ● Level 2 —Valuations based on inputs other than the quoted prices in active markets that are observable either directly or indirectly in active markets. Examples of assets and liabilities utilizing Level 2 inputs are U.S. government agency bonds, corporate bonds, commercial paper, certificates of deposit and over-the- counter derivatives.   ● Level 3 —Valuations based on unobservable inputs in which there are little or no market data, which require the Company to develop its own assumptions.    The following tables present the Company’s fair value hierarchy for all its financial assets, in thousands, by major security type measured at fair value on a recurring basis as of June 30, 2017:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">June, 30 2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Estimated Fair Value</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td>Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"></td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"></td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"></td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td>Liabilities:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 64%">Common Stock Warrant Liability</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">864,371</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">864,371</td> <td style="width: 1%"> </td></tr> </table>   There were no financial assets outstanding that were required to be measured at fair value at December 31, 2016.   Warrants containing provisions that could require the Company to settle the warrants in cash in an event outside the Company’s control or that have price protection rights are accounted for as liabilities, with changes in the fair values included in net loss for the respective periods. Because some of the inputs to the valuation model are either not observable or are not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy.   The following table summarizes the changes in the Company’s Level 3 warrant liability for the six months ended June 30, 2017:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="font-size: 10pt; border-bottom: black 1pt solid; text-align: center">June 30, 2017</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Warrant liability</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Beginning balance</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"></td> <td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; width: 87%; padding-left: 9pt">Issuances of warrants</td> <td style="font-size: 10pt; width: 1%"> </td> <td style="font-size: 10pt; width: 1%; text-align: left"> </td> <td style="font-size: 10pt; width: 10%; text-align: right">1,612,417</td> <td style="font-size: 10pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Warrant exercises</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">(900,493</td> <td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 9pt">Change in fair value</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; border-bottom: black 1pt solid; text-align: left"> </td> <td style="font-size: 10pt; border-bottom: black 1pt solid; text-align: right">152,447</td> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 9pt">Ending balance</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; border-bottom: black 1pt solid; text-align: left"> </td> <td style="font-size: 10pt; border-bottom: black 1pt solid; text-align: right">864,371</td> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left"> </td></tr> </table>   There were no transfers between Level 1, Level 2 or Level 3 for the three and six months ended June 30, 2017 and year ended December 31, 2016.

The following tables present the Company’s fair value hierarchy for all its financial assets, in thousands, by major security type measured at fair value on a recurring basis as of June 30, 2017:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">June, 30 2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Estimated Fair Value</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td>Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"></td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"></td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"></td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td>Liabilities:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 64%">Common Stock Warrant Liability</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">864,371</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">864,371</td> <td style="width: 1%"> </td></tr> </table>

The following table summarizes the changes in the Company’s Level 3 warrant liability for the six months ended June 30, 2017:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">June 30, 2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant liability</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 9pt">Beginning balance</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; padding-left: 9pt">Issuances of warrants</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 10%; text-align: right">1,612,417</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 9pt">Warrant exercises</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(900,493</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left; padding-left: 9pt">Change in fair value</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">152,447</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt">Ending balance</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">864,371</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

NOTE 13: COMMITMENTS AND CONTINGENCIES   Lease Commitments   The future minimum lease payments due subsequent to June 30, 2017 under all non-cancelable operating and capital leases for the next five years are as follows:   <table cellspacing="0" cellpadding="0" align="center" style="width: 90%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font-weight: bold">Year Ending December 31,</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Operating Leases Amount</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; padding-bottom: 1pt">2017 (remainder of year)</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: black 1pt solid; text-align: left">$</td> <td style="width: 10%; border-bottom: black 1pt solid; text-align: right">4,930</td> <td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left">Total minimum lease payments</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4,930</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The total rent expense for the three and six months ended June 30, 2017 and June 30, 2016 was $7,395 and $18,540, respectively and $78,600 and $157,200, respectively. Rent expense was included in general and administrative expenses for both years.     Litigation and Contingencies   On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al., No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of the Company’s directors and officers and the underwriters of the Company’s November 2012 initial public offering.  The complaint alleges that all defendants violated Sections 11 and 12(a)(2), and that the Company and certain of its directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. This action seeks, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount.   On February 14, 2014, the Court appointed plaintiffs Miko Levi, Bandar Almosa and Gregory Harrison (collectively, the “Levi Group”) as lead plaintiffs, and approved their selection of co-lead counsel and liaison counsel. The Court also amended the caption of the case to read In re Atossa Genetics, Inc. Securities Litigation No. 2:13-cv-01836-RSM. An amended complaint was filed on April 15, 2014. The Company and other defendants filed motions to dismiss the amended complaint on May 30, 2014. The plaintiffs filed briefs in opposition to these motions on July 11, 2014. The Company replied to the opposition brief on August 11, 2014. On October 6, 2014 the Court granted defendants’ motion dismissing all claims against Atossa and all other defendants. The Court’s order provided plaintiffs with a deadline of October 26, 2014 to file a motion for leave to amend their complaint and the plaintiffs did not file such a motion by that date. On October 30, 2014, the Court entered a final order of dismissal. On November 3, 2014, plaintiffs filed a notice of appeal with the Court and have appealed the Court’s dismissal order to the U.S. Court of Appeals for the Ninth Circuit. The appeal was fully-briefed and oral arguments were held on May 18, 2017. We are currently awaiting a decision from the Court.   The Company believes this lawsuit is without merit and plans to defend itself vigorously; however, failure by the Company to obtain a favorable resolution of the claims set forth in the complaint could have a material adverse effect on the Company’s business, results of operations and financial condition. Currently, the amount of such material adverse effect cannot be reasonably estimated, and no provision or liability has been recorded for these claims as of June 30, 2017. The costs associated with defending and resolving the lawsuit and ultimate outcome cannot be predicted. These matters are subject to inherent uncertainties and the actual cost, as well as the distraction from the conduct of the Company’s business, will depend upon many unknown factors and management’s view of these may change in the future.

NOTE 14: STOCK BASED COMPENSATION     Stock Options and Incentive Plan   On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan, or the 2010 Plan, to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stockholder approval. An aggregate of 66,667 shares were initially reserved for issuance in connection with awards granted under the 2010 Plan and on May 18, 2016, an additional 133,333 shares were reserved for issuance under the 2010 Plan. On May 9, 2017, the stockholders approved an additional 1,500,000 shares for issuance under the 2010 Plan.   The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:   <table cellspacing="0" cellpadding="0" align="center" style="width: 90%; border-collapse: collapse; font-size: 11pt"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">January 1,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of shares</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td style="width: 86%; padding-left: 0.125in">2012</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">30,018</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.125in">2013</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">34,452</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td style="padding-left: 0.125in">2014</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">49,532</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.125in">2015</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">65,557</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td style="padding-left: 0.125in">2016</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">220,419</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.125in">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">151,477</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td style="padding-left: 0.125in">Total additional shares</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">551,455</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The Company granted 1,716,323 options to purchase shares of common stock during the six months ended June 30, 2017. No options were exercised during the three or six months ended June 30, 2017. There are 100,456 shares available for grant under the 2010 Plan as of June 30, 2017.   Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock based compensation expense of $181,408 and $200,187 for the three months ended June 30, 2017 and 2016, respectively and $336,115 and $392,664 for the six months ended June 30, 2017 and 2016, respectively. The fair value of stock options granted for the six months ended June 30, 2017 and 2016 was calculated using the Black-Scholes option-pricing model applying the following assumptions:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 11pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Period ended June 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2" nowrap="nowrap" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" nowrap="nowrap" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td style="width: 64%">Risk free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">1.86% - 2.04%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">1.48% - 1.55%</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected term</td> <td> </td> <td> </td> <td style="text-align: right">5.32- 6.36 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.58 - 6.06 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">- % </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">- % </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">112.86% - 114.19%</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">115.52% - 115.58%</td> <td> </td></tr> </table>   Options issued and outstanding as of June 30, 2017 and their activities during the six months then ended are as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Number of Underlying Shares</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Weighted- Average Exercise Price Per Share</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Weighted- Average Contractual Life Remaining in Years</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; padding-left: 0.125in; text-indent: -0.125in">Outstanding as of January 1, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 10%; text-align: right">378,924</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">26.25</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 10%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.25in; text-indent: -0.125in">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,716,323</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">.47</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-indent: -0.125in">Forfeited</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,167</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(19,081</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">25.05</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Outstanding as of June 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">2,072,999</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">4.10</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.25</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">51,512</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Exercisable as of June 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">229,158</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">31.65</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.44</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Vested and expected to vest</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">2,072,999</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td> <td style="text-align: right">4.10</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.26</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">51,512</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   At June 30, 2017, there were 1,840,530 unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately $1,427,000. This expense is expected to be recognized over a weighted-average period of 2.10 years.

744977

-1284066

1284066

-2568132

900488 1490833 878126 22362

3871636

NOTE 3: SUMMARY OF ACCOUNTING POLICIES   Basis of Presentation:   The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2016.   In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.   On August 26, 2016, the Company completed a 1-for-15 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 15 shares of issued and outstanding common stock were combined into one issued and outstanding share of Common Stock, and the par value per share was changed to $.015 per share. No fractional shares were issued because of the Reverse Stock Split and any fractional shares that would otherwise have resulted from the Reverse Stock Split were paid in cash. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on August 26, 2016. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split.   Use of Estimates:   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.   Financial Instruments with Characteristics of Both Liabilities and Equity:   During the three months ended June 30, 2017, the Company issued certain financial instruments, including warrants to purchase common stock, which have characteristics of both liability and equity. Financial instruments such as warrants that are classified as liabilities are fair valued upon issuance and are remeasured at fair value at subsequent reporting periods with the resulting change in fair value recorded in “change in fair value of common stock warrants”. The fair value of warrants is estimated using valuation models that require the input of subjective assumptions including stock price volatility, expected life, and the probability of future equity issuances and their impact to the price protection feature.    Recently Issued Accounting Pronouncements:   In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing U.S. GAAP. The new standard takes effect in 2019 for public business entities. The Company has not adopted the provisions of ASU No. 2016-02. The Company is currently evaluating the impact of adopting ASU 2016-02 on its consolidated financial statements.    In April 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation simplifying the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities and classification on the statements of cash flows. Under the new standard, all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) should be recognized as income tax expense or benefit on the statements of income. We adopted ASU No. 2016-09 effective January 1, 2017. As a result of the adoption of this guidance, we made an accounting policy election to recognize the effect of forfeitures in compensation cost when they occur. There was an immaterial impact on results of operations and financial position and no impact on cash flows at adoption.   In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The ASU is effective retrospectively for reporting periods beginning after December 15, 2017, with early adoption permitted. The Company has not yet adopted the provisions of ASU No. 2016-18 and does not expect it will have a material impact on the financial statements upon adoption   In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company has not yet determined when it will adopt the provisions of this Update and has not yet determined the impact on its consolidated financial statements upon adoption.

NOTE 8: STOCKHOLDERS’ EQUITY     The Company is authorized to issue a total of 85,000,000 shares of stock consisting of 75,000,000 shares of common stock, par value $0.015 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750,000 shares of Series A Junior Participating Preferred Stock, par value $0.001 per share, and 4,000 shares of Series A Convertible Preferred Stock, par value $0.001 per share through the filings of certificates of designation with the Delaware Secretary of State.    On May 19, 2014, the Company adopted a stockholder rights agreement which provides that all stockholders of record on May 26, 2014 received a non-taxable distribution of one preferred stock purchase right for each share of the Company’s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if one of the following occurs: (1) a person becomes an “Acquiring Person” by acquiring beneficial ownership of 15% or more of the Company’s common stock (or, in the case of a person who beneficially owned 15% or more of the Company’s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing 2.0% of the Company’s common stock then outstanding (excluding compensatory arrangements)), or (2) a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company’s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is $15.00, so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive $30.00 worth of the Company’s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.    2016 Issuances of Additional Shares to Aspire Capital   On November 11, 2015, we terminated our prior agreement with Aspire Capital Fund, LLC (“Aspire Capital”) and entered into a new common stock purchase agreement. Concurrently with entering into the new purchase agreement, we also entered into a registration rights agreement with Aspire Capital in which we agreed to register 405,747 shares of our common stock.   During the first quarter of 2016, we sold a total of 405,747 shares of common stock to Aspire Capital under the stock purchase agreement dated November 11, 2015 with aggregate gross proceeds to the Company of $2,177,083, or net proceeds of $2,133,973 after deducting costs of the offering.    On May 25, 2016, the Company terminated the November 11, 2015 stock purchase agreement with Aspire Capital and entered into a new common stock purchase agreement with Aspire Capital which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0 million of shares of our common stock over the 30-month term of the purchase agreement, subject to the terms and conditions set forth therein. Concurrently with entering into the purchase agreement, the Company also entered into a registration rights agreement with Aspire Capital, in which the Company agreed to file one or more registration statements, as permissible and necessary to register under the Securities Act of 1933, registering the sale of the shares of our common stock that have been and may be issued to Aspire Capital under the purchase agreement. As part of the stock purchase agreement we issued 49,736 common shares as a commitment fee. The value of the common shares issued as a commitment fee of $198,523 has been reflected as an addition to common stock of $746 and $197,777 in additional paid in capital which will be amortized over the life of the stock purchase agreement. As of the date of filing this Quarterly Report with the SEC no shares of stock have been sold to Aspire Capital under the May 25, 2016 purchase agreement. In connection with our public offering that closed on April 3, 2017, we agreed not to utilize the financing arrangement with Aspire Capital until June 30, 2017 and on June 30, 2017 in connection with the temporary modification of our common stock warrants to allow for the net exercise of those warrants we agreed to extend this stand still for an additional 45 days.   2016 Public Offering of Common Stock   In August 2016, the Company completed an underwritten public offering of 1,150,000 shares of common stock at a price per share of $2.50, with gross proceeds of $2,875,000 to the Company, or net proceeds of $2,561,896 after deducting underwriter discounts, commissions, non-accountable expense allowance and expense reimbursement.   2017 Public Offering of Class A and Class B Units Consisting of Common Stock, Series A Convertible Preferred Stock and Warrants   On March 28, 2017, the Company entered into an underwriting agreement with Aegis Capital Corp. relating to a public offering which closed on April 3, 2017. The offering generated gross proceeds to the Company of approximately $4.4 million and net proceeds of approximately $3.9 million after deducting underwriting discounts and commissions and other offering expenses paid by the Company.     The offering included 664,000 Class A Units at a public offering price of $0.75 per Class A Unit, which consisted of 664,000 shares of common stock and warrants to purchase 664,000 shares of common stock. The offering also included 3,502 Class B Units at a public offering price of $1,000 per Class B Unit, which consisted of 3,502 shares of Series A Convertible Preferred Stock convertible into a total of 4,669,333 shares of common stock and warrants to purchase 4,669,333 shares of common stock. In addition, the underwriter exercised the over-allotment to purchase an additional 530,000 shares of common stock and warrants to purchase 530,000 shares of common stock, which are included in the gross proceeds of $4.4 million. The warrants had a per share exercise price of $0.9375, are exercisable immediately and will expire five years from the date of issuance.    Series A Convertible Preferred Stock   The terms and provisions of our Series A Convertible Preferred Stock (the “Series A Preferred”) are as follows:    Rank.  The Series A Preferred ranks on parity to our Common Stock.   Conversion.  Each share of the Series A Preferred is convertible into 1,333.33 shares of our Common Stock (subject to adjustment as provided in the related certificate of designation of preferences, rights and limitations). Holders of Series A Preferred are prohibited from converting Series A Preferred into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our Common Stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to us.   Liquidation Preference.  In the event of our liquidation, dissolution or winding-up, holders of Series A Preferred will receive the same amount that a holder of Common Stock would receive if the Series A Preferred were fully converted into shares of our Common Stock at the conversion price (disregarding for such purposes any conversion limitations) which amounts shall be paid pari passu with all holders of Common Stock.   Voting Rights.  Shares of Series A Preferred will generally have no voting rights, except as required by law. However, as long as any shares of Series A Preferred are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred, (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders, (c) increase the number of authorized shares of Series A Preferred, or (d) enter into any agreement with respect to any of the foregoing.   Dividends.  Shares of Series A Preferred will not be entitled to receive any dividends, unless and until specifically declared by our board of directors. The holders of the Series A Preferred will participate, on an as-if-converted-to-common stock basis, in any dividends to the holders of common stock.   Redemption.  We are not obligated to redeem or repurchase any shares of Series A Preferred. Shares of Series A Preferred are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.   2017 Warrants   The terms and conditions of the warrants included in the 2017 public offering are as follows:   Exercisability. The warrants are exercisable at any time after April 3, 2017 and expire 5 years from issuance. The warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and, at any time a registration statement registering the issuance of the shares of common stock underlying the warrants under the Securities Act is effective and available for the issuance of such shares, or an exemption from registration under the Securities Act is available for the issuance of such shares, by payment in full in immediately available funds for the number of shares of Common Stock purchased upon such exercise. If a registration statement registering the issuance of the shares of Common Stock underlying the warrants under the Securities Act is not then effective or available, the holder may only exercise the Warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of Common Stock determined according to the formula set forth in the Warrant. No fractional shares of common stock will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.   Exercise Limitation. A holder will not have the right to exercise any portion of the Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days’ prior notice from the holder to us.   Exercise Price. The exercise price of the warrants was initially $0.9375, which was reduced to $0.26 on June 30, 2017. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock. The exercise price may also be adjusted downwards if we issue additional Common Stock (or equivalents) at a price below the exercise price of the Warrants while the Warrants remain outstanding.   Transferability. Subject to applicable laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent. There is currently no trading market for the warrants and a trading market may not develop.   Fundamental Transactions. In the event of a fundamental transaction, as described in the warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the holders of the warrants will be entitled to receive, upon any subsequent exercise of the warrants and for each share of our Common Stock that would have been issuable upon such exercise immediately prior to the occurrence of a fundamental transaction, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable as a result of such fundamental transaction by a holder of the number of shares of Common Stock for which the warrants are exercisable immediately prior to such fundamental transaction. The holder of the Warrant may also require us or any successor entity to purchase the Warrant from the holder by paying to the holder an amount of cash equal to the Black Scholes value of the remaining unexercised portion of the Warrant on the date of or within 30 days after consummation of the fundamental transaction.   Rights as a Stockholder. Except as otherwise provided in the warrants or by virtue of such holder’s ownership of shares of our Common Stock, the holder of a Warrant does not have the rights or privileges of a holder of our Common Stock, including any voting rights, until the holder exercises the Warrant.   Accounting Treatment   The Company allocated the proceeds from the sale of the Class A and Class B units to the separate securities issued. The Company determined that, on the date of issuance, the warrants were not considered indexed to its own stock because the underlying instruments were not “fixed-for-fixed” due to the price protection and fundamental transaction provisions and, therefore, the warrants should be accounted for as liabilities. At the end of each reporting period, the changes in fair value of the warrants during the period are recorded in non-operating income (expense) in the consolidated statement of operations.   The Company allocated the amount representing the fair value of the warrants at the date of issuance separately to the warrant liability and recorded the remaining proceeds as common stock, in the case of the Class A units, or as Series A convertible preferred stock, in the case of the Class B units. Due to the allocation of a portion of the proceeds to the warrants, the Series A convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of $1,284,066 based on the intrinsic value of the beneficial conversion feature. The discount on the Series A convertible preferred stock of $1,284,066 caused by allocation of the proceeds to the warrant was recorded as a deemed dividend upon issuance of the Series A convertible preferred stock. As a result, total deemed dividends of $2,568,132 was recorded upon issuance of the Series A convertible preferred stock, which is reflected as an addition to net loss in the consolidated statement of operations to arrive at net loss applicable to common shareholders.   Net Exercise of 2017 Warrants   On June 29, 2017, the Company offered to modify the rights of the holders of the warrants issued in the public offering the Company completed on April 3, 2017. The temporary modification included (a) lowering the exercise price of the warrants to $0.26 per share, (b) setting the applicable volume-weighted average price (VWAP) at $0.52 per share, and (c) allowing for temporary cashless exercise of the warrants for all holders that accepted the temporary modification before 8:00 a.m. Eastern daylight time on June 30, 2017. Holders of warrants to purchase a total of approximately 3.0 million shares of Common Stock accepted the offer resulting in the cancellation of those warrants and the issuance by the Company of a total of approximately1.5 million shares of Common Stock (including shares held in abeyance). The shares of Common Stock are registered under the Securities Act of 1933, as amended. If delivery of the shares of Common Stock pursuant to the foregoing would result in the holder exceeding the 4.99% “Beneficial Ownership Limitation” (as defined in the warrant) then the shares in excess of such 4.99% will be held in abeyance by the Company pending further instruction from the holder. In connection with the temporary modification, the Company agreed to extend the “Lock-up Period” of the underwriting agreement between the Company and Aegis Capital Corp., dated March 28, 2017, by 45 days and the Company agreed not to enter into any further amendments to the warrants during such extended Lock-up Period without the prior written consent of each holder. Upon exercise of these warrants, the amount of the warrant liability at the date of exercise was reclassified from warrant liability to additional paid-in capital.   The following table summarizes the 2017 liability warrant activity:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td>Outstanding as of December 31, 2016</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="width: 74%">Warrants granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 10%">5,863,332</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 10%">0.9375</td> <td style="width: 1%"> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td>Warrants exercised</td> <td> </td> <td> </td> <td style="text-align: right">(2,991,666</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">0.26</td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Warrants cancelled</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td style="padding-bottom: 1pt">Outstanding as of June 30, 2017</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,871,666</td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.26</td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td></tr> </table>   The Company estimated the fair value of the warrants using the Monte Carlo simulation (MCS) model, which is a type of income approach, where the current value of an asset is expressed as the sum of probable future cash flows across various scenarios and time frames discounted for risk and time. The significant assumptions include timing of future rounds of financing, timing and success rates of oncology clinical trials, and the probability of a merger and acquisition adjusted for a lack of marketability discount. The MCS model also includes a full term and an early conversion scenario that are each weighted at 50% in the final concluded fair value.    Inputs used in the valuation of the warrants at the issuance date of April 3, 2017 and June 30, 2017 were as follows:    <table cellspacing="0" cellpadding="0" style="width: 70%; border-collapse: collapse; font-size: 10pt"> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Initial valuation</td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="width: 85%">Common stock price</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">0.75</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Exercise price</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.9375</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected Volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">50</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Dividend Yield</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0</td> <td style="text-align: left">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Risk-Free Interest Rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.79% - 1.88</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Expected Term (years)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.24 - 5</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>June 30, 2017 valuation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Common stock price</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.50</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Exercise price</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.26</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected Volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">50</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Dividend Yield</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0</td> <td style="text-align: left">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Risk-Free Interest Rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.79% - 1.88</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Expected Term (years)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.08-4.76</td> <td style="text-align: left"> </td></tr> </table>   Outstanding Warrants   As of June 30, 2017, warrants to purchase 3,273,894 shares of common stock were outstanding including:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 11pt"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding Warrants to Purchase Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td style="width: 43%">2011 private placement</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 15%">283,470</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 15%">18.75 - 24.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 20%">May 8, 2018</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Acueity warrants</td> <td> </td> <td> </td> <td style="text-align: right">21,667</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">75.00</td> <td> </td> <td> </td> <td style="text-align: right">September 30, 2017</td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td>2014 public offering</td> <td> </td> <td> </td> <td style="text-align: right">77,790</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">45.00</td> <td> </td> <td> </td> <td style="text-align: right">January 29, 2019</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Placement agent fees for Company’s offerings</td> <td> </td> <td> </td> <td style="text-align: right">16,135</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">31.80 - 186.45</td> <td> </td> <td> </td> <td style="text-align: right">March - November, 2018</td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td>Outside consulting</td> <td> </td> <td> </td> <td style="text-align: right">3,166</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">63.60</td> <td> </td> <td> </td> <td style="text-align: right">January 14, 2018</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">2017 public offering</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,871,666</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">0.26</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">April 3, 2022</td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3,273,894</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td></tr> </table>   Conversion of Series A Convertible Preferred Stock   During the three months ended June 30, 2017, certain holders of the Series A Convertible Preferred Stock exercised their conversion option and converted an aggregate of 2,663 shares of Series A Convertible Preferred Stock into 3,550,664 shares of the Company’s common stock based on the conversion ratio of 1,333.33 shares of Series A Convertible Preferred Stock to common stock.

NOTE 10: NET LOSS PER SHARE   The Company accounts for and discloses net loss per common share in accordance with FASB Accounting Standards Codification (“ASC”) Topic 260, Earnings Per Share. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the conversion of Series A preferred stock, and potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.    The following table summarizes the Company’s calculation of net loss per common share:     <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30,</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Six Months Ended June 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Net Loss Per share</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 0.125in">Numerator</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.9pt; width: 64%">Net loss</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 6%">2,241,489</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 6%">1,722,383</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 6%">3,945,043</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 6%">4,049,920</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Deemed dividend attributable to preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">2,568,132</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">2,568,132</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Net loss attributable to common shareholders</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">4,809,621</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,722,383</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">6,513,175</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">4,049,920</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Denominator</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Weighted average common shares outstanding</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,476,046</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,587,871</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,641,671</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,485,853</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Basic and diluted net loss per share</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.64</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.67</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1.15</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1.63</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>     The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the three months and six months ended June 30, 2017 and 2016 because the effect of them would be anti-dilutive:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Three Months Ended   June 30,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Six Months Ended June 30,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 48%">Options to purchase common stock</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">1,121,567</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">394,090</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">754,093</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">394,090</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Series A convertible preferred stock</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,184,356</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,098,212</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,139,797</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">402,228</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,286,862</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">402,228</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">9,445,720</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">796,318</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">5,139,167</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">796,318</td></tr> </table>

Basis of Presentation:   The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2016.   In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.   On August 26, 2016, the Company completed a 1-for-15 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 15 shares of issued and outstanding common stock were combined into one issued and outstanding share of Common Stock, and the par value per share was changed to $.015 per share. No fractional shares were issued because of the Reverse Stock Split and any fractional shares that would otherwise have resulted from the Reverse Stock Split were paid in cash. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on August 26, 2016. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split.

Financial Instruments with Characteristics of Both Liabilities and Equity:   During the three months ended June 30, 2017, the Company issued certain financial instruments, including warrants to purchase common stock, which have characteristics of both liability and equity. Financial instruments such as warrants that are classified as liabilities are fair valued upon issuance and are remeasured at fair value at subsequent reporting periods with the resulting change in fair value recorded in “change in fair value of common stock warrants”. The fair value of warrants is estimated using valuation models that require the input of subjective assumptions including stock price volatility, expected life, and the probability of future equity issuances and their impact to the price protection feature.

Recently Issued Accounting Pronouncements:   In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing U.S. GAAP. The new standard takes effect in 2019 for public business entities. The Company has not adopted the provisions of ASU No. 2016-02. The Company is currently evaluating the impact of adopting ASU 2016-02 on its consolidated financial statements.   In April 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation simplifying the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities and classification on the statements of cash flows. Under the new standard, all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) should be recognized as income tax expense or benefit on the statements of income. We adopted ASU No. 2016-09 effective January 1, 2017. As a result of the adoption of this guidance, we made an accounting policy election to recognize the effect of forfeitures in compensation cost when they occur. There was an immaterial impact on results of operations and financial position and no impact on cash flows at adoption.   In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The ASU is effective retrospectively for reporting periods beginning after December 15, 2017, with early adoption permitted. The Company has not yet adopted the provisions of ASU No. 2016-18 and does not expect it will have a material impact on the financial statements upon adoption   In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company has not yet determined when it will adopt the provisions of this Update and has not yet determined the impact on its consolidated financial statements upon adoption.

The following table summarizes the Company’s calculation of net loss per common share:     <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30,</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Six Months Ended June 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Net Loss Per share</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 0.125in">Numerator</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.9pt; width: 64%">Net loss</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 6%">2,241,489</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 6%">1,722,383</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 6%">3,945,043</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 6%">4,049,920</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Deemed dividend attributable to preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">2,568,132</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">2,568,132</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Net loss attributable to common shareholders</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">4,809,621</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,722,383</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">6,513,175</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">4,049,920</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Denominator</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Weighted average common shares outstanding</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,476,046</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,587,871</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,641,671</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,485,853</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Basic and diluted net loss per share</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.64</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.67</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1.15</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1.63</td></tr> </table>

434733

-328350 -328350 1612416 Conversion ratio of 1,333.33 shares of Series A Convertible Preferred Stock to common stock.

EX-101.SCH 7 atos-20170630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SUMMARY OF ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PREPAID EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - FURNITURE AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - PAYROLL LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - CONCENTRATION OF CREDIT RISK link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - STOCK BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - PREPAID EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - FURNITURE AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PAYROLL LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCK BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - PREPAID EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - FURNITURE AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - FURNITURE AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - INTANGIBLE ASSETS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - PAYROLL LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - NET LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - NET LOSS PER SHARE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - CONCENTRATION OF CREDIT RISK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - STOCK BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - STOCK BASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - STOCK BASED COMPENSATION (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - STOCK BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 atos-20170630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 atos-20170630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 atos-20170630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Class of Stock [Axis] Reverse Stock Split [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Software [Member] Range [Axis] Minimum [Member] Maximum [Member] Plan Name [Axis] 2011 Private Placement [Member] Acueity Warrants [Member] 2014 Public Offering [Member] Placement Agent Fee [Member] Outside Consulting Firm [Member] Series A Preferred Stock [Member] Related Party [Axis] Beneficial Owner [Member] Aspire Capital Fund LLC [Member] Type of Arrangement and Non-arrangement Transactions [Axis] New Common Stock Purchase Agreement [Member] Stock Purchase Agreement [Member] Sale of Stock [Axis] 2016 Public Offering [Member] Antidilutive Securities [Axis] Equity Option [Member] Warrant [Member] 2012 [Member] 2013 [Member] 2014 [Member] 2015 [Member] 2016 [Member] Stock Option and Incentive Plan 2010 [Member] 2017 [Member] 2017 Public Offering [Member] Underwriting Agreement [Member] Legal Entity [Axis] Aegis Capital Corp [Member] Class A Units [Member] Common Stock and Warrants [Member] Class B Units [Member] Series A Convertible Preferred Stock Convertible [Member] Over-Allotment Option [Member] Scientific Advisor [Member] Series A Convertible Preferred Stock [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Stock Option and Incentive Plan [Member] 2017 Warrants [Member] Additional Paid-in Capital [Member] Measurement Frequency [Axis] Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Level 3 [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Trading Symbol Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] Assets Current assets Cash and cash equivalents Restricted cash Prepaid expenses Other accounts receivable Total current assets Furniture and equipment, net Intangible assets, net Other assets Total assets Liabilities and Stockholders' Equity Current liabilities Accounts payable Accrued expenses Payroll liabilities Common stock warrant liability Other current liabilities Total current liabilities Commitments and contingencies (note 13) Stockholders' equity Preferred stock Additional paid in capital- Series A convertible preferred stock Common stock - $.015 par value; 75,000,000 shares authorized, 10,032,410 and 3,786,913 shares issued and outstanding, as of June 30, 2017 and December 31, 2016, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] Operating expenses: Research and development General and administrative Total operating expenses Operating loss Change in fair value of common stock warrants Warrant financing expense Other income (expense), net Loss before income taxes Income taxes Net loss Deemed dividends attributable to Series A Preferred Stock Net loss applicable to common stockholders Loss per common share - basic and diluted (in dollars per share) Weighted average shares outstanding, basic and diluted (in shares) Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance, beginning Balance, beginning (in shares) Issuance of common stock in Class A units, net of issuance costs of $65,816 Issuance of common stock in Class A units, net of issuance costs of $65,816 (in shares) Allocation of Class A unit proceeds to warrant liability Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231 Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231 (in shares) Allocation of Series A convertible preferred stock to warrants and beneficial conversion feature Deemed Dividend on Series A Convertible Preferred Stock Conversion of Series A Convertible Preferred Stock to common stock Conversion of Series A Convertible Preferred Stock to common stock (in shares) Reclassification of warrant liability upon net cashless exercise of common stock warrants Reclassification of warrant liability upon net cashless exercise of common stock warrants (in shares) Issuance of common stock upon warrant exercise for cash Issuance of common stock upon warrant exercise for cash (in shares) Shares tendered for liability warrant exercise Shares tendered for liability warrant exercise (in shares) Amortization of commitment shares Compensation cost for stock options granted to executives and employees Net loss Balance, ending Balance, ending (in shares) Statement of Stockholders' Equity [Abstract] Payments of stock issuance costs Payments of Series A Convertible Preferred Stock issuance costs Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Compensation cost for stock options granted Loss on disposal of intangible asset Depreciation and amortization Change in fair value of common stock warrants Warrant financing expense Changes in operating assets and liabilities: Change in restricted cash Prepaid expenses Other assets Accounts payable Payroll liabilities Accrued expenses Other current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of furniture and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issuance of Class A and Class B Units, net of issuance costs Proceeds from issuance of common stock, net of issuance costs Net cash provided by financing activities NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, BEGINNING BALANCE CASH AND CASH EQUIVALENTS, ENDING BALANCE SUPPLEMENTAL DISCLOSURES: Interest paid NONCASH INVESTING AND FINANCING ACTIVITIES: Common stock issued for cashless exercise of common stock warrants Amount receivable for warrant exercise Allocation of Class A and Class B Unit proceeds to warrant liability Common stock issued as commitment fee under stock purchase agreement Amortization of commitment shares Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS GOING CONCERN Accounting Policies [Abstract] SUMMARY OF ACCOUNTING POLICIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Prepaid Expenses Property, Plant and Equipment [Abstract] EX-101.PRE 11 atos-20170630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 14, 2017
Document And Entity Information
Entity Registrant Name	ATOSSA GENETICS INC
Entity Central Index Key	0001488039
Document Type	10-Q
Trading Symbol	ATOS
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		117,010,75.
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 3,690,023	$ 3,027,962
Restricted cash	55,000	55,000
Prepaid expenses	228,370	171,601
Other accounts receivable	2,736
Total current assets	3,976,129	3,254,563
Furniture and equipment, net	18,989	55,119
Intangible assets, net	585,683	640,440
Other assets	128,577	194,250
Total assets	4,709,378	4,144,372
Current liabilities
Accounts payable	495,811	254,320
Accrued expenses	44,017	16,964
Payroll liabilities	482,420	769,899
Common stock warrant liability	864,371
Other current liabilities	19,157	6,083
Total current liabilities	1,905,776	1,047,266
Commitments and contingencies (note 13)
Stockholders' equity
Preferred stock
Additional paid in capital- Series A convertible preferred stock	744,977
Common stock - $.015 par value; 75,000,000 shares authorized, 10,032,410 and 3,786,913 shares issued and outstanding, as of June 30, 2017 and December 31, 2016, respectively	150,486	56,804
Additional paid-in capital	63,126,929	60,344,050
Accumulated deficit	(61,248,791)	(57,303,748)
Total stockholders' equity	2,803,602	3,097,106
Total liabilities and stockholders' equity	4,709,378	4,144,372
Series A Convertible Preferred Stock Convertible [Member]
Stockholders' equity
Preferred stock	$ 1

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.015	$ 0.015
Common stock, authorized	75,000,000	75,000,000
Common stock, issued	10,032,410	3,786,913
Common stock, outstanding	10,032,410	3,786,913
Series A Convertible Preferred Stock Convertible [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	4,000	0
Preferred stock, issued	839	0
Preferred stock, outstanding	839	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Operating expenses:
Research and development	$ 824,094	$ 168,992	$ 1,368,396	$ 318,963
General and administrative	1,072,169	1,553,391	2,214,712	3,730,960
Total operating expenses	1,896,263	1,722,383	3,583,108	4,049,923
Operating loss	(1,896,263)	(1,722,383)	(3,583,108)	(4,049,923)
Change in fair value of common stock warrants	(152,447)		(152,447)
Warrant financing expense	(192,817)		(192,817)
Other income (expense), net	38		(16,671)
Loss before income taxes	(2,241,489)	(1,722,383)	(3,945,043)	(4,049,923)
Income taxes
Net loss	(2,241,489)	(1,722,383)	(3,945,043)	(4,049,923)
Deemed dividends attributable to Series A Preferred Stock	(2,568,132)		(2,568,132)
Net loss applicable to common stockholders	$ (4,809,621)	$ (1,722,383)	$ (6,513,175)	$ (4,049,923)
Loss per common share - basic and diluted (in dollars per share)	$ (0.64)	$ (0.67)	$ (1.15)	$ (1.63)
Weighted average shares outstanding, basic and diluted (in shares)	7,476,046	2,587,871	5,641,671	2,485,853

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) - 6 months ended Jun. 30, 2017 - USD ($)	Series A Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance, beginning at Dec. 31, 2016			$ 56,804	$ 60,344,050	$ (57,303,748)	$ 3,097,106
Balance, beginning (in shares) at Dec. 31, 2016			3,786,913			3,786,913
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in Class A units, net of issuance costs of $65,816			$ 17,910	811,774		$ 829,684
Issuance of common stock in Class A units, net of issuance costs of $65,816 (in shares)			1,194,000
Allocation of Class A unit proceeds to warrant liability				(328,350)		(328,350)
Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231	$ 4	$ 3,234,769				3,234,773
Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231 (in shares)	3,502
Allocation of Series A convertible preferred stock to warrants and beneficial conversion feature		(2,568,132)		1,284,066		(1,284,066)
Deemed Dividend on Series A Convertible Preferred Stock		2,568,132	$ 2,568,132	(2,568,132)
Conversion of Series A Convertible Preferred Stock to common stock	$ (3)	(2,459,792)	$ 53,260	$ 2,406,535
Conversion of Series A Convertible Preferred Stock to common stock (in shares)	(2,663)		3,550,664
Reclassification of warrant liability upon net cashless exercise of common stock warrants			$ 22,362
Reclassification of warrant liability upon net cashless exercise of common stock warrants (in shares)			1,490,833	878,126		900,488
Issuance of common stock upon warrant exercise for cash			$ 150	$ 2,450		$ 2,600
Issuance of common stock upon warrant exercise for cash (in shares)			10,000
Shares tendered for liability warrant exercise			$ (22,362)	(775,233)		(797,595)
Shares tendered for liability warrant exercise (in shares)			(1,490,833)
Amortization of commitment shares				(39,705)		(39,705)
Compensation cost for stock options granted to executives and employees				336,115		336,115
Net loss					(3,945,043)	(3,945,043)
Balance, ending at Jun. 30, 2017	$ 1	$ 774,977	$ 150,486	$ 63,126,929	$ (61,248,791)	$ 2,803,602
Balance, ending (in shares) at Jun. 30, 2017	839		10,032,410			10,032,410

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical)	6 Months Ended
	Jun. 30, 2017 USD ($)
Statement of Stockholders' Equity [Abstract]
Payments of stock issuance costs	$ 65,816
Payments of Series A Convertible Preferred Stock issuance costs	$ 267,231

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,945,043)	$ (4,049,923)
Compensation cost for stock options granted	336,115	392,664
Loss on disposal of intangible asset	17,695	163,333
Depreciation and amortization	73,193	152,574
Change in fair value of common stock warrants	152,447
Warrant financing expense	192,817
Changes in operating assets and liabilities:
Change in restricted cash		220,000
Prepaid expenses	(56,769)	(15,836)
Other assets	25,831	110,527
Accounts payable	241,491	(531,657)
Payroll liabilities	(287,479)	(666,368)
Accrued expenses	27,053	(387,903)
Other current liabilities	13,074	(41,473)
Net cash used in operating activities	(3,209,575)	(4,654,062)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture and equipment		(4,941)
Net cash used in investing activities		(4,941)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Class A and Class B Units, net of issuance costs	3,871,636
Proceeds from issuance of common stock, net of issuance costs		2,133,974
Net cash provided by financing activities	3,871,636	2,133,974
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	662,061	(2,525,029)
CASH AND CASH EQUIVALENTS, BEGINNING BALANCE	3,027,962	3,715,895
CASH AND CASH EQUIVALENTS, ENDING BALANCE	3,690,023	1,190,866
SUPPLEMENTAL DISCLOSURES:
Interest paid		383
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for cashless exercise of common stock warrants	900,488
Amount receivable for warrant exercise	2,600
Allocation of Class A and Class B Unit proceeds to warrant liability	1,612,416
Common stock issued as commitment fee under stock purchase agreement		198,523
Amortization of commitment shares	$ 39,705	$ 6,617

XML 19 R8.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

NOTE 1: NATURE OF OPERATIONS

XML 20 R9.htm IDEA: XBRL DOCUMENT

GOING CONCERN

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 2: GOING CONCERN

XML 21 R10.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

SUMMARY OF ACCOUNTING POLICIES

NOTE 3: SUMMARY OF ACCOUNTING POLICIES

Basis of Presentation:

Use of Estimates:

Financial Instruments with Characteristics of Both Liabilities and Equity:

Recently Issued Accounting Pronouncements:

XML 22 R11.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES

6 Months Ended

Jun. 30, 2017

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses

NOTE 4: PREPAID EXPENSES

Prepaid expenses consisted of the following:

	June 30, 2017		December 31, 2016
Prepaid insurance		156,532		121,333
Trade show				20,000
Retainer and security deposits		29,968		14,218
Financial exchange fees		21,000
Other		20,870		16,050
Total prepaid expenses	$	228,370	$	171,601

XML 23 R12.htm IDEA: XBRL DOCUMENT

FURNITURE AND EQUIPMENT

6 Months Ended

Jun. 30, 2017

Property, Plant and Equipment [Abstract]

FURNITURE AND EQUIPMENT

NOTE 5: FURNITURE AND EQUIPMENT

Furniture and equipment consisted of the following:

	June 30, 2017			December 31, 2016
Furniture and equipment	$	170,916		$	210,528
Less: Accumulated depreciation		(151,927	)		(155,409	)
Total furniture and equipment, net	$	18,989		$	55,119

Depreciation expense for the three months ended June 30, 2017 and 2016 was $8,773 and $32,734, respectively, and $18,434, and $62,353, for the six months ended June 30, 2017 and 2016, respectively.

XML 24 R13.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 6: INTANGIBLE ASSETS

Intangible assets consisted of the following:

	June 30, 2017			December 31, 2016
Patents	$	639,000		$	639,000
Software		113,540			113,540
Total intangible assets		752,540			752,540
Less: Accumulated amortization		(166,857	)		(112,100	)
Total intangible assets, net	$	585,683		$	640,440

Future estimated amortization expenses as of June 30, 2017 for the five succeeding years is as follows:

For the years ending December 31,	Amounts
2017 (includes the remainder of the year)	$	48,282
2018		73,433
2019		70,285
2020		70,285
2021		70,285
Thereafter		253,113
	$	585,683

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

PAYROLL LIABILITIES

6 Months Ended

Jun. 30, 2017

Payables and Accruals [Abstract]

PAYROLL LIABILITIES

NOTE 7: PAYROLL LIABILITIES

Payroll liabilities consisted of the following:

	June 30, 2017		December 31, 2016
Accrued bonus payable	$	280,008	$	609,337
Accrued vacation		134,865		94,514
Accrued payroll liabilities		67,547		66,048
Total payroll liabilities	$	482,420	$	769,899

XML 26 R15.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 8: STOCKHOLDERS’ EQUITY

2016 Issuances of Additional Shares to Aspire Capital

2016 Public Offering of Common Stock

2017 Public Offering of Class A and Class B Units Consisting of Common Stock, Series A Convertible Preferred Stock and Warrants

Series A Convertible Preferred Stock

The terms and provisions of our Series A Convertible Preferred Stock (the “Series A Preferred”) are as follows:

Rank. The Series A Preferred ranks on parity to our Common Stock.

2017 Warrants

The terms and conditions of the warrants included in the 2017 public offering are as follows:

Accounting Treatment

Net Exercise of 2017 Warrants

The following table summarizes the 2017 liability warrant activity:

	Shares			Weighted Average Exercise Price
Outstanding as of December 31, 2016
Warrants granted		5,863,332		$	0.9375
Warrants exercised		(2,991,666	)		0.26
Warrants cancelled
Outstanding as of June 30, 2017		2,871,666		$	0.26

Inputs used in the valuation of the warrants at the issuance date of April 3, 2017 and June 30, 2017 were as follows:

Initial valuation
Common stock price	$	0.75
Exercise price	$	0.9375
Expected Volatility		50	%
Dividend Yield		0	%
Risk-Free Interest Rate		0.79% - 1.88	%
Expected Term (years)		0.24 - 5

June 30, 2017 valuation
Common stock price	$	0.50
Exercise price	$	0.26
Expected Volatility		50	%
Dividend Yield		0	%
Risk-Free Interest Rate		0.79% - 1.88	%
Expected Term (years)		0.08-4.76

Outstanding Warrants

As of June 30, 2017, warrants to purchase 3,273,894 shares of common stock were outstanding including:

	Outstanding Warrants to Purchase Shares		Exercise Price		Expiration Date

2011 private placement		283,470	$	18.75 - 24.00	May 8, 2018
Acueity warrants		21,667		75.00	September 30, 2017
2014 public offering		77,790		45.00	January 29, 2019
Placement agent fees for Company’s offerings		16,135		31.80 - 186.45	March - November, 2018
Outside consulting		3,166		63.60	January 14, 2018
2017 public offering		2,871,666		0.26	April 3, 2022
		3,273,894

Conversion of Series A Convertible Preferred Stock

XML 27 R16.htm IDEA: XBRL DOCUMENT

FAIR VALUE OF FINANCIAL INSTRUMENTS

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

FAIR VALUE OF FINANCIAL INSTRUMENTS

NOTE 9: FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair value hierarchy is broken down into the three input levels summarized below:

● Level 3 —Valuations based on unobservable inputs in which there are little or no market data, which require the Company to develop its own assumptions.

The following tables present the Company’s fair value hierarchy for all its financial assets, in thousands, by major security type measured at fair value on a recurring basis as of June 30, 2017:

	June, 30 2017
	Estimated Fair Value		Level 1	Level 2	Level 3
Assets:
	$		$	$	$
Liabilities:
Common Stock Warrant Liability	$	864,371			$	864,371

There were no financial assets outstanding that were required to be measured at fair value at December 31, 2016.

The following table summarizes the changes in the Company’s Level 3 warrant liability for the six months ended June 30, 2017:

	June 30, 2017
Warrant liability
Beginning balance	$
Issuances of warrants		1,612,417
Warrant exercises		(900,493	)
Change in fair value		152,447
Ending balance		864,371

There were no transfers between Level 1, Level 2 or Level 3 for the three and six months ended June 30, 2017 and year ended December 31, 2016.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

NET LOSS PER SHARE

NOTE 10: NET LOSS PER SHARE

The following table summarizes the Company’s calculation of net loss per common share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Net Loss Per share
Numerator

Net loss	$	2,241,489	$	1,722,383	$	3,945,043	$	4,049,920
Deemed dividend attributable to preferred stock	$	2,568,132			$	2,568,132
Net loss attributable to common shareholders	$	4,809,621	$	1,722,383	$	6,513,175	$	4,049,920
Denominator
Weighted average common shares outstanding		7,476,046		2,587,871		5,641,671		2,485,853
Basic and diluted net loss per share	$	0.64	$	0.67	$	1.15	$	1.63

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Options to purchase common stock		1,121,567		394,090		754,093		394,090
Series A convertible preferred stock		2,184,356				1,098,212
Warrants to purchase common stock		6,139,797		402,228		3,286,862		402,228
Total		9,445,720		796,318		5,139,167		796,318

XML 29 R18.htm IDEA: XBRL DOCUMENT

INCOME TAXES

6 Months Ended

Jun. 30, 2017

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 11: INCOME TAXES

XML 30 R19.htm IDEA: XBRL DOCUMENT

CONCENTRATION OF CREDIT RISK

6 Months Ended

Jun. 30, 2017

Risks and Uncertainties [Abstract]

CONCENTRATION OF CREDIT RISK

NOTE 12: CONCENTRATION OF CREDIT RISK

XML 31 R20.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 13: COMMITMENTS AND CONTINGENCIES

Lease Commitments

The future minimum lease payments due subsequent to June 30, 2017 under all non-cancelable operating and capital leases for the next five years are as follows:

Year Ending December 31,	Operating Leases Amount
2017 (remainder of year)	$	4,930
Total minimum lease payments	$	4,930

Litigation and Contingencies

XML 32 R21.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK BASED COMPENSATION

NOTE 14: STOCK BASED COMPENSATION

Stock Options and Incentive Plan

The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:

January 1,	Number of shares
2012		30,018
2013		34,452
2014		49,532
2015		65,557
2016		220,419
2017		151,477
Total additional shares		551,455

	Period ended June 30,
	2017		2016

Risk free interest rate		1.86% - 2.04%		1.48% - 1.55%
Expected term		5.32- 6.36 years		5.58 - 6.06 years

Dividend yield		- %		- %
Expected volatility		112.86% - 114.19%		115.52% - 115.58%

Options issued and outstanding as of June 30, 2017 and their activities during the six months then ended are as follows:

	Number of Underlying Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2017		378,924		$	26.25			$
Granted		1,716,323			.47
Forfeited		(3,167	)		15.00
Expired		(19,081	)		25.05
Outstanding as of June 30, 2017		2,072,999			4.10		9.25	$	51,512
Exercisable as of June 30, 2017		229,158			31.65		7.44	$	—
Vested and expected to vest		2,072,999		$	4.10		9.26	$	51,512

XML 33 R22.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 15: SUBSEQUENT EVENTS

XML 34 R23.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Policies)	6 Months Ended
SUMMARY OF ACCOUNTING POLICIES (Policies)	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2016. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. On August 26, 2016, the Company completed a 1-for-15 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 15 shares of issued and outstanding common stock were combined into one issued and outstanding share of Common Stock, and the par value per share was changed to $.015 per share. No fractional shares were issued because of the Reverse Stock Split and any fractional shares that would otherwise have resulted from the Reverse Stock Split were paid in cash. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on August 26, 2016. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split.
Use of Estimates	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Financial Instruments with Characteristics of Both Liabilities and Equity:	Financial Instruments with Characteristics of Both Liabilities and Equity: During the three months ended June 30, 2017, the Company issued certain financial instruments, including warrants to purchase common stock, which have characteristics of both liability and equity. Financial instruments such as warrants that are classified as liabilities are fair valued upon issuance and are remeasured at fair value at subsequent reporting periods with the resulting change in fair value recorded in “change in fair value of common stock warrants”. The fair value of warrants is estimated using valuation models that require the input of subjective assumptions including stock price volatility, expected life, and the probability of future equity issuances and their impact to the price protection feature.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements: In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing U.S. GAAP. The new standard takes effect in 2019 for public business entities. The Company has not adopted the provisions of ASU No. 2016-02. The Company is currently evaluating the impact of adopting ASU 2016-02 on its consolidated financial statements. In April 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation simplifying the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities and classification on the statements of cash flows. Under the new standard, all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) should be recognized as income tax expense or benefit on the statements of income. We adopted ASU No. 2016-09 effective January 1, 2017. As a result of the adoption of this guidance, we made an accounting policy election to recognize the effect of forfeitures in compensation cost when they occur. There was an immaterial impact on results of operations and financial position and no impact on cash flows at adoption. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The ASU is effective retrospectively for reporting periods beginning after December 15, 2017, with early adoption permitted. The Company has not yet adopted the provisions of ASU No. 2016-18 and does not expect it will have a material impact on the financial statements upon adoption In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company has not yet determined when it will adopt the provisions of this Update and has not yet determined the impact on its consolidated financial statements upon adoption.

XML 35 R24.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES (Tables)

6 Months Ended

Jun. 30, 2017

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of prepaid expenses

Prepaid expenses consisted of the following:

	June 30, 2017		December 31, 2016
Prepaid insurance		156,532		121,333
Trade show				20,000
Retainer and security deposits		29,968		14,218
Financial exchange fees		21,000
Other		20,870		16,050
Total prepaid expenses	$	228,370	$	171,601

XML 36 R25.htm IDEA: XBRL DOCUMENT

FURNITURE AND EQUIPMENT (Tables)

6 Months Ended

Jun. 30, 2017

Property, Plant and Equipment [Abstract]

Schedule of furniture and equipment

Furniture and equipment consisted of the following:

	June 30, 2017			December 31, 2016
Furniture and equipment	$	170,916		$	210,528
Less: Accumulated depreciation		(151,927	)		(155,409	)
Total furniture and equipment, net	$	18,989		$	55,119

XML 37 R26.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

Intangible assets consisted of the following:

	June 30, 2017			December 31, 2016
Patents	$	639,000		$	639,000
Software		113,540			113,540
Total intangible assets		752,540			752,540
Less: Accumulated amortization		(166,857	)		(112,100	)
Total intangible assets, net	$	585,683		$	640,440

Schedule of future amortization expense

Future estimated amortization expenses as of June 30, 2017 for the five succeeding years is as follows:

For the years ending December 31,	Amounts
2017 (includes the remainder of the year)	$	48,282
2018		73,433
2019		70,285
2020		70,285
2021		70,285
Thereafter		253,113
	$	585,683

XML 38 R27.htm IDEA: XBRL DOCUMENT

PAYROLL LIABILITIES (Tables)

6 Months Ended

Jun. 30, 2017

Payables and Accruals [Abstract]

Schedule of payroll liabilities

Payroll liabilities consisted of the following:

	June 30, 2017		December 31, 2016
Accrued bonus payable	$	280,008	$	609,337
Accrued vacation		134,865		94,514
Accrued payroll liabilities		67,547		66,048
Total payroll liabilities	$	482,420	$	769,899

XML 39 R28.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Schedule of warrant activity

The following table summarizes the 2017 liability warrant activity:

	Shares			Weighted Average Exercise Price
Outstanding as of December 31, 2016
Warrants granted		5,863,332		$	0.9375
Warrants exercised		(2,991,666	)		0.26
Warrants cancelled
Outstanding as of June 30, 2017		2,871,666		$	0.26

Schedule of inputs used in valuation of warrants

Inputs used in the valuation of the warrants at the issuance date of April 3, 2017 and June 30, 2017 were as follows:

Initial valuation
Common stock price	$	0.75
Exercise price	$	0.9375
Expected Volatility		50	%
Dividend Yield		0	%
Risk-Free Interest Rate		0.79% - 1.88	%
Expected Term (years)		0.24 - 5

June 30, 2017 valuation
Common stock price	$	0.50
Exercise price	$	0.26
Expected Volatility		50	%
Dividend Yield		0	%
Risk-Free Interest Rate		0.79% - 1.88	%
Expected Term (years)		0.08-4.76

Schedule of warrants

As of June 30, 2017, warrants to purchase 3,273,894 shares of common stock were outstanding including:

	Outstanding Warrants to Purchase Shares		Exercise Price		Expiration Date

2011 private placement		283,470	$	18.75 - 24.00	May 8, 2018
Acueity warrants		21,667		75.00	September 30, 2017
2014 public offering		77,790		45.00	January 29, 2019
Placement agent fees for Company’s offerings		16,135		31.80 - 186.45	March - November, 2018
Outside consulting		3,166		63.60	January 14, 2018
2017 public offering		2,871,666		0.26	April 3, 2022
		3,273,894

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 40 R29.htm IDEA: XBRL DOCUMENT

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Schedule of fair value of financial assets on recurring basis

The following tables present the Company’s fair value hierarchy for all its financial assets, in thousands, by major security type measured at fair value on a recurring basis as of June 30, 2017:

	June, 30 2017
	Estimated Fair Value		Level 1	Level 2	Level 3
Assets:
	$		$	$	$
Liabilities:
Common Stock Warrant Liability	$	864,371			$	864,371

Schedule of changes in the Company's Level 3 warrant liability

The following table summarizes the changes in the Company’s Level 3 warrant liability for the six months ended June 30, 2017:

	June 30, 2017
Warrant liability
Beginning balance	$
Issuances of warrants		1,612,417
Warrant exercises		(900,493	)
Change in fair value		152,447
Ending balance		864,371

XML 41 R30.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of earning per share

The following table summarizes the Company’s calculation of net loss per common share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Net Loss Per share
Numerator

Net loss	$	2,241,489	$	1,722,383	$	3,945,043	$	4,049,920
Deemed dividend attributable to preferred stock	$	2,568,132			$	2,568,132
Net loss attributable to common shareholders	$	4,809,621	$	1,722,383	$	6,513,175	$	4,049,920
Denominator
Weighted average common shares outstanding		7,476,046		2,587,871		5,641,671		2,485,853
Basic and diluted net loss per share	$	0.64	$	0.67	$	1.15	$	1.63

Schedule of antidilutive securities

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Options to purchase common stock		1,121,567		394,090		754,093		394,090
Series A convertible preferred stock		2,184,356				1,098,212
Warrants to purchase common stock		6,139,797		402,228		3,286,862		402,228
Total		9,445,720		796,318		5,139,167		796,318

XML 42 R31.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Tables)

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum lease payments under all non-cancelable operating and capital leases

The future minimum lease payments due subsequent to June 30, 2017 under all non-cancelable operating and capital leases for the next five years are as follows:

Year Ending December 31,	Operating Leases Amount
2017 (remainder of year)	$	4,930
Total minimum lease payments	$	4,930

XML 43 R32.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of automatic additions to the 2010 Plan

The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:

January 1,	Number of shares
2012		30,018
2013		34,452
2014		49,532
2015		65,557
2016		220,419
2017		151,477
Total additional shares		551,455

Schedule of stock options, valuation assumptions

The fair value of stock options granted for the six months ended June 30, 2017 and 2016 was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	Period ended June 30,
	2017		2016

Risk free interest rate		1.86% - 2.04%		1.48% - 1.55%
Expected term		5.32- 6.36 years		5.58 - 6.06 years

Dividend yield		- %		- %
Expected volatility		112.86% - 114.19%		115.52% - 115.58%

Schedule of stock options

Options issued and outstanding as of June 30, 2017 and their activities during the six months then ended are as follows:

	Number of Underlying Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2017		378,924		$	26.25			$
Granted		1,716,323			.47
Forfeited		(3,167	)		15.00
Expired		(19,081	)		25.05
Outstanding as of June 30, 2017		2,072,999			4.10		9.25	$	51,512
Exercisable as of June 30, 2017		229,158			31.65		7.44	$
Vested and expected to vest		2,072,999		$	4.10		9.26	$	51,512

XML 44 R33.htm IDEA: XBRL DOCUMENT

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
GOING CONCERN (Details Narrative) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 2,241,489	$ 1,722,383	$ 3,945,043	$ 4,049,923
Net cash provided by (used in) operating activities			3,200,000
Cash and cash equivalents	3,690,023	$ 1,190,866	3,690,023	$ 1,190,866	$ 3,027,962	$ 3,715,895
Working capital	$ 2,100,000		$ 2,100,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Details Narrative) - $ / shares	Aug. 26, 2016	Jun. 30, 2017	May 31, 2017	Dec. 31, 2016
Common stock, par or stated value (in dollars per share)		$ 0.015		$ 0.015
Common stock, outstanding		10,032,410		3,786,913
Reverse Stock Split [Member]
Description of reverse stock split	The Company completed a 1-for-15 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 15 shares of issued and outstanding common stock were combined into one issued and outstanding share of Common Stock, and the par value per share was changed to $.015 per share.
Common stock, par or stated value (in dollars per share)	$ 0.015
Common stock, outstanding			0

XML 46 R35.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid insurance	$ 156,532	$ 121,333
Trade show		20,000
Retainer and security deposits	29,968	14,218
Financial exchange fees	21,000
Other	20,870	16,050
Total prepaid expenses	$ 228,370	$ 171,601

XML 47 R36.htm IDEA: XBRL DOCUMENT

FURNITURE AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Furniture and equipment	$ 170,916	$ 210,528
Less: Accumulated depreciation	(151,927)	(155,409)
Total furniture and equipment, net	$ 18,989	$ 55,119

XML 48 R37.htm IDEA: XBRL DOCUMENT

FURNITURE AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
FURNITURE AND EQUIPMENT (Details Narrative) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 8,773	$ 32,734	$ 18,434	$ 62,353

XML 49 R38.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	$ 752,540	$ 752,540
Less: Accumulated amortization	(166,857)	(112,100)
Total intangible assets, net	585,683	640,440
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	639,000	639,000
Software [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	$ 113,540	$ 113,540

XML 50 R39.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details 1) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
2017 (includes the remainder of the year)	$ 48,282
2018	73,433
2019	70,285
2020	70,285
2021	70,285
Thereafter	253,113
Total intangible assets, net	$ 585,683	$ 640,440

XML 51 R40.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
INTANGIBLE ASSETS (Details Narrative) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Software [Member]
Finite-lived intangible assets acquired			$ 113,540		$ 113,540
Useful life			3 years
Amortization expense	$ 6,759	$ 7,857	$ 19,614	$ 15,714
Patents [Member]
Finite-lived intangible assets acquired			639,000		$ 639,000
Amortization expense	$ 17,571	$ 37,254	$ 35,142	$ 74,508
Patents [Member] \| Minimum [Member]
Useful life			7 years
Patents [Member] \| Maximum [Member]
Useful life			12 years

XML 52 R41.htm IDEA: XBRL DOCUMENT

PAYROLL LIABILITIES (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued bonus payable	$ 280,008	$ 609,337
Accrued vacation	134,865	94,514
Accrued payroll liabilities	67,547	66,048
Total payroll liabilities	$ 482,420	$ 769,899

XML 53 R42.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details)	6 Months Ended
STOCKHOLDERS' EQUITY (Details)	Jun. 30, 2017 $ / shares shares
Class of Warrant or Right Number of Securities called by Warrants or Rights [Roll Forward]
Warrants Granted \| shares	5,863,332
Warrants Exercised \| shares	(2,991,666)
Outstanding at end \| shares	2,871,666
Class of Warrant or Right Exercise Price of Warrants or Rights [Roll Forward]
Warrants Granted \| $ / shares	$ 0.9375
Warrants Exercised \| $ / shares	0.26
Outstanding at end \| $ / shares	$ 0.26

XML 54 R43.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 1) - $ / shares		6 Months Ended
STOCKHOLDERS' EQUITY (Details 1) - $ / shares	Apr. 03, 2017	Jun. 30, 2017	Jun. 29, 2017
Exercise price (in dollars per share)		$ 0.26
2017 Warrants [Member]
Common stock price	$ 0.75	0.50	$ 0.52
Exercise price (in dollars per share)	$ 0.9375	$ 0.26	$ 0.26
Expected Volatility	50.00%	50.00%
Dividend Yield	0.00%	0.00%
2017 Warrants [Member] \| Minimum [Member]
Risk-Free Interest Rate	0.79%	0.79%
Expected Term	2 months 26 days	29 days
2017 Warrants [Member] \| Maximum [Member]
Risk-Free Interest Rate	1.88%	1.88%
Expected Term	5 years	4 years 9 months 4 days

XML 55 R44.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 2)	6 Months Ended
STOCKHOLDERS' EQUITY (Details 2)	Jun. 30, 2017 $ / shares shares
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	3,273,894
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.26
2017 Public Offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	2,871,666
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.26
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Apr. 03, 2022
2011 Private Placement [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	283,470
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	May 08, 2018
2011 Private Placement [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 18.75
2011 Private Placement [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 24.00
Acueity Warrants [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	21,667
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 75.00
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Sep. 30, 2017
2014 Public Offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	77,790
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 45.00
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Jan. 29, 2019
Placement Agent Fee [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	16,135
Placement Agent Fee [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 31.80
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Mar. 31, 2018
Placement Agent Fee [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 186.45
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Nov. 30, 2018
Outside Consulting Firm [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	3,166
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 63.60
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Jan. 14, 2018

XML 56 R45.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)					1 Months Ended	3 Months Ended		6 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Jun. 29, 2017	Apr. 03, 2017	Mar. 28, 2017	May 25, 2016	Aug. 31, 2016	Jun. 30, 2017	Mar. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Nov. 11, 2015	May 19, 2014
Number of total shares authorized						85,000,000		85,000,000
Common stock, authorized						75,000,000		75,000,000		75,000,000
Common stock, par or stated value (in dollars per share)						$ 0.015		$ 0.015		$ 0.015
Preferred stock, authorized						10,000,000		10,000,000		10,000,000
Preferred stock, par or stated value (in dollars per share)						$ 0.001		$ 0.001		$ 0.001
Number of new shares issued, value								$ 829,684
Proceeds from issuance of common stock									$ 2,133,974
Initial exercise price (in dollars per share)						$ 0.26		$ 0.26
Number of shares conversion						1,333.33		1,333.33
Allocation of Series A convertible preferred stock to warrants and beneficial conversion feature								$ (1,284,066)
Conversion of Series A Convertible Preferred Stock to common stock
2016 Public Offering [Member]
Number of new shares issued, value					$ 2,875,000
Proceeds from issuance of common stock					$ 2,561,896
Share price (in dollars per share)					$ 2.50
Number of new shares issued					1,150,000
2017 Public Offering [Member]
Initial exercise price (in dollars per share)						$ 0.26		$ 0.26
Common Stock [Member]
Number of new shares issued, value								$ 17,910
Number of new shares issued								1,194,000
Deemed Dividend on Series A Convertible Preferred Stock								$ 2,568,132
Conversion of Series A Convertible Preferred Stock to common stock								$ 53,260
Conversion of Series A Convertible Preferred Stock to common stock (in shares)						3,550,664		3,550,664
Additional Paid-in Capital [Member]
Number of new shares issued, value								$ 811,774
Allocation of Series A convertible preferred stock to warrants and beneficial conversion feature								1,284,066
Deemed Dividend on Series A Convertible Preferred Stock								(2,568,132)
Conversion of Series A Convertible Preferred Stock to common stock								$ 2,406,535
Underwriting Agreement [Member] \| 2017 Public Offering [Member] \| Aegis Capital Corp [Member]
Proceeds from issuance initial public offering		$ 4,400,000	$ 4,400,000
Net proceeds from issuance initial public offering			$ 3,900,000
Underwriting Agreement [Member] \| Common Stock and Warrants [Member] \| Over-Allotment Option [Member] \| Aegis Capital Corp [Member]
Proceeds from issuance initial public offering		$ 4,400,000
Number of shares included in offering		530,000
Number of new shares issued		530,000
Initial exercise price (in dollars per share)		$ 0.9375				$ 0.26		$ 0.26
Warrant term		5 years
Beneficial Owner [Member]
Ownership percentage												15.00%
Percentage of common stock outstanding												2.00%
Entitled to receive worth of common stock												$ 30.00
Initial exercise price (in dollars per share)												$ 15.00
Aspire Capital Fund LLC [Member] \| New Common Stock Purchase Agreement [Member]
Shares agreed to register in common stock											405,747
Stock committed				$ 10,000,000
Aspire Capital Fund LLC [Member] \| Stock Purchase Agreement [Member]
Proceeds from issuance of common stock							$ 2,177,083
Net proceeds from issuance of common stock							$ 2,133,973
Number of shares issued for services				49,736
Number of shares issued for services, value				$ 746
Number of new shares issued							405,747
Aspire Capital Fund LLC [Member] \| Stock Purchase Agreement [Member] \| Additional Paid-in Capital [Member]
Number of shares issued for services, value				197,777
Issuance of common shares as commitment fees				$ 198,523
Series A Convertible Preferred Stock Convertible [Member]
Preferred stock, authorized						4,000		4,000		0
Preferred stock, par or stated value (in dollars per share)						$ 0.001		$ 0.001		$ 0.001
Description of preferred stock conversion								Each share of the Series A Preferred is convertible into 1,333.33 shares of our Common Stock (subject to adjustment as provided in the related certificate of designation of preferences, rights and limitations). Holders of Series A Preferred are prohibited from converting Series A Preferred into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our Common Stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to us.
Conversion of Series A Convertible Preferred Stock to common stock (in shares)						2,663
Description of conversion ratio						Conversion ratio of 1,333.33 shares of Series A Convertible Preferred Stock to common stock.
Series A Convertible Preferred Stock Convertible [Member] \| Underwriting Agreement [Member] \| 2017 Public Offering [Member] \| Aegis Capital Corp [Member]
Number of shares included in offering		3,502
Series A Convertible Preferred Stock Convertible [Member] \| Underwriting Agreement [Member] \| Common Stock and Warrants [Member] \| 2017 Public Offering [Member] \| Aegis Capital Corp [Member]
Number of shares included in offering		4,669,333
Number of new shares issued		4,669,333
Series A Preferred Stock [Member]
Preferred stock, authorized						750,000		750,000
Preferred stock, par or stated value (in dollars per share)						$ 0.001		$ 0.001
Class A Units [Member] \| Underwriting Agreement [Member] \| 2017 Public Offering [Member] \| Aegis Capital Corp [Member]
Number of shares included in offering		664,000
Share price (in dollars per share)		$ 0.75
Class A Units [Member] \| Underwriting Agreement [Member] \| Common Stock and Warrants [Member] \| 2017 Public Offering [Member] \| Aegis Capital Corp [Member]
Number of shares included in offering		664,000
Number of new shares issued		664,000
Class B Units [Member] \| Underwriting Agreement [Member] \| 2017 Public Offering [Member] \| Aegis Capital Corp [Member]
Number of shares included in offering		1,000
2017 Warrants [Member]
Share price (in dollars per share)	$ 0.52	$ 0.75				0.50		0.50
Number of new shares issued	3,000,000
Initial exercise price (in dollars per share)	$ 0.26	$ 0.9375				$ 0.26		$ 0.26
Warrant term								5 years
Number of shares conversion	1,500,000
Description of exercise limitation	The shares of Common Stock are registered under the Securities Act of 1933, as amended. If delivery of the shares of Common Stock pursuant to the foregoing would result in the holder exceeding the 4.99% “Beneficial Ownership Limitation” (as defined in the warrant) then the shares in excess of such 4.99% will be held in abeyance by the Company pending further instruction from the holder.							A holder will not have the right to exercise any portion of the Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days’ prior notice from the holder to us.
Fair value of warrants								$ 1,800,000
Initial fair value of warrants								$ 1,600,000

XML 57 R46.htm IDEA: XBRL DOCUMENT

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Assets
Total assets	$ 4,709,378	$ 4,144,372
Liabilities
Common Stock Warrant Liability	864,371
Level 3 [Member]
Liabilities
Common Stock Warrant Liability	864,371
Fair Value, Measurements, Recurring [Member]
Liabilities
Common Stock Warrant Liability	$ 864,371

XML 58 R47.htm IDEA: XBRL DOCUMENT

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017
Warrant liability [Roll Forward]
Issuances of warrants		$ 1,612,415
Warrant exercises		(900,493)
Change in fair value	$ 152,447	152,447
Ending balalnce	$ 864,371	$ 864,371

XML 59 R48.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Details) - USD ($)	3 Months Ended		6 Months Ended
NET LOSS PER SHARE (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Numerator
Net loss	$ 2,241,489	$ 1,722,383	$ 3,945,043	$ 4,049,923
Deemed dividend attributable to preferred stock	(2,568,132)		(2,568,132)
Net loss attributable to common shareholders	$ 4,809,621	$ 1,722,383	$ 6,513,175	$ 4,049,923
Denominator
Weighted average common shares outstanding	7,476,046	2,587,871	5,641,671	2,485,853
Basic and diluted net loss per share	$ 0.64	$ 0.67	$ 1.15	$ 1.63

XML 60 R49.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Details 1) - shares	3 Months Ended		6 Months Ended
NET LOSS PER SHARE (Details 1) - shares	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of potential common shares excluded	9,445,720	796,318	5,139,167	796,318
Series A Convertible Preferred Stock Convertible [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of potential common shares excluded	2,184,356		1,098,212
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of potential common shares excluded	1,121,567	394,090	754,093	394,090
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of potential common shares excluded	6,139,797	402,228	3,286,862	402,228

XML 61 R50.htm IDEA: XBRL DOCUMENT

CONCENTRATION OF CREDIT RISK (Details Narrative) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Risks and Uncertainties [Abstract]
Cash, FDIC insured amount	$ 250,000
Cash, uninsured amount	$ 3,440,023	$ 2,777,962

XML 62 R51.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details)	Jun. 30, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2017 (remainder of year)	$ 4,930
Total minimum lease payments	$ 4,930

XML 63 R52.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 7,395	$ 78,600	$ 18,540	$ 157,200

XML 64 R53.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details)	6 Months Ended
STOCK BASED COMPENSATION (Details)	Jun. 30, 2017 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	551,455
2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	30,018
2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	34,452
2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	49,532
2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	65,557
2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	220,419
2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	151,477

XML 65 R54.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details 1) - Stock Option and Incentive Plan [Member]	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Dividend yield
Minimum [Member]
Risk free interest rate	1.86%	1.48%
Expected term	5 years 3 months 25 days	5 years 6 months 29 days
Expected stock volatility	112.86%	115.52%
Maximum [Member]
Risk free interest rate	2.04%	1.55%
Expected term	6 years 4 months 10 days	622 days
Expected stock volatility	114.19%	115.58%

XML 66 R55.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details 2)	6 Months Ended
STOCK BASED COMPENSATION (Details 2)	Jun. 30, 2017 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning \| shares	378,924
Granted \| shares	1,716,323
Forfeited \| shares	(3,167)
Expired \| shares	(19,081)
Outstanding at ending \| shares	2,072,999
Exercisable at ending \| shares	229,158
Vested and expected to vest \| shares	2,072,999
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Rollforward]
Outstanding at beginning \| $ / shares	$ 26.25
Granted \| $ / shares	0.47
Forfeited \| $ / shares	15.00
Expired \| $ / shares	25.05
Outstanding at ending \| $ / shares	4.10
Exercisable at ending \| $ / shares	31.65
Vested and expected to vest \| $ / shares	$ 4.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Contractual Life Remaining in Years [Rollforward]
Outstanding at ending	9 years 3 months
Exercisable at end	7 years 5 months 8 days
Vested and expected to vest	9 years 3 months 4 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Rollforward]
Outstanding at ending \| $	$ 51,512
Vested and expected to vest \| $	$ 51,512

XML 67 R56.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
STOCK BASED COMPENSATION (Details Narrative) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	May 09, 2017	May 18, 2016	Sep. 28, 2010
Share-based Compensation	$ 181,408	$ 200,187	$ 336,115	$ 392,664
Number of shares granted			1,716,323
Number of unvested options outstanding	1,840,530		1,840,530
Unrecognized compensation cost	$ 1,427,000		$ 1,427,000
Vesting period			2 years 1 month 6 days
Stock Option and Incentive Plan 2010 [Member]
Shares held in employee stock option plan suspense shares					1,500,000	133,333	66,667
Number of shares available for grant	100,456		100,456
Scientific Advisor [Member]
Number of shares granted			1,716,323

XML 68 R57.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Aug. 11, 2017	Aug. 14, 2017	Jun. 30, 2017
Subsequent Event [Line Items]
Number of warrants outstanding			3,273,894
Exercise price (in dollars per share)			$ 0.26
Additional common stock warrants exercised			2,871,666
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of warrants outstanding		1,215,000
Cash proceeds warrant	$ 434,733
Exercise price (in dollars per share)	$ 0.26
Additional common stock warrants exercised	1,656,666

EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
&PO=V]R:W-H965T&UL4$L! M A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H965T ME*M\M@$ -(# 9 M " 28G !X;"]W;W)K&UL4$L! A0# M% @ &PO=V]R:W-H965TDL M !X;"]W;W)K&UL4$L! A0#% @ T 0 T@, !D ( !U"X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .2-BT 0 T@, !D M ( !EC0 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% M @ &UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R M:W-H965T&UL M4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ M (,@( !\' 9 " === !X;"]W M;W)K&UL4$L! A0#% @ A6+\" #^"0 &0 @ &2 M8@ >&PO=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H M965T&UL4$L! M A0#% @ >&PO=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H965T M&UL4$L! A0# M% @ &PO M&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " !RB@Y+UR: XML 70 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 127 227 1 false 44 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://atossagenetics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://atossagenetics.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://atossagenetics.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://atossagenetics.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) Sheet http://atossagenetics.com/role/CondensedConsolidatedStatementOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical) Sheet http://atossagenetics.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://atossagenetics.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 00000008 - Disclosure - NATURE OF OPERATIONS Sheet http://atossagenetics.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN Sheet http://atossagenetics.com/role/GoingConcern GOING CONCERN Notes 9 false false R10.htm 00000010 - Disclosure - SUMMARY OF ACCOUNTING POLICIES Sheet http://atossagenetics.com/role/SummaryOfAccountingPolicies SUMMARY OF ACCOUNTING POLICIES Notes 10 false false R11.htm 00000011 - Disclosure - PREPAID EXPENSES Sheet http://atossagenetics.com/role/PrepaidExpenses PREPAID EXPENSES Notes 11 false false R12.htm 00000012 - Disclosure - FURNITURE AND EQUIPMENT Sheet http://atossagenetics.com/role/FurnitureAndEquipment FURNITURE AND EQUIPMENT Notes 12 false false R13.htm 00000013 - Disclosure - INTANGIBLE ASSETS Sheet http://atossagenetics.com/role/IntangibleAssets INTANGIBLE ASSETS Notes 13 false false R14.htm 00000014 - Disclosure - PAYROLL LIABILITIES Sheet http://atossagenetics.com/role/PayrollLiabilities PAYROLL LIABILITIES Notes 14 false false R15.htm 00000015 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://atossagenetics.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 15 false false R16.htm 00000016 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://atossagenetics.com/role/FairValueOfFinancialInstruments FAIR VALUE OF FINANCIAL INSTRUMENTS Notes 16 false false R17.htm 00000017 - Disclosure - NET LOSS PER SHARE Sheet http://atossagenetics.com/role/NetLossPerShare NET LOSS PER SHARE Notes 17 false false R18.htm 00000018 - Disclosure - INCOME TAXES Sheet http://atossagenetics.com/role/IncomeTaxes INCOME TAXES Notes 18 false false R19.htm 00000019 - Disclosure - CONCENTRATION OF CREDIT RISK Sheet http://atossagenetics.com/role/ConcentrationOfCreditRisk CONCENTRATION OF CREDIT RISK Notes 19 false false R20.htm 00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://atossagenetics.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 00000021 - Disclosure - STOCK BASED COMPENSATION Sheet http://atossagenetics.com/role/StockBasedCompensation STOCK BASED COMPENSATION Notes 21 false false R22.htm 00000022 - Disclosure - SUBSEQUENT EVENTS Sheet http://atossagenetics.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 22 false false R23.htm 00000023 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) Sheet http://atossagenetics.com/role/SummaryOfAccountingPoliciesPolicies SUMMARY OF ACCOUNTING POLICIES (Policies) Policies 23 false false R24.htm 00000024 - Disclosure - PREPAID EXPENSES (Tables) Sheet http://atossagenetics.com/role/PrepaidExpensesTables PREPAID EXPENSES (Tables) Tables http://atossagenetics.com/role/PrepaidExpenses 24 false false R25.htm 00000025 - Disclosure - FURNITURE AND EQUIPMENT (Tables) Sheet http://atossagenetics.com/role/FurnitureAndEquipmentTables FURNITURE AND EQUIPMENT (Tables) Tables http://atossagenetics.com/role/FurnitureAndEquipment 25 false false R26.htm 00000026 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://atossagenetics.com/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://atossagenetics.com/role/IntangibleAssets 26 false false R27.htm 00000027 - Disclosure - PAYROLL LIABILITIES (Tables) Sheet http://atossagenetics.com/role/PayrollLiabilitiesTables PAYROLL LIABILITIES (Tables) Tables http://atossagenetics.com/role/PayrollLiabilities 27 false false R28.htm 00000028 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://atossagenetics.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://atossagenetics.com/role/StockholdersEquity 28 false false R29.htm 00000029 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Sheet http://atossagenetics.com/role/FairValueOfFinancialInstrumentsTables FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Tables http://atossagenetics.com/role/FairValueOfFinancialInstruments 29 false false R30.htm 00000030 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://atossagenetics.com/role/NetLossPerShareTables NET LOSS PER SHARE (Tables) Tables http://atossagenetics.com/role/NetLossPerShare 30 false false R31.htm 00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://atossagenetics.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://atossagenetics.com/role/CommitmentsAndContingencies 31 false false R32.htm 00000032 - Disclosure - STOCK BASED COMPENSATION (Tables) Sheet http://atossagenetics.com/role/StockBasedCompensationTables STOCK BASED COMPENSATION (Tables) Tables http://atossagenetics.com/role/StockBasedCompensation 32 false false R33.htm 00000033 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://atossagenetics.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://atossagenetics.com/role/GoingConcern 33 false false R34.htm 00000034 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details Narrative) Sheet http://atossagenetics.com/role/SummaryOfAccountingPoliciesDetailsNarrative SUMMARY OF ACCOUNTING POLICIES (Details Narrative) Details http://atossagenetics.com/role/SummaryOfAccountingPoliciesPolicies 34 false false R35.htm 00000035 - Disclosure - PREPAID EXPENSES (Details) Sheet http://atossagenetics.com/role/PrepaidExpensesDetails PREPAID EXPENSES (Details) Details http://atossagenetics.com/role/PrepaidExpensesTables 35 false false R36.htm 00000036 - Disclosure - FURNITURE AND EQUIPMENT (Details) Sheet http://atossagenetics.com/role/FurnitureAndEquipmentDetails FURNITURE AND EQUIPMENT (Details) Details http://atossagenetics.com/role/FurnitureAndEquipmentTables 36 false false R37.htm 00000037 - Disclosure - FURNITURE AND EQUIPMENT (Details Narrative) Sheet http://atossagenetics.com/role/FurnitureAndEquipmentDetailsNarrative FURNITURE AND EQUIPMENT (Details Narrative) Details http://atossagenetics.com/role/FurnitureAndEquipmentTables 37 false false R38.htm 00000038 - Disclosure - INTANGIBLE ASSETS (Details) Sheet http://atossagenetics.com/role/IntangibleAssetsDetails INTANGIBLE ASSETS (Details) Details http://atossagenetics.com/role/IntangibleAssetsTables 38 false false R39.htm 00000039 - Disclosure - INTANGIBLE ASSETS (Details 1) Sheet http://atossagenetics.com/role/IntangibleAssetsDetails1 INTANGIBLE ASSETS (Details 1) Details http://atossagenetics.com/role/IntangibleAssetsTables 39 false false R40.htm 00000040 - Disclosure - INTANGIBLE ASSETS (Details Narrative) Sheet http://atossagenetics.com/role/IntangibleAssetsDetailsNarrative INTANGIBLE ASSETS (Details Narrative) Details http://atossagenetics.com/role/IntangibleAssetsTables 40 false false R41.htm 00000041 - Disclosure - PAYROLL LIABILITIES (Details) Sheet http://atossagenetics.com/role/PayrollLiabilitiesDetails PAYROLL LIABILITIES (Details) Details http://atossagenetics.com/role/PayrollLiabilitiesTables 41 false false R42.htm 00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://atossagenetics.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://atossagenetics.com/role/StockholdersEquityTables 42 false false R43.htm 00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) Sheet http://atossagenetics.com/role/StockholdersEquityDetails1 STOCKHOLDERS' EQUITY (Details 1) Details http://atossagenetics.com/role/StockholdersEquityTables 43 false false R44.htm 00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details 2) Sheet http://atossagenetics.com/role/StockholdersEquityDetails2 STOCKHOLDERS' EQUITY (Details 2) Details http://atossagenetics.com/role/StockholdersEquityTables 44 false false R45.htm 00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://atossagenetics.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://atossagenetics.com/role/StockholdersEquityTables 45 false false R46.htm 00000046 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Sheet http://atossagenetics.com/role/FairValueOfFinancialInstrumentsDetails FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Details http://atossagenetics.com/role/FairValueOfFinancialInstrumentsTables 46 false false R47.htm 00000047 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) Sheet http://atossagenetics.com/role/FairValueOfFinancialInstrumentsDetails1 FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) Details http://atossagenetics.com/role/FairValueOfFinancialInstrumentsTables 47 false false R48.htm 00000048 - Disclosure - NET LOSS PER SHARE (Details) Sheet http://atossagenetics.com/role/NetLossPerShareDetails NET LOSS PER SHARE (Details) Details http://atossagenetics.com/role/NetLossPerShareTables 48 false false R49.htm 00000049 - Disclosure - NET LOSS PER SHARE (Details 1) Sheet http://atossagenetics.com/role/NetLossPerShareDetails1 NET LOSS PER SHARE (Details 1) Details http://atossagenetics.com/role/NetLossPerShareTables 49 false false R50.htm 00000050 - Disclosure - CONCENTRATION OF CREDIT RISK (Details Narrative) Sheet http://atossagenetics.com/role/ConcentrationOfCreditRiskDetailsNarrative CONCENTRATION OF CREDIT RISK (Details Narrative) Details http://atossagenetics.com/role/ConcentrationOfCreditRisk 50 false false R51.htm 00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://atossagenetics.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://atossagenetics.com/role/CommitmentsAndContingenciesTables 51 false false R52.htm 00000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://atossagenetics.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://atossagenetics.com/role/CommitmentsAndContingenciesTables 52 false false R53.htm 00000053 - Disclosure - STOCK BASED COMPENSATION (Details) Sheet http://atossagenetics.com/role/StockBasedCompensationDetails STOCK BASED COMPENSATION (Details) Details http://atossagenetics.com/role/StockBasedCompensationTables 53 false false R54.htm 00000054 - Disclosure - STOCK BASED COMPENSATION (Details 1) Sheet http://atossagenetics.com/role/StockBasedCompensationDetails1 STOCK BASED COMPENSATION (Details 1) Details http://atossagenetics.com/role/StockBasedCompensationTables 54 false false R55.htm 00000055 - Disclosure - STOCK BASED COMPENSATION (Details 2) Sheet http://atossagenetics.com/role/StockBasedCompensationDetails2 STOCK BASED COMPENSATION (Details 2) Details http://atossagenetics.com/role/StockBasedCompensationTables 55 false false R56.htm 00000056 - Disclosure - STOCK BASED COMPENSATION (Details Narrative) Sheet http://atossagenetics.com/role/StockBasedCompensationDetailsNarrative STOCK BASED COMPENSATION (Details Narrative) Details http://atossagenetics.com/role/StockBasedCompensationTables 56 false false R57.htm 00000057 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://atossagenetics.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://atossagenetics.com/role/SubsequentEvents 57 false false All Reports Book All Reports atos-20170630.xml atos-20170630.xsd atos-20170630_cal.xml atos-20170630_def.xml atos-20170630_lab.xml atos-20170630_pre.xml true true ZIP 75 0001615774-17-004407-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001615774-17-004407-xbrl.zip M4$L#!!0 ( '**#DOF*UIU7[0 +RQ"0 1 871O:+79Y??S,!DB(E2B(E4@)E;IS3XQ))(#/Q9"(!)#+_\7]^S!SAF?B! M[;F_O)/ZXCN!N*9GV>[3+^^^WY^-[\^OKMX)_^?7__?_$>#__O'_G9T)YSXQ M0F()CZ_"O2Q]0WO9EP=@9-_./' MH^_8'_&_ G3L!A]_!/8O[S(?O2A]SW_Z((NB].'_?OMZ;T[)S#BSW2 T7).\ M2[Z"=O\L^DX:C48?Z-/DU94WL?.D#^4#/GXT@D7+2."&]U2#*#A[,HQY^L'$"![IR_$#)&:0)P:>^)Y#@L)OZ)."CUS/ M=:-9,5U6Z'\(7^?D [QT!F\1WS;3[[9_E/\ :,"?BZFC3PJH,T)O\0'^(S"> MB$M"VZ38IE^(NB*^2[0$4?4QH-B](Q.! O+CE X3?GZ6?-#_$5COXL?8^2_O M GLV=P!='Y*FF,:8GAN2'Z%@6[^\N_2]64*C*(4>^UL_6_2??D;K")JH#H>B,OK'A^6/%]U]*.PO[FT. ^!9 MJU2 )OGA%S EOR[825I:/%OYC+A6YB/D>]&]E?LD^3U'0/)C+-+U>K_[WW)O-//<^],P_OY'9(_&/-@(+H9*G&).Y:C%#'^]#D!]^?_%7!'0#?W//A7\&XQ]V\.[7Y+45OO_QH;"++'D?BND[ M96,?FX$.+L>&RZ%, M%!XVRJ";0LI,(1V,.(/1D:>6#@_\XN'84\X="0W;)=:%X;NX<_JF0%',?#?) ME)ED.N <'3A'GE8Z!/"$@$-,)/J9.#R3M60[$?[6_]>,@M"; 1CP2(_0==P] M\!Z>&!K.'2, -:#\,23@LG;G@<^R7]/X@CL,M" DFU-,8\DO;M4/RU7XFL*H$V3W9CPX9!P$)@\^O MWXQ_>3[%0MY[R$G@5)V&]1O=\R@D_KTW"5\,GRQ)[0VCHI1D3APMR\O,SE;P M8BL.L<0L. SM;$4K;<4AHENV1%UTR&D/,-PJ^DM5Z+D#$DB^MYR\.ZM9$XB-'QV(#PGBK+P[$.\%X@ZN'8"J M^HX=@/@!4*M\P?@TY>'%>YAZ46"XUMBU+ASR3-Q;WWX&&FX=PZ0G$J0 MWLUD KVZ3R<+H?+,=[BJB*O4BH^?X#^7A)SREDG6G3RO.X\4X-4M&M_: M4'TK#W7F,1_(8>3+]F[R?-[-/4Z=#V.:MF_8! M\\2W8G@"YC%W9[CTB]Z,>7R3V]B<0^[$#=^;W(,^\O6^>VB,!.-;G\ 2V"?6 M*6:T6[W=F[ZRGOL3QX&*E\BE48J#S\0E$V#3<&Y>7.*?!@+NB(-YZ&\-/WQ] M\ TW,$Q,*A5\?LT^R4.B4!!'!$,\4(V" 3J0X/^E6\+!W/9)G'+K,G*MKXX9 M3T7Q&]?D)9,(\C;RS:D1D/&33T[H$*$*>M@6\UJYU3N%/;S.R5D;4.SAV M@+P<28\PJQ;%L(3_IJYB-(/_MY%Q]0UJR4ZKQ!8EI&V-W@XS5ZB&F5QR5[QJB/H5W+=J+0?B;WQ(Q\F#1()VE:Z^EXQ9PFR_2N?#KB7CQQ5$*&0:[F7 W?"BGC@^EP\<^^%!/'1]J MAX]]\*&=.CZT#A_[X$,_=7SH'3[6[RJ+9^+H3![F#@'9,G+L6E>NB3P_DUB2 MXLE"I13?1]Q^CH>I^6 @J8,"YU"(AZE1*"S-%!T4^(3"(<*?-5;OX&BCN[>0 MM(.4]Z #T5XAZ8>Y4#$\D]3V"BEFX.!GP'E_?7"RYC;/8.>OK\&'>B;*"3[@ M;R4]P+BZO*_X,Z]^[0MO4JNF04_;B MGMW8M?)Y$CL][_3\8%=NF*YO0.,;LSJ<.QG'6U]\[@Q19X@:5_W/G>ISI?IQ MSIYSSWTF?HC5RO+I>S(/.M/0F8:&3$-E%':FHX6FH\S:J#,OG7EI@WGA:X76 M&;N\L;N!X1P[CA>B-+(WW@ZRO_,&;-A: 7M)EFF&/KV0Z\-YBGE[G'Q7(X]@S";7"=#&F"Z[K MEL&M#*Y#)%=6,25SR>@ "3AH9'ZJ8BPC!?'OO4GX8OCDRH4IXPE7[N,@(">2 MF./2=NV0?+6?B;7$'QCQ;\:_/)\=H^;TJ91DC@JX'1-PY*YF-+B5D/,16G8# MH6#UQ>'W9E""6^V2W7=_E37W'K!FX#7I;IN;ZIK;@&W:=G56;KV6SJ> MEVMK@==9NO9:.OX MUC>:6?BJ$N/R'UZ1!RFHZT"\Q<13@,&)8M %K%^;*^) ML_5AFCIR:7^Q \TQ09/+B=E\XM#.9/ Z^@?:0AR>26(R><#?"SN .V_DKPC% M]DQ.Q8%=8@KC.9=6/$5<'WOBP#&J/''@8#;MA': X0,P*SF"#U\G=OM2Y#0 M46T9PH?]X,SQK %%J='Y9KOV+)IUV*KG@L,=7FS(&[B'Y&:1 MG)5PA^2RY6F[F9W3F9W;FK/[H*B;V=_@S'[B2.YF]C3@.$8][EDRG>VV@@.@7/BLB.C1BY M\3ABZ&.X<&,[]+09/%TB608%<]LGL;-[&;G65\?,+X6H_WD;^>;4",B2)]YVJ%7.!KU> M7(=;&6T:D&-O<>ZTJZXTG4TFN2+4[3>U?[^IT4M%V]VZL679:"(,Y]:PK2LW M-@72B0%EPZ[$9@ET+EL) ]2!B"\0'>G.8H<&WM%PC,.-2\/V_VDX$4RU1A#Y M5';!'2YC?%CFG 8H4AX_OV:XO/3I133S-7\8448@;Q4C5RXLA(.OY)DXRLE! M(_WS/Z$? ]8[KY31->A8%<6I@F)#C<=N3ZBU>T+MJA'8 :VU0#M\C;G29NHT M+\]PB:E*VZ0\W[WASU3N!?Q3NFMSDL#GYJH.S\ O?2K>6?S6 )\GB\_9-N]> MP.\L/N? Y\GB&SG14@6_8.I?NOVL 5G;6K:[,3RUZ!&@ M8SR5[F9B. %A/>0:R+9\'OD^_FP'IN'\00R_*B]G24# IM96 ? [<9S_=KT7 M]QZP"I.$=14$$FD[Q ]V[&ZIE0)X,SG< MD;GGXP4MG!BC\KW]@39F6VNKO5)JSD'<3YY?7J7N9X8#WPEI\P+.VX;[FB4A MUW21(K A9P"^A-_*,_L_?,-"<;_.'CVG MDF5D7>2^+P#)P@UBD^5-%*('BM_D>LLO(MX):,CI@WB.%2QBVC"*P2_OKJXO MP7Q) U$2!UH_!Z(-O26T)0[:-0G/C6!ZZWLX35F?7[\'6+_Q9HX3*=XW-&'Y M21>>9:6RH!G]FPS!(#!%%O'__O&A>O?+A.-G8]?"_T$7]-EPJ/<)S?G^*WQ) M#\+7R'8[G?I(%&5E06>IWFHC,8Z\VDRB* ]&NGPL$K4R) XD;3C2CB?%[0,M M22-QJ.L[DLAV83S_3W@0!VKMBCA9BC6CH,UEB8"VF(18 2HASGZ&:Y(K:-H& M6QH]PJKJ9C(A_K)IV7 4LU)J5,'B32 M@[^'[<,153:8@]HN"664M1Y5&%K&! 7DU'. RH!M[=P1T(6 ,'=B[L RM4 & M.CHLLI9^3#;"_.^&G^=^?PD_XQP3:%(+PU2&_O,._/PJ2. ^% M!WL&GL1'NO)GA]M@//0&O:4S>X<!,A7+3-WAS*TN 3 M>D*HNZQ%X3V^E3R6Q4\QO\)]OK_[17_PFO3IY[XP#H!.Z"IRPJ2W_,=($?VN M)^#OKP*PLZ#.QH4/L.I:@I=S)S/$O1 ?Y\;9HPTK)<%V0T^ -=.Z3VG;V#0S M3HR*'B4#7T4"YX8O/-,9=XX[DO2#%P-$,L73 GC'$W[J@WNP>-S'X?V 8YJ, M]0.0RE)J?B F;GTR-VSKXL>FH(QW+PW 9D@5 M*;@!!?7K%80XS,IA?0?[D5)*(KJH52*%3H67M@M3'\QZ%S^8A;HD2RO9JCYZ M/,<6-KPLA2]D[@5V. X"$N[>ZVBD#Q>,Y]JLW&$I2:NR5+;#> 3&%KT4&:S9 MSBC3J[SLRBTWO*;K*S>(?'1O=I6OI.F:(J_TG+:[2[^EQ"Q+BJ)4Z=>#.35\ MQ5S,(2P9<*:U3>^.(FDD#Q:TUT7/(?DLA5I-4\51\WRN M??$WWPMVMJ720!Q)>@F$T5[VIZF4X9-$31[N2A/,0W9(OMK/N&T*?OP3WDQG MMGHO20TT&09Z0=6V?NJ@JXRTCD'7GJ8Q%T%51+2FI:C1E MIK;L%+;SW*/K0VU0BLXU/3=#>ZE97\*USZ%HSWP6+^W&$U F>G +'^R\D-(4 MT*IR3&PA83]N]F5D(,I#;5<^:F3!B_SCL0"=[\_"P]0GQQL&VGL-3+QX.[.@ MJ,K.&A'WO1\#UT#UPPMQGLDW8&&ZL[^J#N6AO"LGRT0LLW0QFSO>*R%Q)K2O MMO%H.S0J8<_]-:!:E3-V=6M'M5!6RL_61\/1: _*8![P(V+=&X[A[R\H?:"I M^=5U0>.[DU#*S]!%=;@C"?\T3(JW/:4@*>I0UU9H6&I]=QK*B&&D:AA'OQ,) MGSTW"O;&@CP$_WYU)/*-[TQ!*2B((T59A>-F"K+;(W7$4DE#5H5Q^;76^6/ M,M[C@HY#T)Z3_KKKX;>#]E">O]][*\E[DI[UY6\FRS@[@HD=Z3GG:"-Y^S-3 M5)6Q1F:TP2&9J6>*4, [E?D8@?)$#U0MY] V+^E-%U7WA TLU48''8"5*I'U M\3+([=@>/?V4_3UG$.^M8YC9*@1;^9&' MBIJ-Z3H".V,S(GB3;UW,^SK*)5T?<#0.N 4=$AB)7$!U66X&@\'HN,.00F?\ MA)?C""E+NJ3#:N6HI./;MD7./1>#I^&;2]N?E25?D7(7?@Y(?6(7TUL!9=1U M .0>GMX2.4RVXT26M-R:L!;:+WX0W[0# @;0).G#('X:2*6W%=<'(\O;Y+V- MAJ89*6M)-W YT/I;AX87-G>RNQMX5UO$>SE3MX%97>GK;6&VO*.S9C>DE$2D M87^P;?YJLT1RNRRE)"*K[5&(-6[+/H!0I/[P9-BO/OK24.^KW"H$K"ZU,VF4 M,OB9N&1BX]6+FQ>7^)48Y=SN;VK-%+X-Z6;W.[V^H'@H4NE/?3VLLE3 MM?O3D.>F:M"GP>&FBK"GP.'FLA.'M]ST1N3%C[GML\L_X)Q"6X5-7GLTXR)N M'O\^M:&&J);@:=0$[-9A0H[V)!+I%9:!BDM M)7K:DZC5". FB,J7E:Y56"R5W%(VA0V=[4]::9$=GK1E#8T+?.<;*GUHJQV' M^)VKM6_E2#T&3AKDIR9FFDPJM937IT2O]=%:-;74,6G=37/YYZ<&\//+9(T: MWC23+-7<-P(6P;H",@*VJXB'"L'4GL-G)OS;>"KDL^JI!$WKO\I&-NM9:7IR M?M_B9W H%^['E@B/FL@7Y=0]W$Y'WE/'3-4.L1Z\.V(2^YG\[OGA-/=IPX=! MBMA/B2]!S4JB3&R5;HRM38ZW4 -8%LB5SF/[V5QGBZZJ$=%<>M]TMQQ7,./O MP%'%+?+LUN,>[-6RF:W)-=%2P[9SG<.^+RTEQPB5@]9@L+Y$N(7&TOFS5J_) M"WVTRU6,I7I))5+AC_+.;#G*ZN.'ZOPB$GJK_J_E8VF1<6@^#I,AO,R!6QDS MLR[J23\N& XKQ,IN5L7CSG6+1UT?Y7(8\B1E;LZ*UPA/4XZNYC!]#A?FM]Q4 MNM:;$H_+SM)-+"5C?L7770:2=L!=P0VQI9EH[DQG%N: MT#5&7@F6AI(T&!QM:*HZ,$6I.09:&2NPF8&BX@7K5X8[YK# [+NCK*RW]EH7 MF?O*6-.EX4@_ N&-V]>B41H,Q*&R [-T71]O^F*'=&V/E0J)#QJY>9=!P^-; MJ0)_ .5LSOI])Y*RM.=Y+>PZ=O]F,SL,U^W)B]J9K#7';('E3D^!2E->R5%@ MOU]Z/OC%S[!F76?M@&\U 70U&>PYSJ.!HI?T%U9XJ6+NN1%$T9WW[1(HYJ$] M JC!(Y!& _B_ TB*%E1HGW2&FKQ]_;E@<.6^NQO:ENU$H?U,[HD9^32EW<4/ MTXDL$"5(@"41B&^B7QB^"ZT&R9'">.9%;F%!I,U.^;HEH:2,I.P=YUK(.QC/ MFUVP=4?J(UW)EIMH%\N;E@'L_".S\5 FOD 51\HI"B/>4BB]G2 /]6&VNF6[ M)+$I+J:HVD-L\^!NR+)[JG+ V MC<\.RH^YU[7V.@6;I%%1^W5PCP:CUDIB4Z:DMS@IK!7&6YL4UD76-Q >*8FC MH2R=E%]5H[!^!/9'UW9^>1?Z$7DG?#BJ-IP"7T7&OSEPRY@26],;!C>6AK_\ MJ2;)T@:"H\2(*O@.E-?2O8 WM[ Y*0=L[=E^J]AEF0(O&??I*C( $EU$([\87U&Z-5]Q?"N[(S+#Q>/]FD0HX<+K8-15S80_4$;: 257*5?^8*CO+#AJ>C_#>Q8:9WB)6NFM%T[*9KM^RS/32RPU9 M5+/EJM^RT$K'B4HPZI"V+ WDTJ@,^Z\@["O^E;X(K M@^%(5EO$_F\TNOO*92$%JZ6 ]_$GI8&D*[E AOJ)Y4<>Z1:0:4.;]L0VQ]:S M'7BKU_=.2%R7GC\A-BZ[TWYJ@X^2"QII@-*ZA;%(A5*_,*21.)3JDT8!J?5+ M(TWI4L?$(H\DK8YUUCKJZF;_GR3 8M&NA7L"9HC1KO@3Y]-M6:H;G(5_)Y@1 M"(AX)K[Q1'+9^O9.5*'VI>6[J,U3S9&P*F7*D/6^7,=V4,/2"BI-@Z4E5G;O M=_U58[7*]%4?%[4+L&#J/)@4EY);'YJ7VF59,/$>3)8RR+**/M?,2X,.1J-S MAB+U]1K-8$FR"Z7UN+W;Q\K6EYWKP>_G("C?,,/(.Q#;H$MR!3W9;F";]'["K@>]FJ1) M=6QW;Z/O\&Y_B_S;_9BI6RRJ=+*]5P?O54C1Y21K.OJ\>BM&DLB M#24U5X'X\/*M%%\B8RC!8%]ZV>_4SB8S*Q?/HB?65+MPJEC;!*;W]*=;,J*4H^ MAQ 7O YH>8A1W;QJRUER:F%VG_/3^-3TV; =-/VPZJ?[)V42F-8D$U%4LT&[ M37%4F^3H?W#&3.\75W"3Y#^D;_JRFU03%76[D=<>S4)*EB2[7V[RH2IJRK(& MU$_D2K+71+G8U?ABL:=MT0X"FO$^^_S<"S __Q\$6#2])[=\IO:"*5>5!SE3 MT!B%6]/AUU4J'319D=7LLFI35_N252720!])RD&IVB>1Y4'IK2/QYD&'G4[, MB]Q#=P16?P&;,^_GCEWZUMAA49K*MV3=@6TW=O8=YMW*'PR5T6&EEN09*4X0 M(NTLOGO#(3!3(#WY:8/E#KER'V#Z"0P3.SU^=L\ZTI]68+CEPCI0/MFW(U 4 MUN=*PI+>J*@:N-.H:*+:'+"P2!KNZ[=,8K_>:G_$ M^0[7LK07X^NB;%>3.5@X(+&!E2W:^ICH01[#@ M60!E6T=U$%;F:K(JJ:HRD'LZK M97/2J+I!T8!8=B(A?UM_H(Y6F&M5&\39 9[_D\@F9W3UDDC41M,- +'?.XZ=TZ+P-]250' MLEZIQ-_36M[T%$&3'HN9H,)6D PPC8L.H3!7BR4C8(:%W[>Q%2 M"A7Z*!?M58$0S' 5W!JO&*FPKSA&VE"2FFJDDM66XZ&("!A MR;B"$EL(K+GRG>RT'5#<"54%]NC:<\T]55T>:H-E75]N?&<*2@%[I,K9Q6(I M"MCS/<&LC ;@"8Z6Y;T10'MB5P'P:KI2LLL[$H2^C>&SF+-N[-+_06_YV7#P M1M X/#=\_Q4\POUB?_/UE"KVV@#1I1S$6HE.; A\2/''2O2B.0FN2;@GSN1< M)9927>5V:>.=T\36[[S'-]3!O$CQKNQRH[OVF"Z9+PW;I[+]1@Q,K4COK-UA M1DPLDE&F,-EAR+MRYU$8?"7/Q%E-D;4C5>G8%B^0=QVPU5VJ-1WL04PDIND(,-;+'L34&/=53 MH^I5K>C/R=:<4+P6;!LI(A:5ZAI)< M%Y7[KWH;X4P5U=%(KJW_374^=MFTK%D\52\_G,D 674XJG%X*EUF.),&LJP, MR_(_GGFP$/]WG+/XTG8-UZ2WGH*P%K2"YY6]^[RINWU)JPID7<^M]RI0=K\H M#%48K%TY->SZPE,K8=A7T!L8FQ"M<2V7B[)0R39>E*AYU=MBP>* +Q^3L7XA M['_K0(ZNRZ*>68!6Z;]NVBO;2%F#E4YV.M^'>G06X;M;WWNV+6)]?OT>8(Q# MBM&Q&=K/;&< 2+?="'Z+D^1Z;CU:/,0<67K.INQ!4O,,[EV_]2 ,7M'P^UQK M]P.K!T316S&?;KY7#9$$)#N&Z.5\J9'=!: MDL4K8E;A2_==*]'51T!2!THC5*_N,]X-Z]5 9M:N%!Q^[ Q?;:ALE.=JOW716EFJDB1J\D:I[D+LK4_F ML-RJ,;^%I@_TC18AWV4=)%8OAC+,+B>JDOB%S'UHCGH1\+=#XFOCV45\'9(< M*%*V@&Z9;NLBM;I$92WKS^Q$JQW,O;T60R !9C.N\XZD-,A1=7.AYU-1U,324D*'!O/B%/>T.SW[YKTI1\^U M@>O#FTGUQ=VO?W?"3W,A"%\=\LN["7ST49#$>2@\V#-P>*[)BW#GS0RWQW[H M"1CG-/DDS S_R78_"N*[OS^%G[ 1_+9J.^G'C_C']92N+F]N!L_7-U_5H!)8#SW;4=0Q)X@B^(('@O8T'T(SP5O M(GP!#_C%\$E?>("?XT9I0Q//GQ&+4A)ZH$+/Q/'F@N%:*((_22C 4]L$JP:/ M;!.Y<(Q'[-?S7T$TN)V.+Z/O8LQ)1#F!A@S+\DD0"(\X)8?"E!A..$5=8@>" M08Z0A#MI\"F@E$QHJ3KA%4OE$=<*D$.8WND!CJ!(>2YL9,*, B:(F /< T+& M;:!O/C7\F6%2XJ#5N>\]^<8LZ*_!3F:#8L4:Y,Z7,SOM7R(_37Y"CX]A\.F3 MH'1"ELWQ((HZP*5[A7Z;(W7W\'>5%P[VCU2G0X*>\@X,%1S5K'S%PEP#>J"4 M"7E=U [=$5>E(OX;IFG7BU:*K"]?%]J5TJ.RO?N%)%D5=4U9=K-:*83*QN.L M^)"S)6SO;W'.9%4;#4;+ER\;E@(+3SFHYJ_-/Z")JR[]SA0?E__=LMZ65?/!#,DD'8='?I^4TB\6PP&FBXQ;A#_\V3OB/\ MSF19P?-XOGG:'7-G@X$F*\K^#.;#^U#(-DW=4I"$=/>X7!KJ6**[^BFK0]35 MZ5_$B/\+7((D9J>8@N+,K'?DK\@.[##)4\IFN#C;*+ZP>G.DKJ3O#=/,J8QJ M ,JQ),E2#"W,(_.,P D"I_.1O@T29A4!W9&HJ@.ATF2HZH4K*,_L6.9[VG] MCL;8R/ABNY)16]KK])+.&&0X8\F7[^S@STN?D"0*^0YWOJNMS3-'1,M9Q./L M6@G^O]FN/8MF*WB_C7Q24%-.E(9U9!4OR_8)R=GX44G.LEA'&>=6R;G@7/0 M>%;KJ.KZ!N5<$<^25D<-NU;)N2AOXKKT@3OC5QS447[W#&U:;F^7;PF%=3^Z3G0#.YH\.,!2WU);LP#+F;\I&1=!=4@:U5JREIP+>O# M>\(@:TVKHQSB&Y5U15QK6E/6FFM95TJHO77.T^HH-=M&&9;V?KF7X=I#\VPJ MD>]S+,&5'//NETI%492^DLM>4IF )GF01V7&:"+<%V0T^0>@R20L#.N>!K+_(%MNS8,SMD M$<(_]X7_9/F*\8,"?I!;H&!J/]K8X00&G5*1,.D^%4H!VDA M:P8P$D0.#7T.(G,:BPZAUJ,"9KF4X6_OB6#,MO!BAU.,DJ8T&),)6!W@'=A[ M\2+'$KP75YAY0'(X-5Q![8]&?TO&*L2*?X)+2VC0_M:/!;SNPD#2/$HH+V]1 MCXK*_*6-SXJ-G83P1.L#PF4?YR?SN M>B$&PI,?)D:B UTC)+^W&'_@*:2?)MU0$N"3Y1Z -<>A[3T2@4PF!&^F$[ M M8*0%71(LXQ5D/X&E'OL4WL3"\$!85"+,O+RYV%Z58^D4)CEZB9^N.PD"&SI< MV)M-]K30GL@%#>7/3!)UEQU3Z,<;HB*(1FQK/A(XA M[1AQ2I+@'#JB&+[!)CQ\*687II@L8-^OS"#"8O;X.8;Z8PI;YY52@M-)#G"Y M&67=7,*FN,RD(=@SO)8$73FOL=U]LI_Q 3/.B>HE;%%U1FPS!5T8=B]5)ANU M!AJ:H>)0O)NFYUL4\91#.N6A04ZHC34J6,Q@0HG9BQFIO68P(0+O4X"IRZ%W MJ^+Y)W.)"F8X&[J,9R%4PNS(;9F5]E;#W,IHEW+*FU9&."56O>6SZ^X/%J=2 MOLG:GE]G-^O=7_4+])XAN07@,[CX@]_9L\ZJ2W(_9D^0V(KH;# M\E]OQ3_D;[+>2:O,D2*K5_@&!+7OF3;"2GP;]JN&D^I?;]4_1M_4XPFK[@WL M+S;NL+A6$^>B*_OS6Z\T'X/#?6:U=G!8[[F4V/292I8=7N17XYG44>1'UXK7 M)+SU/=R^"I"SE>M==/&^74.4;!'#8&[[) [_OXQ%@J MD5PB66]R*:@,[44% MB%%BS.<4ZS,#T1UUR^Z%EG,;GLV5/#5=_6G),-E4Q0 MR7KB]F.CQE)P:]@0ZV+B)K,;Q>> 9"BL@:&C#\T&=NZC1WP4VH;SQ8L>P_&C M%X6_>30#/VBS[SX ,Y^=-7:H-=F\Y(_";S=7U[\)YS?7YQ=WUUT:KV,SD!PZ M%>2Q0J0%GF-;]%AYPE*_&PYT S_0R2,^"29S@YY(!:AXF S,Q]UR86R:9(Z? MQLE6\>FM;T,C=VN"6[G>7'B+3/%_L"->;".,9$&@:@C&?._"_>&J.&\P" M.X0RF4KTA)>IS0Z(@9XYGGX'[$R &$Z26A(:,U@*U#C'EX"N1# QS.2QDTGJ MFSE.=SU_1C,A1GY #](?D3\2Y/-^"5.6R2RB1]PN"07'@^Y8;RYY,N@IJY?D M Q=,(Y@*$\=["01HS<1@ !02D-(7+CUZGL>VU^T? LS>X300Z F>\%^12P1% M%%##>[G3*Y_@+C\>2Z?]4Z[G<]^#%1H[8?A)Z8^$F>TXR#321I.-K;PC)^\D M T'IA9%:<&"D*1" +:/CAU,Z0&^X+D,2P&,KTG'UR?/Q(WP M;'Z"!SY 0Y)2SO2>\500,)092"_)&P=8]U[@J4#?9 DM62!##JV,LJ2.5WP MDQ"Z^5-V"(JG.WA2B2$@GIO[W'O$.D%T="P0(?768VE!RY,(XQ52RF. LI-_ M&^,!L#@.C2F9V"BCI11[)DCK"5!,J7 ]5*?(1Q>S"XGC6S-"0BIL%WW:GD"U@O6S.'E*>DF:8$VS_'D&M3NL M4SSMHJ??67'9R'V>J!7!]01:UYH= >(!N(G1%AZ+ M-1V8&1,-+&HQX,*/CW\W?):?@5C$ %B2'N(-WJ(GU#%NL:9:K\AX@;-.YP7H MM9@' >D/,O:#6J7T,S08>9,3Z]+"4L==L62AR?EV '-?DO,3YT)0I6 1W8.* M JK@AV=HUX1'S_>]%^2!'9 _&NZ?P X--9@F 7Q^?"2?1 >"JQ:^OH?6?J9V M&"5#K#ZE(HT!F*4LH_%'4Q#'FS%3D-A_9I97A$T-NHG'_9/(2<(0P#V#J9?. M4.YKFM4497@$Y90[[<2/?V>VD]#=,3:8&*I"?MBT+E(&S<43-?,KX L<1SKW M+F;$!/\NT W_B*C2+IS:3\(T%S*Y00/3SAE4EQV:E<["%^* R\WZZ2S_D9>5 M._F[0L[7I:%"U)&*VT(DI08&HZ=2^T+[8);9(H'IVX_Y"$(L"@,Q$A+IPB$&UT[8 "RE2@T M<\X M1];RF;%<6**;A+'">8&F@(\D:'_GN,D%O\[)N3%ML(I4B+^[1-Z:^"1 MG9D@,&,>D(]"\MK&D_?Q+V,]UXE^*3$,\F _5O]4[NV+?MQFOZBL.6S' UD+1I M(MY(PUI)<4,5O:.R($NL@2Y)TWN:(I^$J'B@@4_)- TBF=Y";IFH*AKCEZD= MDCHL< V;(KYAX:5%[Z6DR/E 7CW,UZ<$[UK# A]"XW;\=J9%%GNB*+9!)!QX MCOOS>4?HX;K/#J#8>=1KVKM%YEZ Z1!)!?CD3R3M]3TOTT ?\L.GPT.X%RA$!KR'GBYH.@!N=4KTG:NT%X+$\U56.Y;Y6!\\/7A(MBT3,V0&6D$2F M[*F(-=%8+[XI4?0^@$.:T,:?FB7R /L:\K"GP"11_^9"8RBN;>HX-CVGC]C= M9XZ!U--%J8II_D#CRO"G^%;_NCC/U6O0&'0:OF+FC7#L6A=_1?8<(_>_V('I M>$'DD].($=4^"I??[ZZO'K[?70CCZR_"Q?]\O[K]=G']0.6W)G[C%$,0^6/@ M,O)=.P2HI7G8G9'+/P>L0Q[HV']6GGL$>>-G@Z!:ZF$>4&2VHS M@BEB<0IY.LE4Z:R&FZ+"BQ$(/PU[ M@X%"?_M)D7L#1>UAHJPY*^;IO/;8([".*CZB_]#EGJ(I/>R14D#3S*W)+KO4 M9[[Q[3F-JAQ&+Q]DQSF"@UOC%4$(__0C8GU=)(&$]FC,9^:G1;/GF'_7#4_C MJ'OP4;@=_W%W\_6K\/5J_/GJZ]7#59<1Z?@, #1]SV&N9S8[:7?$W8HC[OHT MM3M7Y.Y<G5JW@>86H*L[M3[N3E*=!]2Q9YGV_>BY40#K,.IV5APZ M'L[XN#K#:_J,;HB)'_8_H^-AW'B@X2UA1Q='/479_PSI;1SEUF9GA6?#K'(^ MRX\R<**7=>V8*VIOJ&OMDPD?HW!Z@!BI/4U2VR 2+ES01@YPEWW1.=MARM:^ MV7\QP=OY41=%UEUQKWTRZ,() MZB>R)E54AW)/E>M/-W'L(>>-G@Z":ZD<+0^I*7 W&:OK3=SD+\<)G#E M8K'2!^/'J=UOEZ2/PM7U^MS?'>U_^A(7:ZP(=LV>/)'PA9%& >E&:U2=SSP^3NF/8Z*.!U9CRM:US!&)],B!@1@Q4 MD:0V-W$-$\G#)GQ:+MMV!0(DF&'*Q"LQ_%@,<7WM<.H%6$IW!E08_FN.:.R$ M%1!DI?D>TU*P& X!WA@)0X=8?6$L/!M.1'<"6<5D6D'2#I+2D@LILK*PE 1@ MT(I')CL<6*JP1V7 ZOT^&[9#)4JP)6BW1^G"PI4KM&%E<"QXV7;$MIZ!<5SA M&V/,(B=3#2@K/:B-=IK/\#RR8FEA9I"/EQK%G=E@UUK>,C5BV*]\# MLU.V?QM$G30B[,P,*%#D(8*F940!D M>>!MSK"8\(L=3H7?QN-;P/]?D0U*D/4M0#=GQI\+SS[VK(,@FLU9[6GF;U 7 M.O7$KH"O@?ELRO@>SB=Z KX\CMZ?."%6^CN[M%V!7P;9ZXKX,NS!G0%?$\2 M#QRR< 2'M"O@VUTNVV6)UQ7PY6=4WQX NP*^7-]N[ KX[DUM5\"WNPG9(?;P M!7SYAV#!Y%%T5W/?6,O2U8A/)3JSJW2[@8&V!VER%/G4QFBM]H76=7&;;:6Y M!>#JXC;++EV[2K?K1I2'8+BNAFB5A4-7Z;9#*>\H[2K=\IH/M*MT^\;/++I* MMWP,YYM$7E?IENL3LZ[2[9L\B^@JW78(/"H"3[O2;8GJI6N/N^[-*;$BA]Q, M+FTPS>2K_4RL*S/E=[]DU7)U1& M-5P@XN,LA@<:.NSPCIV*9G7GHYM&]B/OO4GX8OA5\S9U&^+MV1"7)*6GJ>V] M/](AL$-@JVXP\9DZA9[!"':Z[Q4G92XY*/PX0)SX8G75JM+D&E3C"#+A8Q0Z M0!Q1)H=R?(\>LV3,,)7\O[N8)4Y)K2UR1-=[0ZV+6>J0=W#D27)/JF'GHXM9 M:BAF:<5O[J*53CM69*CU].'^J8UY&W+>Z.D@N'XW7!6Q#%H5XUL4#;1#;,^Z M\"!O4Q.7M%+L..,J7[",*"<5-\2XI )?%,G-K@\6Q:B*2F8FI6$G6 (TB$R3 M$%1'6JN6E>4,XIBCH(LXXBCB:%05#P.!.)22&7K+%+AGUY M0_O"3\:L:-V)C@<7RX'81@SU.BX8HLU^;[.2S$%.UWPR,]!R^DFH*"I?U35Z M%V!0/L"@#G)4 -JP;45O*FH51YF>07W*7L[E!_^$ZW,3C$W3CXCUU38>;<<.;7):*0ENC5??^?3YB'<>.!AK>$'5T<]11E_[LC76Q!)3LK/!NF4>%>%C_*P(E>UG7% M6U%[0[T5N_,=( X!B)':TR2U#2+AP@5M9"]]V1>=LQTF(;.[M/]B@K>MY^Z8 M)_%(!CU-Y?0R:Y?VA6=2ZP*@WA/51JJS\#@OM*YN=>V307<263^1-:FB.I1[ M:NF8/1Y/(CL(MAR" WW4&X[>0/K]\@?6&XZZW="V;"<*[6=R3\S(IU]?_* 7 MD2P\VS[W9O,HI%L?-Y,+PW=!)L$M\>^GAG\R1^(/4W;JEIYX"^PLF";KGWA^ M.*4'XFY$+SIZ$V'N88Y@VW" \=G,V84/ M71(*CA<$PAP:HI*'E^G'V \E K\*ISXA C0<3@-:O2:P?R3_)"YVD+_OBZ_@ MZ8WP2$PC"@CMFDPFQ SCT_R9\.)%C@4OP,NA?9:,>G>VWYWMM_% ;]WIJ\[M MZ>L#ZG1*]S>FS!>HS!G&_M'(0J%9<@) MIXNTC6ONSEYWT3)/7;@5WS2W T"G&DYU C2W T"=!>*6YG8 Z%0MT$8/[L ! MG>JPABBJFSGN$662_WC"//+-J1&0=),I],P_*X[BR,4F^@GM239*FG MZ6T+U>M@Q!6,E)':$T=MJU75@8@K$ TT!-'^%T1Y$!4/-/ IF\GY)0[6G:'K[I,+'.)P> M)-HLEC?-?(.8D&#^'/9D:=_,L!TDCD_*FS03%9VI%EUA^=WP?0,SIM>\_=;= M(VC1/8*>I(QZ@U%WEX67@7U[&%1%N2?+[;W,TB&P[0A4>O)0[PWU_6OJ4-36E4^AIZI: M;]#=X>-M?-\D&@4+N[38;'#8H-9ENGV@%1#0 ]OH\\;/1T:][>,!2[H MEDO$-5T%7G_9F"7F_F:[]BR:?25&0&Z-UQEQP^#2\\^-N0T>)OWYM/)MIY>+ M*?O"C/$/J,6MY7DL <&*L%#O8T#^BN#?N/V>F89K$H?> M:?7FQ(BP+3CAF*S_P#(I&1=Y"O_9JZF=B6 N8G]OTGL0DH[LZUY9I/[GNEG MK'+PB8YBQ7V9.LXO"P62U X>U%0[..W[?:Y<\"ZE@C?1>]3HQNHET8^8!+CR MGFF]H9IJ;Z34OX%S!"@<:B/U2+G1BGW!;O5V) 5M/CU:(WK)<6:J79=\RXO( M+W9@.EX ;=U,Z'+S,WQCX8*4N %=D8XQ?N>)T+8_OR[>B?L;OQB^=7(KRJ5T M57.?!'0QB4L^(P)P@&A, >%"[Q;BJA(? 8>B<.L8KA#8L(X4\#_T]B&&/ 61 MP=:?^";#Q%"6Q4\$K.J33XB;_B8A=_Z,Q4S%-:/2IKOU9!/K2>EPZ\D:??3_ M,MS(\%]3,NI=)7*T<7HD:FI9C=8XWM=1?EO FVQ9=++L>:T#147O]#],DY#) M9)]5)#O1%_N2#,9NL8[4ZUE'5@WYX6%9V-&PZB8VZ9JQ9M*5OTY2U@]Z2T11WU-*7% MVL+AS%*V8-9;0.Y)Z8JN]32M;$02A[K"Y%P:JD:#LG)GAF7U#2^(]NB.T"2)O7405O0U?IICQY,IT=%F3/JS-[L[L-P M[#-IWNA9<_PL+\Z?N2:NF?AZ5'BM:FE?[@_#:SZZ7A]>7?SA/2:MB'/+_M-P M(M9C$$0S]MMIAEH;MB\\ [<$P^!HW@[!8_P*3YCG RLTQ:'192LKO1A!6LP) MWHH">NX.#7Q&_3B#G+?=>LT5OUHCMJ.?1M_"3MRA/G5=SRM?) MG#IW &\ZP()'@.]6*&(-)YS(G&_J6H"(6BL_M-FR'1X>? *2A_2%;Z'';BR. ML2\6KQ1TM89HHSL[^%.88 E>&^TR"4+!AU5?13/*0U@8#S1L"$W3ZBBTTA_J M?TN[/A/DOJC^K85BZF@X$%S4818N4E_3^(9+11M:^8QP;QXN?LR)B9MB>!V$ MH\GGV#TV.-EK?44^$_2^HK-L#MS*X"WTV.@X:T,!!UKD;Z";]^W> GA."JXM MX/XM]/C61IA[#^F+_6Q;Q+6$5YLX%D>2.W:/#2+U;$',WUH@B;?0XUL>[19X M2^DZ[MESC-!V[/"5(P$>N\<&P2M),FYBX6Z$I/:E4=G]B+<@]A,;:%C0R6R@ M<6G'TT 7&*C-R5WJ"#@K$\Z6C97+MCXV0W"KPM>3"F'+EH&W06I@C3$$S8O" M(#18WD4CP*BVU3"U<$IL7S"85+!TJ!7Y2> M?H7?@6XCS2T Y^^T66*=;8':&"R@\42VO'7Q@_BF'9"%T&Y]V]SVU6U6.RBF MWP8\VDCSFX/T.=#@@V\6Q564UK_YU9YD@']'$_INM^&VN_CFC_2@Z.1QU$:: M6X#]\=.33YZ2D*?UJ+L"4-MN8)L+>>":[U0-;\$2^2#UCTOZ_VF@C#JL(3+E M9K'D3&F+EYXLGZ,@L<5GQ2'F+<:H]F3AW.9P&PQ[([ELVB2^1<4##5QEG&\8 M.[+>EZM>S>V0TR[)- RA$Y,6#S2TT +Q/=05';S]ZDUL]^KJV=3]C=UX+SF< M_*"9$\6JZ^BO-Y#TGB*73?+*D53X&(?3@T1?W;>6: >&XY-RK,!*CL3RIIG? MC@D.6:CHZ!QP)ZL>G^?2\R?$[KR>8UNU]TH-%;/W)Z-L%40^9']Z,)"TOKAO MX;-N7CL^*9VOTV'BU'V=O7,LY\XN#^KU7/R8VWYIGV<#W4>$5M4ZORTAM2Y_ M2AKUQ*&TI^4HK.U[."^+3^!Q!*PF4M^#![;_ 1Y?(\87-:>-GQK/J/@:-KZH MZ6:_$P=A16>TCHVWPA3II3W3FFZ6;(@FRUYDVE-Y.Z-1V3(\Y77XV*//&ST<0:V),H%]:=\MQ0Y";QM"HSJ"&GD;,M[H.I U; MK+CMP")'0&NB*KS4USOWH\/0/K0,^NK^%[IX&S+>Z#E]#[8]B*GH<=86N+B= M_4.[H_\D <8WIIZH:PDD3<3N 9]!V.D=O]1VNZDM0^/Q37RWB=HAAS\7=-27 M]0Y"?$TN+71!NTW4C$M;-O%JM=2H2;)5(_2"C_3U*YIA] O-$\JJY+)<@, 1 M?11()=.I_F],Y?_>^F1"?)^P/+#?".8L?"=$KLU:8,V_$RQBVC/#"7YY=W5] M^>Y711/E?WRH0E>.%_S-<$T0#0AD!J*@+]^X7VWCD::Q_MW &NMADE?N*GZC M*G-QZU4XDT3XOYBU7%C*L$ 3&HR MA^RG0-_OO]RNM0E]25LPL*7K&BC=K!2;*=650U*Z&>B;*!7[NGI@F6X [Q9* M!SM3>N6:WHP\&#^P(H4;D,_$)1,[W F?[X0?@?W1M1UP^OR(O!,^[-';5HS5 MVMM6G-3-V^:Q+MO;5R\(L$U,>6J[$8S[S1RL%G5,/Y.)YY.4*A)\LUW/!\_@ M*BZT"Z#(MW+Q5P2/OY%PZL$3W-7$4@-EO9IE#A8P%0&DRDC51#6C^P=D@#/9 ME4!V7G:JJ(Y&[JP7]XDU M$)O96JR3I.<6(6L[VXNJ&F:TJE*HI"O*\ 2V'7>8ZMZU_2)$9 OA/WOE1NO M&BB1F4%30T8ZT M[#]GUD=+Y3E(&HYT66^$EOUM>A5:8M6N!2WKP9+TLA,958&R'B=[D5%9H]=" M9%]I5(+'>G2L(^,W6.7XA@/3^MB:V:X=A/C^68C7T:9JBC*2=2;PC 3%\29.-X<74';5L*S MN6'NNN.8GRDT?2@IF5&L0D #Q%<2<*W$7Y-PX<^-GPW;HHY%O$# MNC]A\G)#'8(O(DL\\;#_,F5/'N*RN<'- M) UZP/" )+Y-@G%>Z7,?E@T0V6QE](&L2+$9 MK]1[CN[$&MVX[,MSSZ71WC F^3;J#(G88#.K$7485L:69>.FJ.'<&K9UY9X; MT;XIE%7!RM(74.PFI/4 MFKUYN*#!:)+V4;C__OG^XG^^7UP_"!?_A/_>TPBUQS1V+1?35G/%Z&8#\%I1 MWGH!+$IDZ!66_O:]Z&GJ1:$PCIY )01)2A\+1JH<@M33-;VGZSJ@$FT:4(00 M?6&NB?5$7M#12E+XSIOQ-ZU)B><$JPZCC\?ZDG2UI/%,4UM 2A[3C9RN?]K6.9 MB99SC)46)0O8MTO(K=PXRI2,9X?C:+BT1_YSPB*.&/Z0# 0# M?]OQS"M8X.73H9W[MB,H&1SFD?E"#EQ?_N#68I=:\H-Z2LG7>]>M!E"!B0$# MDZ*H9$#V$4+J,_57#]\[AWNQ MR360(_8';2L(65$OCFI/DQ#Y2KK #_(Y@'L=$!\I>X.<1V3O5[>P5N8NDBOK M__0<\!LP,N0-@IVG^YS:\0NU_(T'$]X<>\D>D_"'39RN0M61C?S1I5$;VCDR MZW=V\.?9I4^(D,38IEW?&>%;]&>XPGQ_,/J;<"9(_>&^2>PX@C^?QCYUOQ+##[IR=,?&OZP"_#O7_B@8XP-*IX?J=HGE@,9];W;RQQHMV.+N\,Z= M6+BWXSOOP)_20'*QZ\C!#LR)&?!N-YT'7.^=)XY'7'.TZ=+MI?/FHG!@R4]\ M>Z7;2^<([B>$=H[,>K>7SC7FN[WT;B^]W?@7]R*F+P[/U/Z@K;Y]-M5NS3'A M1;=@DY5H/TAUSWR069X&:2,%!O?AI=DE5,^+BUMZ74-#1L M^-*P?90G&5O_BEBRI<67%:\"Q9_A@Q*W?P NV0R])VE2%FF M^]PQ@L7XW/AW: _2Q*+$C'R0!0G.#<!N>25)ZD6[I@DGI?-"ZIC?!^9JL2W?@+?HVSIGG1C!-$Z>,:7IP MNYYL-6>RG%.AJC2L)/7P/.O%=AR:E2TTW">\? =&EH3!%SLP'2^(_"-_77W^>B&,[^\O#GK#KB:V#G?+#@ENYJ;= FV44(-"#O$5 MV%AJ*;D7Q:XS 8*;O]#4'*\'N.@DB?7<=#ID+$.BG4OB6:.*&QUGK^L3V\2W*RHD3T\A$_) MQL-X^L07/N!#.2F\>_(CU4::6X N<%>H![= F+2",/U$1VOCWE"Q]06[OG7/ M:-/>4'(75JWAYM>M$>(-[XI#PL-]P90&'JHWI;/VWQHITZ0K([SKSY.$]A\W M'FCHL,,I=FHRJ_0D:I,M;60FN?"%AB/8Z=Z7P/:]2@[*\?#*D>HT MH!H#3=Y!-3B0"1^CT &"KU/V0SF^34P$7TD0?$Q)&)MF-(L< P\$C)D'S/S; MJ' 9J'-3VN>FO)=TO3?4!GSZ*64#H#KDM1%YDMR3*N]\'!UY1W","^NW-\$U M]9=3(E;\YI[@DG#/\3I<[?D*2*=$"987 :\\[#E6)+*N&QU#K:3>!N^X)%0N+/;!=^BP(RB1S!L2>$$1T22JKANI'A.*^4"D2U M/9L;MH^AXNLU&=25LC- J0'13'.%;5J;R(1IU:"G#22F5:RR\3EU$8Q;,4P->>K>RZ); +"G4X < $ M1E,((A.+5( /Q/"+J#YD<8(&A[K%I)]B&')-,8XUN>-.'!)XZ2V"&U$IF!(0 M6EDE-]-1X9]>E&/[8E+'U%<)3G0\CK!'F!2LT!L)":-3SGO;-9W((D%.UWR" M/B. *[E#@LI7=>.^BSI<0\PR-37MLZ@ J*',DX X.GMM1'W*)E X'OXYVK%M M(L9 Z:E*U;WM-L/\N)%7@/A1A_CC(EX$&]_^/-"<&W:Y[&$%']CJ8-YZF!_; ML,M2A_@.\2=NV!^PE*\Q"8E?4E)TKX!+]T=C>, I@OK>6I+ M6$_[(\L*5"V;76^W_$[+V:$RZ?FP4L'47E,\[>HDP[GK@G$01*3QXHO>%(%0*:APSWGIA5.NC$_WN*K@7&>VSX->4JI M^Y(D?Z_]G+UH_CF\W(^KW6^!WT["I]=C@WNJ]1=/^@\,R9Q,=JDN$#OBJE)# M. PLI"0L#?8,%E68@UTG& ]=4>!?PM)G_24C(TNH8JZ'24P<[YP)[XX-3 M(PU[EY2K%Q?2L#_0TJ[/!%GM[YXQ[C1&J $5EL4:Z/IFO K#7MKWQL"OBA/* MX=G>BWHN6]%IB>J)P M1-^^#D=>%>;1HV.;@C>9P._N$[>C>E(X&@QZ@U&GLR\+\30@)Z)??.[;BU33"DY6\OJ$),TO'-:-QK%O%?%&SYH+1'+V!E$;:6YD21-?5&GY MD/-"#T=&L1L-#N@IF!2*[N3M?*NNRO6\!^QWS_MXF9R4J?S*W$J3MM]*6[XS MF=Q3.PN].;VK%O_39PGU%C\DHRHV.Z*GP^7#E-U78;E7\?8ANX,71#/HS/XW M?(Y)\N@"UK&-1]O)1%@)F!CY&7XXP$5%'H1U_-N,[W+FHQV71SA;./!V;:R[ M&GCZ8_P[S?Q*K)3.,2BL\42$Y,Y@2^\*-K_.W9N+S/W?.#'Y2BD!;OWYM[V" MZ'KL1OC@)FKGE?N/#P^<%N#J0(?9'RJ!JQL/##DD+/+?4"I+822YK!T]S(CO8-/Y> M[HU&5C?KK&=O*K?Z5-[^!V& M(\!RHWM?8&*7Z[P7G]"OC_(H%[*2CS1)8E2,T L^GCM&$-Q,8EYCO!L M!EHB9N3;H4V"
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
.J6(2V#HT H:W<=@A\@9X =."%&F M=U,PE.%"S\U'^GYKZ%9"QAW/W'[ZXR9#OY;YG^Q]0KQBYLOLW9RL"X7J*B_/ MGO_A$L^^-25SI9!RZMG)M\OL%68\\FG^38/$3V;B''-6QYQ5&8;&#;&-G8@F M9]\>KNN^6DY$YF&/R&0=QMNLR%W3=['[N+OHZGK%'H ?G*GTHWJ'>VJ0MW:^ M#)-BF=2)N*>:4%,=(,JH30/2:-6!KW/L2S\%J?6FE\V32?07W#M>,NT4Y;ND M9Y?&/79OY%\^CK'JEZIC&T1[(X5WJZL.MMT?[5W@9EX#$6R/7JKH.-16](\APR#'WC=4+$*IC!U7Y<>X6J2P9Z.O65<'^#G[&-7%N!\B4__==4 MO8P$0 _C_2@>?;>JYR-:B(M\%(0U*A[KTW\MQ0,E "G>I7K%R[QSG.7]/L^D MFR%_R7'%JOMF,U2M.M8A';M263(!YNW/V7G[[*L@W+S]N2+=2EB&0$+K'H5O/K>V6 M1E$^=+^=FK0!4Z)LH6N>F2XF=YU3"+FQJ34I/'OQ9@LO"DS7IK?8.N@9N6,? M/Q,/B5!EQ3QRL\7R RA*(P.*[Q5EH>SU"@#&L")$G*]M.)"+ ;.MJAO Q/*& MR05E6[)PTXCWO,@/$<$\NG>P-7IX0#YV'W-H/6\ 56FTO&HOY $T&"5CLYMR M!MF.9:B5B;\J9:OHF&K:Q MZ:^F)GU!0.:Y7KA+@[QUP6V%OLT;U@"M:%]1=/QK@T]%*0A=VTH*AY).T:K(:JLHAB\4,S-0P>!2.Z-U&" Z&Z;#0:O5D$R1 M3\U>QW.?D1_22U?'I#GR?63')"5^P34TN<=1%:'G3!+O4'8T#=MOF$ES($JE M<#K-/^L*G23M$$Z?2X[+KM]%NB-BX==79]JICHL*9@= +[@Y_E+T5"M/KM>2 MWN0(4=:YEN48ND;N%36?TXB)? MY(PQFQ/^%%5IPA/&DR4;SN"4?,(^ZIA/.#2=7N3: \?B'W8#.\S;BHZ\ MB04N0S@H\L*GW\J9"S/R@=%#XM8+OL< --?;.>#RJ-LM, DR \.UAYYKOOTD MN3B+EJW< ZGQ(/C@>(>QI*DGH0ICG7V0"O6@UIC>$+UTO.72<^/MYCCRK849 M(./11^+C]E)]E1G"HK//*\0@;#"+9C.@(&Q^G/C4JTKR'0Z/F"\0E<*7,0.H MW+EDW!>:J'0?Y4#A])BW%05-2\!$R!8(R6?%9["VKMFZB)%6!'AN+ BYO"R[ MF]Z>IA3/W#OA% "U1ZLHM $T5YREY0KB,0,P YW MR?G#-V4A+I'4%5B\+O-SG:4O1SUH>MJ*;R1^'\?HY5RW_$?G/[[CD]?'H_,- M!U!KGZ\A1^NC^!Y\$2A@E_EY8^:)'"N@S2EEY@3(^O[1>SZS$:9X7=*_ M4)@N$S"1'\T'Z-%TNFZ(P4HPTBK32%-'C44J).9/-0IY30]HL4F3=(N:'2N. MV#R PDH=IFK$JJ6[DUOTM;HQ!GK$P28.T/'\)WYA#K-Q_;85TE5/CE38EA:M M_H0NH?;(U^/3CH$1A0O/QW^^W0.Q?]\TJ^W\0E&UM/A> '-D(RU"<%*P)(- M;#8('UGB]8S0)@L$3'_DQ_S:\8-+VP/$4H!!G1L%')\)T$ZK?>4C=?)'?K+Q M^^D/FPS]H&W7"+'\LTZN?],0+#;WU$;LUTF)6T2TSNZ[SRA8;T]I 7BPP$^$ M!8O\VWSD@"D]A/YXYF0%@K1H>0;T!L;NLZ.'Q%+/O\HQ?EU"V%%C2/(P4';" M!;JYSXUO4+-GW@19"#^C7ST_7*1( Y"0Z*DY%-(<5!EA.?"MU* ?!!'/HTBV MTA@/D%I(]I\5%_81Y5B3>1/1=X3(M,;>VD8.T4O\&VZ!GT3W!J ESP8$XQ?% M3I]G(60']+HF2JWI6DBT]NW\)$%7_>&39 '<(I=^:B L@L>ZIE[<56,\\K$ MXE%RD=)F]T;KK6,3^8B#$/E]5PR'1$_-T9#F 2CEA,:FZM@EDL.R"^:H^(\#@9A0ON55:BKLW&,<$"B%W)88LW]XC&*R-ZP?RVJ!BJ1X-[ M:"Q]*-3T!!N_W/QV]/0($Z9F/-1IMUADYT.JD^9(R! /)F+5UCS<;-)9VP>_.U[ G#F;]LSF&J,C M)AO$16V) VMF]ZDX32?]0GN^$!QS"/WQR\D*B&G)40=@!9;%B;.(-PVG8JR M..GSXFA$!4/^D=AQ]]U$ 3AG5Y-C%(V1+_ 7#EX .$4NVI4BU>J-0>Z /8 G$O.6#!?CL<^4O 5P'; M:XR&!-V@N-764(!O&R3M[MV3YZX;!EQGI,!@&H-Z*%,@XFK++4!^J*[2%TT/ M 3HS1H/Q!7B!8"W[5%21I3W/DBH82F/@#F,)Q$]M**9G8C].Y!CV?Z)-?? # M)\B\Z)4<9ME$$/+B$">')+IJC$4^%D \U(93W@@.9AYPR51B MJ;]!]^&O.%R\K>X]9(81[W!)65_06!,JX114F)+? [K!S]A&KCURUR\_@88= MF,72_34&L ?(#Q:AG+BQ>E-T;;N6_8_PJ-2AZ#1&M*-A^*B4$2F-@/B(7A=@*OK>\Y5DL@YV/.'KH M8==TZ@91S?DX)N9Q6L=\]HFYJ&9+2U$$Y']]81H+X-E%?O_ MZ]4M,NGLH(ST?/1'A%Q+\'ZB5&=-;]/*PP((J![0L0@77: IU5G-%:AY( ' M%$M$NUJUJM'4\H*P.A#7^5Y\%OG!A+K!U&46W28ITUO1[?EY9J(84193FJ_) MUZO=7W_"R"<4+E8#](P<:8O*[=\8HRHA!=WN;V)J8):/(FLR9QCEME8&*8FI M*A)4(PQOU7 WQ!A7K!*-L,Q]]RD*@YCOMK1!SG92]49*L3D*@ JP!9IB36QQ M@FSXWGH.K]LKX14];%@5A$FVP+59/P@OBD"XZ317%)FM"L(D6^!"JOC!J2! M86#^S$ MR2NQKC,::Z_P$,W@LE-NCFY3#+2E8@7DY?:;J1*K0%J>@&)(J)?Z)^!VAR'2 M&;A/AV3@6NU_)!BOA+DA"@?D-]L[;KG9Q,_[O R[L]9@-)VVQMU):_J3,>DF MDH=*" =0^)*#NULBNE#:*)PK[BGFH!^'2#*J$U6AMH% M_JL#7^?POGX*HG,:8'T_O]3;CIFFBE+OTO.14;"[3[Z>J_9FRRP")-5,5?ZE M(!I9VC5-LNSB1YN3D3)/I,-=WK>#)925;I4023I%-I'55HT+)!8S\S(+!I?: MN2R' :*S6W(X:+6^';H^XF: 9]P2O^ ^*YI[G'E;41::,TN\@_D!C9OB_/.! MQL!8>I'+RWF6,?R&\J\^[(?R.Z-AISN<38Q9?S2D.97.I'O3G[4F_>G/;T']W:B5 M)R;6CS/$J2'#M0FW(8$'N18!D9==N6IG&;N][<_6&2%C>$,9G?6'W[K#3K\[ MK2_1(N9'@-AY,<9JA"Q>HJ_- -ET:A'+'NLF%ZV+?::FLU'GY]:U,>U2AF[' MW>%TK9%:'*>+0QC[#!ITK_48>Q_7J[Q4/'%N+3)*0 MD0#B1#J)=/ GM,D?E:=18.:H)#R:D30:.Z9+HR/\$$*ZE091@[(P\CALZAF, MV](HVH[NMU,3&V!*E"UTS4,!Q>2NF66O+7PAPB7<">HNU ;NI:5X4660GB_'2QDY7JH]O2 MQR2=X)I;C1RO M9.1XI?8(@;0.FD:H*9VDY M)NF$Y'BE.(E9=!.W?2WB[;+"S>.Q4;CP?/RG\''V:CXZ_ZSH,$%EF^&*9:5E M@)@;C6,7>%]=Y@['J2WS/MYO=;S?ZAA/RG6YQC$H= P*'8-">@2%$D63AFOW MXX0N?D:4(G[9AZB?MJ$C*.;MW9<@B):Q5Q'0$KB>CU"?+!P^"L() M,8<51-%D/SU75%V9[XW4RB4@$2%3I7CW8M[O97COOCXA*T0V?8"-\Z1G==]L MAJI5Q[J>VX92Y]>6Z>UC.34N;JQ/-T/C*I> GENH2GC_Q7/(,/2B(06JE_[X M7U/Y&#( ]S#:9I_.V=FGJ_S9IW.U1>V"DOW,NS%BAA+5^AKDIC(J?DRK'=-J M982<$%G%Z*+GAZL960\#TXI7N>M5\C>"8&N.,32/QN:6AFY.;I).4?*(U591 M\#:_W&'@-$_M'8:0UB'?\E&L-PEH89H$>\"683_CP//YJ3]V:U7.,&<&>')$ M0V+^I$<)PE^M\$/MGO58^-$DN>ML%1I;^$$:?RA:_/'6MXD%(&GJ]71TI]%] M$#]#%G:?Z7I+OB>XK0KJH+>Q$/!9WGWME<$B6LHX713=.R40N1 @S6U,F1CI M;'E*PE'G\A3#B0='-CO$36/5;L )OLGUG[<55;3(O^*2@P^-,^!%>C?D(.\>VZRR?'6R&4\/FH MGS>-@GA>K)L*U"7/4 U1AOPLZ;E9/_A4W>8LW;.)'>J*]CP_5O8*%A#!%QNB M.)5QKJE37[1<:+-R#NEED0&QSFD95%":Q?]@0[2K*L8AY;I4JER[U1?YS]A" M[/FUXRMF-IAYH>DD?]_Q@G#HA;^A<((L[]'EG]BN[)/Z*UC%K$,J=J5^_2JR M9L?_^X6( KN/:[=/5$]:TE?T5Z3RN85TYZ/2ZJET5$#RAM#,(WG3N^MI]U]W MW>&LU?TE_22>'G5&:38SX LC0@,]:H[V8CB"RB-F:WWJCP28".)7S:M%>@\A M?1X(!P;VM=1OX$ M/R["410&H>G:Q*>%01+U5'637DY'0XH-/9,L8]^S$+(#^NC$AO[N*S'N..!% MHWB]&H*9D(4&S;4MX6,?6VCWRV#SVX"S0R\T7$,0+LZ;GCD-)C^[J.;N&9D. MV6$A^WJUSUI.)9 ?N,GJD)-+B60$%)#9_)S^CX:JR4_^'U!+ P04 " !R MB@Y+ " ]KN98 1#P4 %0 &%T;W,M,C Q-S V,S!?;&%B+GAM;.V]>7/D M1K(G^/^:[7>(U1N;ELS(EJI*QU._US.6O-2YS2(Y)$L:F6Q,!@*19+Q& MDX MR&)_^HT#-^("$@AX4MMF74IFNGNX1_SB\O#P^,__^7D;HF>?[HY7=Z?K]1'J.G+-O]Y>NO7UY>_IR^WXB?_NS' M6W1\3$7\)_W['W]A_SQX*494E2C]R^>4_/6+!M_+AS_'R>/7[[_YYMW7__OC MY9W_A+?>,8F82C[^HN1B4F1\[W[\\<>O^:\E:8_R\T,2EF5\^+I4IY),?R4: M^H8F*?E+RM6[C'TOXS5J+ 8I*=A?QR79,?OJ^-W[XP_O_OPY#;XH&X#78!*' M^!9O$#?S+]GKCK922K:[D"G%OWM*\$:N3)@D7S/^KR/\R)J1%?0C*^C=]ZR@ M?RN^OO0><,1P$.2B69",T(S$O@$T,ANY(>^RVY(1O-XT1J.Q>Y\=('+C=/CQ\] M;T?EO_OA:QQF:?G-,?OF^)MWQ?#];\77O]-.FN$MCK+S?^8D>SV-MSLZQT99 MNOI,TK) ;NU?O[#D^;IK#>->):5)7N(;ZJ6@^-J/Z:RVRXY#T0*"?9/$6VM5 MBDJ,+1E^#Q^J>+C00W?M&I(#1=:;D/*Q19).#K^=/?% M_Q"DJ*9%OS'J__.?7]>"181Z?>CM )60L: X]+ %FIWP23 ME@$,L&RT[(*LYD&,B>Z84,$&#'*W./-(A(-S+XG8_E"+-16Q2Y#I%6ZB2TX) M!E9:]7IX\OU\FX=\JW^&-\0G&3 @5=/V:>BEZ?6&CZ\V"ZD^_2*+*)7:T@54 MEQ@,J$P:]B9#1H;B33D=3K)JHM^D'";??/_A&PX2]@T%/'-U85[2W2XDF72L MT9.Z@(:-L@P5.KK% 6&A7!<+!74!!4X/;(RY(!')\"5YQG0:SJCNY"'$JS3% M67KR^M'[KSCA>-:,.H,DN!R'1IC6')D&L"\.S?$Z=Q$K)!QS$:B6@800YA/G M8I 8Y2!M"6_H,$VWJ=K55H?&)1JEZC7QUB( @RB95EW,%#3 1C;FN<@SG-S% MF^S%2W"G0YC! TP/-Q0':^\K6YJ:),X7:Y* ME&NM5AN_@\&"1*G>6I7^A1C-O(Z9^Y?X_BG.4R\*5E%P'N)G'-TDY)FNE*D& M/O(<*#E2Q3#;^*$"W\G-,LM=? MO"3Q5#MA':$S*&D5K5 CI8(!$)UJ_7,&3HM*XKE1T ;O!34ZPQ2^^4-(_.O- M!BK0=>O3<"PT]-B8IAAX=*PQD#=97,O1\BP0]*AGFAEPUPJT>Z3\7&*OQ MI21U!B:#LA5R%'0P8*)73K+H*68@3HXH_=R0N,ZSE 3X-([2/,PH!B]((M_Z MF,F=0<-"Z0H>&EH8$#$KV(5)P8%J%L1X@&V;[NB0AM/5#16)DP0'YB P+8?3 MDW&SZJVS<37YXA"SU['GI>4<:(4J'I"!8[>8AX;<>$GV>D\7;JGGL^BC].2U M^8O.K3M @-MHGZ&&M2. ;+G!0'2PROU3?!$EQ.E N9A/<,0CE[SP^B7"B784 M5-"ZA)Y6W2;*I(1@ *73KHN=FA9QXME] .F.)+@(C+S(H^ R]#6. VU.V^ M4>7:): D71P<=OKUG .%G"]63'_Q:/8=:BG/06MRV%& MJVYSF)$2+HXD&^VZ.&*T+.:P08T\BJ6K.#KV&M\UY[]Y/>!7^*5Q?>"&5LR3 ME^+58X(-SF]+1F?#TR!#JI'*BFMQJ U6M8L[RHM:MS]*=E3QSSWC#<47$%@- M0A-\$(W SNR F\GKGA=@B"E]-[]378%*[Y6E0$2\.+EL->^"B M5(Z"\-#2U^E:BBI?UJ\;>7Z2 XTOI_M0&.B2X911K$9YAEY MQG?8SQ.2$9R>?_;#/,#!!6T7$=;(@&61F+='I M!RK-%-D%!"6PT;P(U-"BI$/C$B%2]9KH:!& 089,JRXJ"AH'X0H1_5:S M:.M2N Q.D*C6C$EH_+QXVZIUDBSBWCMJU@_&9OVP5+-^T#?K!X#-^L'4K!\< M->NWQF;]=JEF_5;?K-\";-9O3ZVAK3][R8N&) 9HJK<(U]LRMCQ8<6.^+T9)L#1 /*#<0#Y8:D!Y ?] /(# M)#1(=9(,(#\ VX.O;ZZU^^_&[R[WWCVUFOONZL?%FUZED;3A'=\5^!0%.'EA M#L+HT>*T5DONK.=;*%T- QK:Q8%AJ6 7)TV.F<]I4^S_^3%^_CK A(T6W[(/ M#$7?-@8)^M7OE_C1"\_IW"2-P952N$"+1C4&$,G/BV-"K5,7!IP*";)YCU17 M^)&D15#<:9SL-!&,"DIWT8M:5>O(12G9XHUOUJUWUL.(JX!%1C[WC"%25GV* MB.Y*JX3(&024"E:MWZ. T? JM>0I#5>(4\[>W'4L&MW F"\SZ^G=@V P0)PL.$#(%VP/$"I?.$:/:36>)DGAQ)-IJV+L]3>F/*X:I0UM48Z%/ MF(-V0_Q5\$S26'X%4$_J;ES3*UN/7G*ZQ9%AH5QO)*JH44$.;*P9<(U^^?OS MMA?G0=^8'W-57C>/P<(3B]/'_\S96T//]!]V+\UP5T)*[?JFA$;E[CT)"2D8 M;.GUZ\&KHD:<'/%;A*""=MOVZ -WY;0+(DD3P"LCA(HB_1#5Q=!R@0BC@A @ M!2 ,#SX IQ!:@X-.I@94(632A]R("%R!ABE@A5 >A0P *%22WH*[ZDR4KU^L1)2^X4(G3M^A!7;[,.K>)#?P_NPB/)SUZ8XY/7C]A+ M\X2?GE\D?-KT=2FDK#B=/JEC;TKK*1TSV^)#UG!=>UG&:W)4T8-:3E>V-51- M;]E]/652V&&LBV#1PA@I\\-!H5K;WDA-E19SW"#6YCU#%#W>@K#[^C>"$ MUOW3ZR5^IE"R&BNUS L-EQ8&*49,#2<\F-JHJP-JQ01SW%Q'NSQ+N4'R:V96 M'(M 4*VZ%'=]]JD8[6:S%5$K$[),BQ61K,X8 R*];(:"$C4M/REF>5@<4JQFGCA.@KPY[_C M5Z5Q/3JWP%"HV49&AP@0-.2:*;!1$"-.C2CY$N@HQS%VWB,QJ_VS*RS(E"HA MT/P-1,M+%%).%HQFB5:^3[R ;O+N7K+ 6+D M2Z!C114)N!LS]!XE=G5^=X4&J5HE"EH_@FA]F4:]0XF2!C&B)=KZ-$\2IB-) M?2_\%7N)>C!0D[I"@$G9$@PJ.A"X,"C7BY47Y$C0(\:PZ. @%J:_X##\>Q2_ M1'?82^,(!^LTS7ON+0MZMUL'@]KM+82"& 2(;#14;"D\Q-B._\'X4,F(!.=R M@/HY#O,H\Y+7"Q+B1'9!5T'G%D *-=O Z1 ! HQ<,R50*G+$Z1?T3(A!\!;O MXH3=*K_+O"Q7@T1%[MA/H56ZXZZ0T@)"CE9!.8#^E***' EZ5(A9#DD&0H, $!#Z6BE@4*23X90+SB_U]66>U#IE;UMF7L3<-.HA4*ZQ,* S MXV@X ')0DV5Z[QQO_P("6;4X%[2[R8V<\+55XJ<@ HJ6KFPDKW#\S.5+V M><> KK#XT9/W$':]>BHBMR\8R!1L/U_0I%@<(UJU^K=5"B+T&R<#$J%6J75) M(KRF'Y4W+B6$BZ"CIZ@4(145/)1T5=,@A9$B3@L$+JLTQ5FJB$E3$3E]%DBJ M8.LEGQ8%&'A(U>J_^LJ(($&A<.-8(:)'ZQX8"G7[^.@0 H.)7#O5@9$'"#6G M7OJTB@+V'_:4S[,7LJL%J^S42Y)7NA?C\;D*VRUY7:)JD#E-E%DQ@D'=$&U[ M**1,_'JNSS[@FAT&(&\Q[4/$SW"P#S0'2W$)TI$F-N$Z4 08X([3NPOA6@H' M,0S@WB1XYY'@_/,.1RDNQGI%-2AH':?@4:O;R<'3)P0#*)UV7=@4M @+8B # MWLKWXYQ!/PJNLR>@BD%F0I /<*]PD\0[ MG&2O+)L+OW5%Y^T=8+Y M'@"7#$\^YQ29=0!?$E><;!.LJH[BQ;GN@Y:J"9F)Q>U;4RH'5;5\L! M!FY6:G8!5U,6@QD@J/&9N#" MJMVRE/0.DW,JU.WE9171@@&1CKM%&LE0+.@ M4%P[P2^Q(%*OA" N@;1K'TBM?4F\!Q*2C*4SCT2FUZW:7 MB!EJ5!-3MKQ@1IN!"O=23M3L?,74%/ G)$2 @ZK=*9".82$X6IP'J:DA0F[8 MR5!8,\+ 5.GFN/%>F8/"SAO5)5["_2176.9O:E."P9!6O=XY=.E+V@EJ,.!) MX/:9!6]8PCIU>Z@2$X,"4A:#2588O3 O.3GVUT8OV)\BT,O&X I"SZ7 MV+(VHXDQ(Q,8K-EJVCN9\5ZI['#*^4^?);K4K'O12$'C.D=T3[UNBNB*8/&F MUVFE>%@NY8G"7P1/U>9 5M'GB*++33^X<\J$NGJU1 MM#2 [+"S,&R,GB5KV+1/V,#!AHV2A+\]QAP6IW'$KNGBR*<**BS7="749QA].[#5S# -MBC"<6'.0!^RL&> MR;8G$@/R1+9?1M/%:4HIEWN)3AEO*2$# QRU;I( N.+%.;X$AP$6Q9LA;:M4 MO@T[7J?>HR'FM#Q)-HQ@0#=$6\V#+SP>DT3(%^S'J'HIT6^\E+B#B-O&_7?M M)8D>F>L%F4S)[BJL20,&8PK%M%Z%8_3?_OS-N^\HL!+TS)C^ _WPW=$WWWS# M_H]2D6O R[.G."'_PL$1>D=_^?#^Z-MWW_#%VH>C'_[]^Z,?WWTH:0E+OQ7P MW^(Z1<$1\E(4;]#_FT<8??CF"/&WKQC1&?9Y;GKTX1W_]OLC1,7LL,\>0@N! M3-"*WCNLKX,85P>,I&!PK=?/,%H>UZ,E#"S=XLPC$0[.O22B/2-=^7Z^S;G_ M]PQOB$]4.PD;1K?7R;KS=72NU6[ M72HL#YM2/[F'+06[037%!(T,)8(5Q34F>@L6WBRUE:.OX=?E"S.X:&QOFFZ\ MY#KA.2<"ONJ]P0E/D66U^UQ$@'N.VS2)[VZK:4%E55)]I.72J#%"CLLL!%(T*-8THK#?' M.KI:(16\*9 A=7ZN2BUEQ+(TR17M22!336 MS E&>X"+Y\DJ.HG7>.!"SXIS(=_RD"6>!1L8%-KKJG-*'\K*KI?1U[BLTW(L MA$6;!9V&'"+V+)=R;]V9#8( 1J\#+.#5" MIDFY"&CZJDIA4Y,!!4Y/0?42*J1$,UWGIEHDV$OQ&1;_747X!(EQ,7Q: ^@I0_M)Z$KZ@[28N)^?4N&+N MC:/T!&_B! NZ>^\S3C^2*$[HD+N.,DSKEV4-;DL1H94?*0F_RJSU MUCG2P+U'U6G5]KVT3HJ'MVET,72=T4[]1 MWK%14KOO2DJ5^[#OD8*90?3Z*0XG *'G"F?&O7*'QNEZ0Z9>:XW1)( U<,E4 MZP*"TDRR&YXC O*,/), 1T':.8!;;W?JTZIA(I:+C;0S3ATHJ>>'LF_:0_?> MZ\F8T@0H*'F1EV4)><@SEEX497%]4;^.N;R#=2X44&)@NK^V6 MD:?<-G;B2,(\4P;2&;FGZB2JV>Z1WO$5SE+@'&]X?70B :S ^Q882YQO)_!37B/DP0& M]7NIW_/A%L*0)Z25*5A:>5?D/4-0 ND._?.._M7E6]J5+^+DQ4M4_6"P%,=; M^C$F=K;Z0T2 @?PXO26N ? CB2)#E/*,+3!I]#C(5K'2V-P^ M\&8$;I*X<7&6)U3%&UXA_"+9%7[AOZC<<9:\SK/9V)K3&QY,C&!&^B':]L9W M^B.#92]<@4+S-/12YCG)(U*\ALBH2,GAQVG&D\O]M^^_._KW=]^#AK#HIR,Q MW&,& &*%018H[G!"A[%L.5_D0UODEB'^,@ MO8]M0L:FDNPL%&C:JJ@BAZ81NWC?F-Z67LZ\2@KK LVN@G:%+.9MG/P5%$7/ ML)K+WLEJR9;3&;*'F5(AUXX-!C('Z:H;LFW2*==#^8EY*'___0]'[S^\X&]+%6JE+11A0[T^Q1!CI<1T+E1@UH7Y,8RNQL!AEL4#6'6',N#NE1ZBJB M54HQB$*M0FU#%LQ8%=UBK^ZQ="]2&W*'?4J9J5\$VU,F #_,,/-MG8Q&@8OW MARFMZ.==J4;BYKBNZ2'=@!C0/48L.B?N,M9" ?29@15@[=,\^%XSS(SINXT# MU^Q6\'3[R"PE M.%M&S5,UU5IK6O&+=Z7Y;.IG0&D7PGI7SQ^*8M=L&.;LZ[H8.8KG8B5W;PTOE"^CJK**BJB MK"19C8\4Y"Y3Q#Z&ULDCQDB!T27V4=WZ8)N#O,1^A>]-G'#4.\6PVBC=Y#%> MUL)(MC?7 &:S(,AXMM9^(D@[&**%VOY.^4:95A_V M#6*' =M1.O=>+Q>Q_5DAA:.Q7FETP>H$EQHC=./M""$+H7. @0J 6DB B%%[ MM?>#J8L0MVV<9.1?97P2'>8)/PA4X]/$X2XDS4KU.M1,2PX#9E8Z]HY7&TSE M7"W8"NS \++;'#)S.Q^\% ?4=I81@QMURUY73$F&[W#R3'PLG+!TCQD_1ER* M[L'T^8N%%M8P124.#7?8I\S%NYYC0R7/%U2">+P1GQ7$4CO>\1Q%Z)'-"W2^ MR&(V.?@YR[(K(B/P=A?&KUC?RV=$Y, <*VXO"NE:6Z[7F!0KI:%)FBE M\HIYN4>_."X'**F=A1D3XES@YMXBQ.$FB5ET=W#R^HENYM=1];[$RJ>;:QZ_ M9X#@&$&.,_J--+2S?1\H!0R(1ZO>\]"L[OZ&+BZO?[E#%[?7']'US?GMZGY] M]1-:G=ZO?U[?K\_O8(";C_'7W&ET0TW0OPJ@(G8>>JQ4N.?DZ%&" 9M6O3U< M?C!P=4;279QZX4])G.^NXHS^[8MCI;E$YIXF M-Z$[4A2T/,#[F2'-54GA'Q1D_-IME%$2OF[UTA3*LQAG>)=@GW#SZ.<0LP_L ML;S&P9NJRJQ8G<)Z@#$M#%OP@1F,!RC;O_M7LXJG#1L\CAW1,S[HM?PYS%!- M9WO-:ZZ&V_?U+"!-9%+OP)[.ZB.NV@^4"7N,#[1;"U@VAZK),'WZ5!7WXJ@< MK;)\!$G9$%(_2)HO0S,(A,\UVW]X.0MICH3GR[%V-ZUWJN66U6[4=0L M9<$'*6U-U,QG)A%0EL[[J:^>\I)*P"37".8:6F\2O/-(H'=#F-F6'4;E1N@' MSS8/%#0.U+=WUB"(@+W:+)D&V#N+IWF2X"A;\>'7.%>I'5!A7:"#"KTSHN8T%L<\DY8KV.M*T0G8EE FHW38U/-#Q^F1MTE MX0$)>^VAL96!"EK:N9)\'%AEK(N/F@ICC -GAP\^*)4Z2X9/1GA0Z\6OB"'-VK:1S3(7KK>.TQ"+A1F3(NN L;%M\@D@GLS M>'];9#=@^+W^G KK^$HK>:"[AWBC?8+0+JT@ -W PE +Z&ND@/']CU;=%-JU MOOKY_ YD:%<9Z7L?K_Q_YB3!%WD2$9;_>!4%%^0S^V2Z/&#@7>(6@94YLNL$ M6D9HOJXA2O?V<%2?)T\DQ=J4;.+N)Q6U8W)A(-2^4^[=JZ$.M_L-LP>QFE#K M;5PYD)+U4%8.5="#?N4T;C4Q6#@ R(^L$(ON,% R])7(.'-,JY.+]=7JZA3D MZJ1XA.J"HHAOHMNWU;O3H8K:Z0I$KW)KS2$G!0-"O7[]<]SBP3!6'_6%L,:[ M8FQQ43Z,\TGS, X\[/5RX$D>Z!C MQ0>M6:HD"EE HE1G:;V:&U&>H(&Z'YS MQ"P3SR&M)J9?11S$0GN8+&S&YT!;@K +H5IC]A\U=SU[(MLLB MCU+7J:^HQF$B7,)_C'&MQ#(#^&%!>X3F/2"?WZ/UU>GM^>KN''UY=BX^?46_ M0WQYO+HZ$Q_._]>G]<^KR_.K>^V:V'D[KVCO3I)7VNN4*=:L&!U?"! IA.XR M+\F&M[!*=>D&1]:"1^CD_*?UU17;ZYRL+NFNY_QM-BK$O%"#%!_0I.=79Y;M MZ?#&=+[;A3QO@1>6J0[6T29.MGQZ-:6AL.5V>J=ZF$FM2]9VK& V%GE]=WGV[/[_:^[3%59$J&6: _2T"IC'=HDKB-+^DK MUPXAJ7\' Q>)4KVL]P4)8J'N,'!P15N#8KMVO+,CHV(AO\[PUNA_MN=WNBD< M:E9K_V?+# 9[0S7NK8.OK_B,VCBAII.LS",\UV6UAJ]&O(EW$2>#GWT;(<39 M5;71!E8WU09+6!R>>ZDMR6M2W[TF7%+U+LBB;ZTU3&@D\2]-O$F(/PK! V4M M >11YLKP/$@0.%B/T5Z2:#^/,I1@']--$4M2PK#MZ&V1^A%UJC([FEFQ+1K[ M<,).:$HO^7VLR@[1K)@]A+E[WF%?@^N7'\9*@H'B?=7OP;B2ISOR8WYC<>Z2 MQ?VW^V LC!L35C?3J9QDH4>5W\E6L,W?%P>:1BF;.=Y+FZ^.;#!&.1MN"Z)= M&<#F/288PXE7:[^V4BW&=5F8]2Q.7P*Q4+[UBH>&'MHM#@M=#_01G.ODT8L* M-4_C*(U#$GA%KW 7I3]?,DWIZ?75Z?GL% YU%S@EJ MPPT=F'WSW34=@],%JE'QUO)420T&7485%>E"6+A5R0%NICSQ4I)>;YJS/%U4 MW)''B&R(3_M2WVK3<+B?2)<0G<+X)HCWD0<&YA,8T3]G__AQ=?LKF_Q7IZ?7 MGZ[X\=7-]>7Z%,P%AK/BF12^R2SR1Y)_X:!(>D:K@ ?6B[14+/-U&*?L^IY^ M,-Y;JMO4T)-403MK]%XBP72*:>SHYYHNGN;A8NGNJQ9\A K11WP7)O)2"/&H MEC_A=*)Z;:J5&% Y]AMHW;TA95"W?BY*0;@XXFRT4R5F/ >56.\AY>5O9,&9:\#F^EF-G1N=:CIYI<9P-U51R+8?ST8&*2!A2T];5JR@#5Y\#9;C$["CSFJ =) ,:L=HW7-2%3+XD%M+F75UZ!#3 MIG%XJ!!PJ-:.Q<,D'!:N3>/Q^NI^=?73^N22#LAW=^?Z:UQ.$R^Q8*^4O1_$ M,EAZHECS@QL9.!NI^4M72Q]#X MJNY:18)+T]@Y=2$+G"=,7$&2,XB)2@#38V8QJ]?)5K_>7E]>HLOUZF1]"2@Q MC0:L,,!H%#->Z=2]U?G_[];]>79^>W=W_B#H#[7V'@\\(C";]F M71MC6G3J65RBT$;Y)O!T]&"P9J%DS[_$WJ7D/(U-.;R5I\PRT_AGX%D:;=IQ M3LL &F]&A^9J?8M^7EU^XG%VQ=70U25:7]W=WW[Z:,J,XG!1YB41B1Y9(I@[ M%IUM6IXIR9TNU Q*MY9L"EHP\#(HV%O&%>2(TB/. &X8ZUID&L(T]$NB2CMT M*8G!XLHT9+'L3I?7=W?HYOP6W?UM=0LD+O4\LZ#WS2&3QY(F!QR6PK-1O(DO+ 9:-EIVL<5Y^,%%BPO< M0,;O5T29N +$E+8?T.Q8G:;K'&!,*^&?!1\8- Y0MG<#G-V/N;H7E[C83O/T M]OQL?8]NUW=_AP+'\O8OZW B:^XCCOS6R89A0!PHPRU 1YC71NH 8 @.UQK M6?:"0H9(>=&4 GFI:&6\>:P=)@0/ZGKOX1/+5:W[) MYOP*T V;RAB>=(F%JHO)1SQFS.] <)_!@Y?BH'PQRW3!9D^A3N_73%(!K>LU M>TD$TP,F,:-WN:8>RUF:HX985,@MK]UPT<=<-BJ%@QO_K>OHI%E'I@EA;ZD@ M^X^^"D9U(+G(P^M!6CNDY^/H9'5WSB:4CS?G5W=\S0^C1[#;_OB?.37D_-EB MIE"3N\[)H%.ZFX%!1@L&=08%>W"JR)&@!S?(=@VRR?RAH%\25,:\'E)BL+ R M7R\_N3O_7Y_HVA>=_PSGD+NX2-^Y+O\J_K5,HF!D7B!=@J5!DL0(!DXP !RD M;A>-G)DM.9L9%& @\A/+YGR>9F1+%P6JE%A=(I<(DRO81%*; @QBI&IUD?%) MY+VNR&:ZLE]E:%M'='+-^4KO%Y(]G=+U'YUJ<4*H C[%]TFB+K(E#E@/#Q;A]WG&T''8?)6+Q7[*EX[Z07L^.X M\!6)[,NHF3RL)10&KDP )D_0>J3UE@ND7$QG2V^SY3SC(0[Z2 MVA5Y;_!AY+T9G6$$6EZ1<=E$X$'46E4="#=Y$A&6!)Z4%AM5C4 3*PKNVLG\Q?"!> MS0*6P:NM87*\FK@!XM5291U>R\?+/#\CSQ.\7:9PNS=T[@9:K*@*0?FX(+O4 M*[)JIVF^W?$W,[3HG%RZ,U?[]%52.=FG$[TXZ.>Q1[^BW^59BG(6\$8B]%S* M;/26 QC26:Z/LEJNDUOR^&01L#%>'I0!W\ILV_%?*VSQGC&5!1:S Q"\5UD? MQ&;C(_:83S2XCFZQGR<)B1YY>(%U>@YK,8MD[!AHI#2)AZ4,,%@>J;AV(\GR MS#SS/#/LK^H$57AK$!W7DU(V>F#"@6&]<=++7Z E&\+VW7PB;/5U565]BN*' M%"?\3>8UF]OHSQ2&='/"IS6KM?]BVBS2\Y:I@2/]-*^0#V->AJE=!-0L*JR5]%P1D)\PP' WT! Z4M MLTX<9;)\E3A(%)C^M)_^NOZ A3RT8P]:,X'0X+Z*,A(PX\@SOF-# _?)G7_V MPSS P05%#.O#>?E&[-!$27,4M)"W=^**4GB%)RH%8->:V#1=K_,:1:&T*@M: MWQ/'01])1+;Y]I+.T+B\7'41)T74"_]Z\"G[:,$+';KO61&*,_B14@'VG3U- ML3A)W K9*&12V#&-")[-([J&1%X8HBB.CGVZ.<0A*P'%XLUF.K6QR!5?J""X M@?2SYK7&VB_:O."X8DO11Q$9>?(J]YT.N00[22E+78J=L(I4EV0G* ),WYS' M+NVDEF?QEDKVD1<$A#OO41;S;1;M =_PI]1@]#S3>01WQ%Z+\X?!)UIS%;*0 MBW[""E+X[2Z>MRNU MBBBO$ \1X/:>VE##.DBSY 8S3 Q6609,GTI NT($>GA%7Q:!(U\U=Y"5I)G" MJWZ)DW_0@HJ-LBR$IDOA+,Q)KEH5JM3^>7%LJ'7J-GY!5'H&8 Q._0B06_Q, M/V/^P]TN),H$0#:^#:=^0G9E6%HBV(HU2PY+%'5]2TH'"QRJ@O2@C*9TF]6:V"!? B$11 M"4H:5-!PTE>MBY3[Q OH!/$4O\" R!G>Q2G)1)R?R@7=IG&;O$"B7CL308, M#!QD6O5S:;"'$MBA5Q249\>O*!"6%>#7,;@<.\R*-P<2-?7B>+)6 ML8LKSK#0#L2ZXN4&N=UE9#&+:S#/[PHE>Y,\$W=HB5]^2AK.ZY[Y>B80"5]: M!E@E>^$<8+JWE9J]J0-R8I>5[^?;G"?WIBNB!/LBV)M^#C$_,(V"9HX"904H M*FPZ\2[Q.W6E-)$^E6QH!U03V]7M1)$/=4ZZSGZY^!S,S2I3J>^)K$J@) M:DSYKHQA%&8!,'.9Z>-<3-Q@8#A895W0T"C;F\K%GQ ,SMJ;&IL))J[DN&5HQ0$!)D&0RVQJI ";0\ZV@+S;K.9 M77&AW:;&.L5^4\\!;<=IJ:WE$ 1HMZF#93__YQ7^G-V_X/ 9?XRC[&G$W&@E M%,KX9%\!MF.56>(AS+KV9G0[!$,ABXGBEZE3?BDLP5N/\.N;=%O#OGC%7@(D M0FI8'?Q*%;]_B2>ISTH6W+[0,7=\%R@$'2CRV]I+ /_O!XME6KS*JS1:&G \ M-TW>$]%,U"%CNJ&_!-4_'BJJ+VB]3E9)0AAL3#<-W@_23-(!([JA?A_0[[\Y M6$!3VNGJB L##NB&P7L"FM(>,J!K]26 ?G>(@%YM,IQ,BNJ.1+C0EIH^'M\M M<0<*']>M/M:*K(/0.3T\A+*P-:\91:#C HLU*SBZ\F$ZR(J>+YIY,X MRE.U$Y_8)X8!(HUT/.X(6/3!BEL21!2N! L_/GL^1;86> M'O$"\%$H+,%/AQ(:@.3JJ1#T7%"# L^=%WH)L1QZ>L0+@$>AL 0\'4IHX)&K MIP+/P$?^9FR'\^TNC%\QOL4\HJ/Q;XMVNXMFNJWS[@)/K39U8_M0+0Y:UK/N^EPYIDXEVAL>)*Z-"[41R86![ M6F-ZN8J8=!9C4_"Q5$6<$8DBV$]U(&4Y%4.*?KMEX_!%G+!DMD#B MN/>L/<61#F5LZ53'5U%*(?1,S2]N67@K-HK9+V5_$$TVAOK_\L9;*;KUU8K%\'FDO MK4UEDF&QC".GPV8Y5M\DQ,?5C^,]+];REAT*!YJM'_0LA0$>WH998.]-*>4B M+KA!Y0=Y M.^QD04GH/Y$=D-P;!L6'^S3L!8)&\4#OA:VT@T%0?E]?!1C1(-&^&AO MQ'"Y!X_ZM^)^<+?X/!17@[4A\SL8)LKFR)[_X=8HJJ%)X#0;8T^Q5K;%ZM?% M-_1*E71O,Z$=(_QC]G5'SX5:--E^^G?;M_*S\+8%_="6\>%UU;OK%QY)^$MD MJ_H99W8UTFZJZ MN"7I/RX2C-=1AFFC9:YZK+S<@^VQNFJ_Q0$IZS&A128P8 M-:"N^V"NE(66>MN%XOG:4T6-US3A.5"V!&!*,W2C?M MNO=&= R+G^\KWQ-14X-!HU%%^Q@54,^#2.VZ-#P,8F):'&D] XQHNP3W#(B5 MF@-0=PGM[0^I@8VS@R'UTF);''X2(XP ;/# AF!?46L0'J$&\Q_S0.!;* >^ MTY@QH.EM0C-G"HB@*SN2B%I"P.NE'L3!V/ MIP[AN[1TE6=/<4+^)8\K4A ZZP!:12L02ZE@ %&G6A=,=1-Q:3[T"]NPU9L8M MBR.T\Q+6OU,N STS(:#/YD4NF(^8 B]81\\XS9@7Y_HEPDGZ1':T GSZM_>H MY*1AL5BNSE"WSX@//6(U[\6(E)<-G03K3A%3K0J=J'J/$>YYZUVG- MY6RJLC>AFK?,+(MC:9B>O8&P8F2SFM\,/HOM=IS[["ZBC&0A#N[C6^QC\HQ_ MB9/LJ66!=.EHP^9N!V!O1+VF-_/ P)6]HKUU=\%)5THH$;SHA3%W<09C/A4+ MP'6:YKUEMIS$^0E91[G>F5;Q^^*XT2C5RV['28X0X40+K9TYB(6:9WE"![L; M'O?-UY%7^(7_(O6&6S'"6SD/4UN] XKP2[G_$>UW));-BVV!8A_C(&4;=V8# MNRFA'(2MF> UG[W*_3V/X$2LXGB;,=ZIAV/%5'^%,^L6:DY =GS.)OLA9E2S MO0W3XL/V4$U[ P/.T&Y)A!4NG,<$B^7*(TDSG*PC \"LV-PEP+4WHDZ!:^:! M@2Y[1>4+!>1Q5K&B%,R(1$ZPQ9U,M"*>O!1S ]@^G7_+E">9XD*^'9_;],J6 M9K0S+!N8@.#+7E-IGF6.)$X%9$\B7ZDU%]87<7*'DV?B8U7$R5 A3O3!@5BK]1@, M6^PK84#Y.GO"JC>:+?B@0+9EABU,.=-!0+.I:1>.:\F6I5AZIL7J@"TIT ;/ M]H9'O>=B9Y1Y%."@#$"0K7FTY,X6EA9*5^M)#>WB^+%44 >;7!*BL=+<8MW$I7 F,-?E;$ M;EUOZ'_IXNXT3I4/X2AH7:ZUM>HVU]=2PL7A9*-=[VI]&5T7%\1T\9SN/_), M Q_9:+N.2$:\\"9_"(E?6CC@!$[![Q)F@\TR'81*F<' <:C&EJ>A1(A .RZC MPJ_;E9L-&D?P+[UZ,Z)Q,//B:!RK\8 UW$R(G,@=YH5TI2IN=NI$?YFQ922(K_,X=2F>3 M,!)C$@DL=](T)LNMP FRM87H/"+/[8][^_<[MF^ XF>/N[WU-0@.%[,X6/?7W;A0]"L.X,!F MW9/=61^-9XD $#!6&F:%WAXW?-"J5.Z[-%,_(3PG6GFLTKA /"%R)WR:Q'JV M,B(W81O$+(X4O?5W #8:FT9DBW)>$(,&&-LG70P^*^\N "]Z9[N=GJS M@WAF*;-2NT*,CAH$:"PT-LUV]'$,\ M^1.PJ6X=[?(LO<3/.'SW$;--D&D8EG$L,LVI59=.V#O A'<>Z^^8YJ4TF67U*C:Q(2$# P\U+KUNEY- MZ;C7\75.L0(NM7CM+=6Z!'#..?7J*1XU%+=LR_.+BFVFM7Q7.T7/,] Z6\.; MU%6" DS_L]%.=9@5EO3HM]LX#-%%G+ 7*5Q/AB.[I=O'*L7#M'>9EV3V75/U M'N4)?B11Q$)T'[R0!9S-U!M704#X@R+UQK]7P4T#]/3.>J6-VA4N=,0P>J>% MAJK+;:D#]TNA4^GPECKP^C2NA^B>>MV!H2* T>@*K51#<7E2L,B2:!WY"?92 M?(;%?]>1<30VLS@>GTW+I@$*]Q923^P-)Q9'6;M%#V.*=/M\@_;M=KV"_426 M03D[AA-,C]-L**]P1E$4;_%EG*:K9X^$+!?]?=Q(I?04AP%.TA,O);YATSE: MFLN-Z9XF-S>O(T4M/II/H[_L[@$3A&[*&,.Y;KOD6YPP:MU.3$+D[MZ*2L'Z M)3EJHM0<.4Q.,U,NTN:ZY MQQH@&Z1#-DAWF[J9IJ:0--O9>!1O260:P*5D#D_"E4HV#L![-#"&<;5B_0&@ MHERH<_^"6? 9#E9TM^,]XM9=L<:S V(!$@5G),PS>?;R<9+@N,(GLJ.W'2_$ M(4_(ZR2DLGR=848$G'L)\QNFY6,[%DUM8($W?-LJW/.J,CI$FX?.T9P21>4 MOIMJE3W1#5[_"0<+/QTXZ%[&CUYMN MU>@>5YZZ$*>W@&>IH-8=QTE+6'PJF]6LWI77HA#FG&X6@^IR4%F0N%C?*(HQ ME87QW:^X0 OJF>D]Z^[2\"#U=.)=]LFI*Z45[3*1;##]<&*#NCUPLEYW">V9 M[3TK;K6-\TCEDZQ$*6J>W(G7JMBY R@C!(%"G7>] D=(>(4:-B"!' M'J>' Z!/$;&$3X_2-7@4JG:ATR$#!1RY;G+8Y!%$S%SOV!D''5,OV>%Z>I%G M5,6/)"+;?'OCO3+W>GJ+MQZ) N:?N2"I[X6_8D\5+;^'/)?XV]OL)DI'"P.# MY7TMZ"*>@0U]F90<; Y^I=1 GH.VL?8L5[EGK+FAX;EATE#T4E:W*878I02= MJW&8TO([#UM!CD(F NT*+I 0O<4L(FV'HQ1?8=6D;N!9$(YR]34@;#- '2:E M6G:QQHCH1H-3PF_YR[BN)ZH6N==Z3^%@^L+4%NE\U9S[^(&QHV89J%D(>GAM$18%(5X2+#>U ML<94%69R4$\AV/E;W9-41"\QZ5Y2X?2RJ4R19C\U="E#CP+G@AY=667T07GA MPPN+UU?S["E.R+_TK]S/5>)!=$3[JINDAYJ+._RN:VVCXBIWQ5:XN9=,'CW& M_CK_39KF6YZE)+TEZ3\N$HS748:I2=FMEZES4L]9*+Q(*G+".6M-#'S?*4!1=B\MO;N$154QKR]AS* ME0:5,>Q.!C!9H4#AY<3D7F!P>27@E>!PJ5SQLYC_RJGE.@M8O]@T!- M8;1R2!,Y<)\KK@/?/%V+VF@$;;.<%$5*BJG;P5#806R9K"ILDJZJ+>GP-THV MYDWN]SA"1;'T0UWP@$0L!]FEQ9YT_@8LRSG0CMRNIIGZL"@$4A*=N8WL=N)F MQ_-H=RVS\KR-;O<33QJSCL0C2#\E<3JYNU]7TB%U/4U53=GY),6\F=E3;5NW MUW%**,&R^YI-9^H-)BQJI+)]I@J6EG1(G4Q355-V,DDQT"XXSF=B[W4 0?E6 M>AO=^Q*>6CR:N[=)2SJDWJ:IJBE[FZ28M];;U"9*7#,D6>RQR /=?[AU[FES ME,UOI&$'@HVI!0YIK.89#5FXU*R[?DDYAS5.*ZIIVE&Z4\C;ZW,J$_MC=$7W MUGK;QYH>;>3"W:>"@97 M$0 Q>J9?OXVNWJB(3@:DUKN%[#!AX^H$S5J10^K^XRMZIE6SI19OQJ\XVG1' M)W9'J,H95NB%2L40UTPZHF>KE&6A<2;'&@6'%W>^$FAA>EO[/Q0>9]* M>J0S1T>?4@-0G7WZJAW4X: MM,L/U.%P]@_S&'[H!ZFF6I$<:BW1[P>K<5#]?F0E3]KO!^KP=OK].,/?[)$N MU$WEVS[^M3+]CWDHO(#CR+IT4+/,M%4ZT[$RF#G%]6'SJ#GE#WP$O4"WWU>I M0QH-IFD MX?8?ZRQ8Y+Z^,,=>-=)3,Y(ZHB2[+!2&3;93L)$B&6:3<%>Q[]8&Z'A\$[ MKLK^1LVPE"'O=8APK8GSD629JIXD[\UX-6"-.HO8?FB>ACTJ2;U%4U72NYF: M:Y0FAS0D[%'54PX)(]1X,T/">-O-SHFW,1X,WG:Y'B:F5/"01H_I&V;*064Z M[=[,6#-YE3AT9BA>V9[OQ*=A,MN/K2.^!],]Y;V<+L[>"U^ZNJM'R9=29/&Q M (+U3/\;4HV3]4";0M]4'QQ@\&SQYC/UPR(NUG$OM"GU M8/J@?15.U@/-1;ZI_F=M[IN-^EYR8_.V([L5QOXQ3UC;E>'@(+57X"&=>)@K M;J9CT4YI0/OGG+;^_Z'8#8LK)ZD3K^$>^AR25W'O:G<0>VU6!NC0L&!5'%S$ M]2KDPG$@K[GBP7%%;=LRN^R9PPQJ=B,[SL4/Y4:I:WN*=J![F05?9G@[KXY9 M&-F%D4BOR!Y-3YG(%#V"2WN2_@V'=&]_OMV%\2O&=^PY-&'I#37E+D]Y-Q&D MNAH=)L?Y6F2,F;VN,40(F'%PK.;2(3%%3U00NP6!"U'% WHQ%X9VE 6EA3B+ M%X\/8"-0/@ M[%\]>R1DZYR+..$CP=2CC+&X@UC&6U;:I*^0*\J"U1'G,] X M]W@E(]K$B9B) '7-/?P55W'TS/<1[8J:R3NB+.V0G&>&*IO2R;\Y>;.5MA8/KGW!9V>^BG**E(D-^,H/5C*%ZIT4L) M_@]SNM%!1FQ@M<=,DQ5Q$(M63>5,LE"5R ?3RV8P2N;K90>XPE$-I"/E#RG^ M9TZ-.7^F_]RSY;&JAJ2D3H&M4;8%4 D='*"IE>MY'"I2Q&G1;YP:RGV#MB&7 M),+K#&^5VPXE^8(0ZBFM@5%%"Q5*707-<&(YR&7II>;W[QV$"; M72>W[ )0(]I%UBXF'G@N=VN-U;NE%\$+<)=TD\0^QD%Z01NVL+#,-:4:"_0L M+L<#&^6;V-/1@QD7+)3L NW42Y_0KN KP09I3*B<"]C/$Y(1G)YZ88B#D]>" M+BT(IAAX)W>#3CQ@] MQ6% )P7V,6&-R@)&=E33)Z\Z;]Y^)$*>[\=)X-$:1B\D>^*,&4ZVG(K] M0:(T2[C>1RA/93]>1$@5#"]\4BP MCDZ]'>CCE#AB?@@H)HN"I5ZM$POB?= 0JJH$B@R8I@PT6C:!G8;\P=58*-RB3:Q,E6N&:]![HO*'KA,LVQC9., M_(MK<[TYI4L(DC&C^^=J%N3 FL=&UVXSK5D/*UHJK4=?KR&+_>U7THJ9>YG& M2]E%I0*!%WD47(:^JC\I28$UFDE/:8,UQ\EF]VH,EAX77,V<&RH:A:&O;;<] M;E@6%K##F$LZM4S_O!Z.C>QJ_&Y9SQU",X6^_$+Q%MP">R MHXU'MT\XS?CFBK9/LHO%$T'+M=*)L95.8+>21+VWUTI=OTTK)W^]GI=YLD8+ M =C6XRS0K[!\)KCA*&=;4.$=*1U7Y=ZXZ4LO:!8<7KMUP3(:VK4[HSR QFVH MV6W!,YSZ"=F5O9G-BV7K,?_4,HW"G9\\/GP5!0:'HXX86-.8-34/M]REX=A+ MO@@]0W#;/-L@+L< QY-70VRQ9ZV M=WZP- CN<110>#9KH9AN!F)AD""PD!ACQ0!D9(7X-C:J"7@X0O;90<=1FH<9 M+4*S:>[1N-LG*]1K8*]- U34NU&;X K<8L,&&?DF004N]?1'4[8,2H+JTTR M\A#2[L'TIYCF7:/72M:]O=?W3__V___O[=#__17HHLT\S5H^%G%(5T2RR/ MVHDS]C./TGHB_E/7[]%(*M('Q=0E (/03.9),_2)$2-@:=ZESB$4Q9GXF<=" MO+"B9&2X+NZ(;8)/3W_]]?CCQ^.S,R0&ID6P>$$B+_*)%YY_]I_8988++#F/ ME5+!PH1.1I@FW]$RS ]?3J)5DF29JAU MQ'7;Y0!N9^3N>V;3ABS5+ MN4[=Y0\40HN,/=26]^KJ?P^T^M^_F>J/_ 1[*3[#XK_KJ%BRJ ,3S2S FLM6 M7\N *5+(0U\&A<2O&H&)U2BZ3-#;.J+CMQ=>>"3A2?Y6P7_E*8_FJD\Q)2UJ M9H+6IM8:]ZX5"(\0;4@L\LVA+VF+QEO:BLV8JDH@^VM#RZD! *2ETS1G$?35 M+I8'ZUU'%:H[]VS6D2+P<:P@8(C8SPI]WX^J2V^D**9Y9E#<;XAJ0%00*0\: M "&$]Q=UO5C"PR#E$+!A9X+MI'"0N& .]3P*<*">&M2T4-M8I6BW)>_IRJON MV+1)CP5;[4@I3I.=^/W_3C=F7G1"X@S[3Z?Q91:H]TEJ6F>[)I.Z%8!4A+#0 M8]!2!IT4\T5$B!^9#X>YB=E1DI>F,=V LU4$WW9[;+2($[VC;0_87'GB@A8_ M]<*TS2Z]!Q;D$B>O%W%RPI:GV=^P%V9/=!FL1M0H,<[ MH>1%0Y'R( %T?$& MC#VFBHH2!34K$H55F3R.XH&7BIYXL6QCM,A\=H6SYOWRS84 MU:,_V;1A.@@4V)QM\@40G<6:"."MV[Q]R6[?%Q>+?/;X,7G(^3A1-/""]_N4 MEIM7M?:L!]+8MFO>]NZET;UIQV50J/)M(9(7\E,3YKG?#LU4; M.G)W"U&STC7DU+3 @&94="2\EA@>6 HK$N B!I0N22Y(LE6TD(865@N9%9UY M@SI7:Q59*U.6)XA%8J[:$9[E_,9OL[[KM=\@;E@M.D9UY>(]SC.Q=J,[,G8U MMQ&QRD,+P]=Z-=^6W5%8MTM:T]AH7 8]I=:*DA@VG:W40'5)9["#=->(&Q M5>-5=)";K:MDK\%Z:9BZ3;/!RQP]LJ>MZ#"ABOAJ_PRN"?JZZ6K^X56\O15Y M6YZ6+/-(Q+.4Q<6RJWC,L/6@@5>G=U_&OU*8^4'?0A\ M]"'/T8+?:MOH6\! MM]"W?XP6^D[?0M\!;J'O_A@M]+V^A;X'W$+?_S%:Z =]"_T N(5^>.LMU#US M:J5MZ+>8EAQ8"]KH*MDF!3B*LR(G=C_'!)0CM)YUE@UV" UE:*#.X6>_1>H3 M,-YL2[7/SB-!\1QZJKY6IR($UT8Z+65N;79:D6 4U#?>FFX&(:\,WU^F#]WB M9YRDXM7FNUU(5*XA!1VL%M(K.=8=E BIA6LZ97(7::H[_PD'>8B+9T![SZ65 M0P>+!Q=/K*5IOA4O@/+7K=0=<#K1L QN5V]3NX]Y*&7-'LXOUFUR^G(G*21HGBMZNH(/6N#HE#S1-4G&,JDP6U/A!U79# M)0!KU9'J+Y+2=H\CI3N<96'A"C<>)VF(G1TE&15N(%!!"0UI>C7U(PC5B\<> M+'HV-/IIU>*!<9ZD!0?K2#RORM\V7K/@V"@E/K]7UF_?PB M'M*[4)@/IDE7OC/E,96J]^"Q4(H-=N(V&(5TQK-M%(J)"X$'B>F+.-E@DKE% MM4VA;PO7 RQ6WUSW?*IE+M9> =F4MW,>);#1Y+2A?DZTEUVLN !"#XKA?5WO0LD MB+1Y?,['#"!\35JXKH1H-M$OGKI16-U(CSTXP\=@"1";?;CZMCD]"CA4&<+% MX,&BJ8$E;FA7!!\M-;5A@(&)'3(&+'6WS-UQ..U?/YUPQG-2B$E4U,T5?N$_ M22Y*6/(!:_%!2JN?J6=WW%J/0\!X+%1A'D?V\*;LL!U$2\IU[N7#%3=4R';G M^5F9!%/R\HF<,RHO_RV_+%1?7&1?:$O2^-:2L&7O+: M_7DYQ(AE]"JB*VAV"80\XR+:Y!N54]&&"R!>+%5^>V$U&NN'-_&!-:_9CUS- MWL6%)_%4%]N^D5(0;_3EFL[V2OKAW$2?\0+ZJ%OG;INO.#UCCR)3I2V;LJTNI8#6S3D59NVX]VC[YMK\OIC-G MW;0/N%P_L83&49T(B.479QX3-A0_O(;>RS*SY_U+?/\4YRE5@TXNYR%^QM&- MR+IJC>NC53]L+&:R%->$6YO"IS=761#$#K7M"ZS# UMI7J MRJIU=:R06]=";_-EP%X;;PJI(+8YGY@7YB4A+-#$M(;2T,)J1;.BDO="BN=" M2*\!\X:TA==,A>--54 ?^^%11BM MJ'X! _9[%_N];@'C<8-?XN0?% FG(O-DOP%:/P.K?IENRMD];?NS13@93\K) M>@1_+"S%E,K;L,U5@(/&/:\C = L/<$O6>/A.SR!A?$J(+$>Z%PI'_E3%J:LW")M.!]PB$_1,$I M!<++5WPCP41U2VI$X&1T9$D]7P355&7[1<0Y96#H+2L#,<)G\VMDP M5[]]63U]V8A7I%\]B@(.$4;E"GER(%6"WQ24NE;- *9RRW&0<*JBCZ^34[8Z M"*<'EJ2(-P4QM7TS@,TO2H"#M58FA/JQM5'3GIVL T#/($/Z+SZWXH[I^J<( M,J;MS_Y@L<;E%*9X#MHV[RH-(6;TY#5<[N&C MR'Z:LL*3=%8"BJU;[+54[G$/NWBZ IG;/,=XK3J<:WDS,K'0Z85#PMI ML]BF=A77'OVD4[#4%8ER6GCE 6'%UP< W8"41?-%3%N-RGL=\Q3SEA%IN"%2 M([,7!?/F,'K&''=D)^I49(=(Z>=;9EH/:3IB6'BQT%3=ZOVC=K^2@'A>BT6: M:E6]Q77CD6 =%6<+JY GSA"6,F1^HC-U^3[4?6P\QII&+*SFG]0FS1W42A[[ MBTM$*[%2JI[0J@\]&Z,#C!/.7G6L5E' /YP,Q=!82 M8#UB=X[0;T+H_W'<>'EZ_.AYN]]7_.#X5)P1-YM+2O#[^\4;2*]7KX=QJB-4 MT"U4R9?UT;NFIOM4@*I;HURWSAND2U<\7]4_Q6% %V?BBJ"LXOM4OW\+IN(U MRG4KODGZ)U1N8>&!V$KVJFB[#)WU!OE C M58$F92Y>6:OTB U@UJW;KU7E*@D7;K.Z9(@WN++.-77>DT&L=XEVJEK7A"C M+QGY5PM5?ZTP>S#Y-&;Y*W.J7*%E'*4GF*[?L*"[]S[C]".)8O88XKI(;2DN MJ3:DB#[\$6=/<5"_G"IM5H?% X++$E;WK[TTP">>LZX50;4FZ(&K4DZJH@#4 M*.&HQ#'7\PA=4="QA]#C,!0@%PHOA.]VDM)JUY^!-A7<\D\,5#4^W87Q*\:WXF9BPSUCUX9J?M#-::&V9G\Q3)&ON_20"PL!$AO2.JW&&F%Q4"F;) MFK[\))[5^@K5'MI:_I'<.[:45TLDCD_OXY7_SYPD^")/(I+E"68Y<,AG]DF* M#"M&0 8IF_/@55PL]._@A]5 OAQ4RD"5M<7WM46O@=TAPZR#PTY1TA(0I(EX5+A9]LXRG<2KW M>.GH ;6CE9J2:-"*B46!GN&'#+&TYSQ!"^==JI7JMW3.6$H:EKB#*DD_A[A( MT-Q4G@XZ+(_V*\O5S(YH&01W6U5\X42R(;7^U";UD-)XVZA9PA&JRN #0+.4 M(U260S^QDHZJ2"->V$+0NF"I]?$E>6;37D:-9$^/"C=NP\JF(3(0#9<"""Y[ M*-\%AA!US&6A6A@JPV";P&D*/)2[O7/D#0!R6#F%"=)7>L?)/!1$S)4?X(!1 MT3=B"EQ44@\%&2[S !PP6G3F3($;B?RE8VPOV8XGO@$$F89$T_>2$ M!HOY;>M=36%BBH>4FF6A1F',1]6D*PI$O,0C5)1)/]2E'B%1[H$"L!@;F>N] M?.IV#@A*B@$T4LUIW9PP;)3+(\EXR0<*Q'/V8KUP^,X)1$DQ;PB(.NOF!&*C MW#< 1+Z89,%@\TW)O4+>% A5MLT+P:K4 Y^2?\8I<[9%/*"817??Q^PK)TM% MV[+?$%P'FSPGBH4RPBU>J,-B)MC7;VG5V;#D%\SVZ+0!GNEN[Q&WMO(S;X9T M1;_-+9*5QN4)0L9T:ZONG(H&;6 5-CN_IBC^D07P&J\?@ M/+4%NM"G7@P?+-KM%WNN1W++H@\)Y1-;[&R]_3:Q;5X9NH;\?AJ]H9XP447 M6,J_S=[3,'$=90F)4N+_S)X/FWE5WR[L;:[C%38Z6[E7Y2.NP!+G\?O69A%D M4JX8^2/D:IPZ*A( 6EU;*L4L.M%C]J3 ;$'7PFP)650H0<%:!AUS/=X">*N( M!I?PM2GTK0!XD*WS0;A2XRV"F!\:N86PNS%7\ M8-Z-MVOVG7*%.TMIT+9U\QKIS*'Q/\Z&5X_EW::&6@07S1 M.EC,:='J'I66%AVE^=4E_42_+K^B_S"-Z#?_'U!+ P04 " !RB@Y+/E+Z MS:\Y 3_ , %0 &%T;W,M,C Q-S V,S!?<')E+GAM;.U]6W/CMK+N^ZDZ M_T$G^V&O774FD[GELFJMLXNVI8DJLJ0ER9F5IQ1-P39W*%+AQ3/.KS\ J0M% MXM(@":&E41XR,S8 HOOK;@"-[L8__OO+*N@]DSCQH_"?W[SY]KMO>B3THJ4? M/O[SF[OY*V=^/1Q^TTM2-URZ0122?WX31M_\]__[W_^K1__[Q_]Y]:IW'1,W M)_4MO_K8W\ /:-_F_O='H^E7O*4W7?W_]^O/GS]\F;Q^*7WWK1:O>JU=T MB'_0?__Q=_:_>SE?I_??1O%CZ_??O?=F]?_OAW-O2>R MFGGU[GO]TVK;7\[V=SFYD^EM?TKXT MD\3_>Y)/;Q1Y;IIS5/F9GK %^]>K;;-7[$>OWKQ]]>[-MU^2Y3=; '(.QE% M9N2AQ_Z\FPUW7W73*$G<1Q*2U/=ROK]F35[?1%ZV(F'JA,M^F/KIRS!\B.)5 M/F5*1C[F4TP>_OD-&X%^^LT/WWW_[COVX?^ ]$U?UE1.$G^U#BA;7K>:ZW44 M+DF8D"7]2Q(%_I+)VI4;,);/GPA)$]6,X2,<=]Y3-Z9\?&+]W* ]$=SAC%,T M3^G_F3PDDX?)FL2Y'#2#1#[4\2B9/,S3R/OC*0J6U"[V_\RHD+5R6LW>1H$T>?V(ED;J4LZQFZ:Q41'A<0]NIS7QXBNV)0C'HF5*P.O M;9=SF6>KE1N_3!X[IM30%")N[1J19HKTW'67L&KA__Z@89-4D#/Z3;$M\-AG1K'.>[127S M@-T[M;DD'='?3$D\?Z+KE-+@\IMWJP?TKV3A?E$+&Z=IQ^NJ1_E>K"QT[8O) MTD]G?O('8!F5=^QVEJN5G^8"0DT4_30S[/3X"E!60-?.M?;*S;<7*V;F06:]NU];[A/R947;TGR'J*FI_I/6^@W7_B.O_PJ4KE>XNX+"3\;T ;(Z KB;W M!;!)RGN9W2, H5;T,[M?@,U1U>^(>P>@;.H,8G ? 9NMM-.1UDC83,$#F%\O M-217T=?4&?F&I*X?)&,W9CN@9^6F$M+W2&NJ[M0;#&5PC=U\4G.1K?0ROLH" M9PGI>ZRY@N5!:Q"3NP0@DQ7=CC##-PVG^.:(999**57W/,H\WS:>Y]NCSA.^P()'..)>'+J":8UR_/DKA5IS&(/G"2#' MY;W,ST_)446WHW@O=550>Z CG=R ,@$?X;CSUN"_]E#F3Z$ZJ[>J\]%F"UO% ME;V/-E_8:J[L?;3YZJWJX%%,^OCU#_RP_K(YKV.2T+XYS2/Z@X,NY$M*PB59 M;@=BL^XDEHW^F(WT7?'?F]ZKWK97^:]NN.P50_3*8VSFOZ4@B+R#207R^) M_YK._SW["R/D_:OOWFQ"#_^#_NCW8@XS\NBS3X?IV%T1SLQI4W[+ZD3+YR%'K[PG/]@)TD,9!C4F@)!>(,/!0'5-F#8TK&@P_*Y?]@"R/2WF)C. MH]$&KQ>QRP+3YR^K^RC@,[O2!,CM=YBXS:72IFC3(YL?41*6-VZJD/%*4R#[ MWV-BOY1J&S X=#9+-J-!X#[RV5]I F3[!TQLYU)I@]W766 M"KZX-1"$[S&!H*+=WC[G$PF"7\+HB98I6JRC,G9_Y]4\RR=(\J9AJJ-0^2?M!T4%UFH8SQ.:A MK]@#%H>@ ?V98!61-(>"@^KPK23?/B9L7PY&I-08B@?*T[B = X:_WA=HVY$ M?V#X&D(CR?S@,N)M[U5OEV5*_WX]&=_TQ_/^#?O;?#(:WC@+^H\K9^2,K_N] M^<_]_F+>^]O=V+F[&=+?_%>C^XFR$#ZXR7T.:):\>G3=-9/$'UZ3($VV/\EO M,DHBN?GQ[Z74WUV,Q#1*?,5UQJ8[K'=K'>N O#QT&$#(IIU*SVJ2VZVR:;'W M4-\$!)5WF!CPH!I+AO2O/ -8):'4%ADN!U(E0J T_=W% !(4K@,W239)_\X7 M'P)&O&V182&2KPHL/$KVM\>-X!#N.R@$M>;6 AKD'.;!(" 5!QJL MU V+MZ1_L,#S9S<@+ (SO7;C^,4/'_/ :,GB NMN+1("!$34A"1,(,X(IK72 ;<@E'! ?9C-N"!8#*6AN+4BC 5Q2BG& LDF'90'KD_2) MQ#/B$2I-+/MX3%(E2,#NUD(\&H"FQ1$D();) ^Y#+(9\- &%1V&)^>OMUGU4 M4"V<83Z]-$K=(&]IV2!&:WK">)D&;N%IWN8A4SF3V459+VO1(CJ;2@CA.#1K MX(=^2D;^,UE64X:E(*GZ68LBT8$)1CP.H')3O9E;%'HJ4RAH;BV.1 <6*:DX MT#@L="A:B6Q&B^B?@<]EU2F5$:"FMYZVK?9GP$>P%X^BZV[2Y0H./2O-&NR- MDO6Q%Z'2% 8ABJA=5MLSQM1]80<+\#&KVMY>T JMADT.OAT<==\: M4PO';7/C70 MA_.6G)Y@W:' &?-.: .GQ1<<4)8R?52!,[664(",N2,:+5<\:G%@(1 ?;46" M(V/,"=&5ZN ":,:*BH5DV7?CD#T6ZGA>MLKRX_<->? ]7[*9@/2%PF;,":$- M&YPC.! 4/S<%V?[!$3+FN^A@HWC$AYTZD,8$UN MY#_T>9#I^*YMIF/O;P=?N60^7C(?!?;[DOE(+IF/YE"X9#Y>,A]-8G')?+QD M/EKT --=UB3.A7&9>W"J+]ZJG,+B_J>2*:G'#XP8%B6%G"Q]BF+_K_UV7X5= MO9_MG,J&H(D8@!>LO)2C)E#;/K93*5N!=$@X7H#D%3()ECA7K!J$U6M5L(.MG,DFV.# M<9W2+*LI(JW)"F7,+]\<(=CRA,B'OB.5'C$G:U*\,R>H%/@>YC^?+^@?M_WQ M8MZ;#'J3:7_F+(:T 9*:@<.029!E"=#;^8LBR"0=K-]%E8SOU;<1,T%'(!] MI 8S=@,Z4V>Y\L/\C2WVJ)P2,F5'VV=C7=" G, !6XTX#0MH_RRL"XV0VE./ M\]@15BP&[)U> )#EQK:/QPU7L3J]]J 47+[0*<;$3<@-*?X\SR_[D'<3'43C[ S( +DA*UM'YXUX%)0;!.C;FSF. JC M0S.BW*M(NM@^=.O93R7M.'8G>^L^H/06J5,9G?+^J'U%'J*8%.T6[A>2W/IA M%.>O$Z2$0L!J*1V.4@3WW9+T*:*_>:9-\O.[Z@![I$G8KH*D)T86\#GUG=J. M%1N%NZ*GA0=94+RP@^W*3$U$14@W#GLS)BED UUI9KUDDZ;MYQ%YZFIU>-EY MXS_[2Q(NDPIGAJNUU,FG-XKU4DYZN#=AT1GL\LK2[CR[?L ")1=1Z>YA$_5_ MY2:^!U1ZR$#6*T>U, MP1N$PW-O3Y%YC7U@RR577,J.UJO)Z6'(I 1 M.%#[1/S')SHKYYEN%Q_).&.1E9.'?.*EJT PF$W'LUZ/2@_C=FP[D0O53<@N M/R/KX%[U@^:]*KM6G2\FU[_\/!G=]&?S_^SU_W4W7/R&Y()5R@&MW"2=VAPV M"#SUY*0&>::7["0DF3 CO-E)A2C1;=XMT#@!A)E,W/.P9KZ2^70)#5!D=!NJ;"FH1?)&FCZF MZF0[TD.+]Q""6OK6Z/[^/DJ(?2=*R0>@TBI.4]M1(DU42D@QCI.S0/!4X"BZ MV8X!:0(4B!,X0*L6 E*A)6IO.^:C"4QRVG'@4P]0J9_P9E$0#*+XLQM+_%#: M Z'9=-1.@/5;O"8LPH'OL0I;&?02-F*^\6)7:Q+[$7/=Q2FJO_D?I40-UM;YAGT[CR"-DF2PB8*!T5X,C MB,YM@W>7K# J#""3\T8 -K0S@H#FX8%7,AR9:]=X( E\-P27B%(ZU MU%G^3[8)L5U$ NM1JGYU0^[33W[Z5/PHH6T'Q$TS676.[KZ (.*U@_6X:XX; MTOMM@. D+(JC"6NC"31?HS^& -JVRJ_-+ASJ+UMB]A)'-PU[THXF*8"68$8\=&?P'?WN$J)X7 M[M91.";IM9L\!21)^E]([/D)8=/=N9PV?7BRP+[2]4XU@-X?\H_E*.0EW$]],:CMA@7 T' N* M/59W7PO2+4 KGHY"]9L/!P48LW^O+3--.8GRCRQ8$D"\J55)B=#46]U!H'BB M=O$U8MQ14)3,0Z&B#<:!8HG:_]>4?:;N7%81/2G\M77[[YZAE6*GZ@0%"JL3 M#D(CIH,WQ%N8S_O>S5.I5BR[/J=L1B@O$C^E!\7XV?=(<:2DN\/H,OS>03HWSYNB^;@N2[ M2P7F,+B.$EF1,WDO+.\^-;'#B^"#J8CB9S3'0)-(H(-4 M SJ%N&$TQ)0HYFH?!-%GP=, /S1Y&N#:F?_<&XPFG[ \#5 "?T>OED7E]+)[ MT&$3FL81B^Q87KW<48"'X:[TL..E_G/Q?+22R"9CX3&Z0C3KIZ.&',-QA#)< M_L\04"VX?EJ'V\F:L70:N*&R4*^HO>T4KLZPDC,$!V@W?K*.$C?X&$?9>ARE M]-]>42*6+'<58C^Z?LCD;1)NFXM1;3R@[?RMSF!OR=+3+^=X0^C$/3^GD_X] M(#F$X;+LTI<($*BW[;RN[J1%@UFF+O_/^?&#]D U?A?A\K:!(33@SQZ@JE2P MHW*;\ 5YEPT\ANU:5=0%>$&5FMI4' G],OUU!"\3!@ M-Y?PTK&LYXQU=PT/X!D.[^8V%F@1.=Z?F1^301:'/BMYXH3+@?^%_0T0RJ;H M;CU[K 5,_! W$+]._Z +YUL7I@!!:EIG@J+/N3-=/G:W._)%M/&2HCV^]:RZ M[I:9AKQ%LO1L2B*RAXCS/;PJDT;8P7IN6\?P5%\MM(@X,QYO$IP M#&'02>4U_T!0Q^)P7GG<\VR]#G(VN<&63O=5)QD'&.,H]"@Y>^\66JV;,]S<>#XFO. M^=8&W]:,Q+' ENP.KWS%;ETJMX("9\XAUA0X+CF8X#BL:K@C2E'X1=X+"I>Y MS-F6<$&8TG$TEIT2)./\39C) \>_>E!JY,?>JQ[+&@ZBA+:G_Q@[B[M9GQ44 MF4S[,VD4W^IY1JP#6"H%?8QRZQ-Z) [Y"OI354$_3H;CCZP0T'5_-KYH M)E[-G&?WK-1@2F=V$V7WJ7,?96D9\ 45F:M >O&L,\89:[(^*]%H^#Q;K=SX M9?*P22]BC_E0UGCEJ*JRPK_YKJKP\[O;6V?V&UN2G>OKR=UXP0S =#(:7@_[ M-M?F.D5JM9;UL:BK5V[B)Y.'LIQ2L9W[CV'^;DJ8UN<-T-YVHUK69S6Z%27M M@H=HU/8P55B@JF^JJCJ=]:?.\*;7__>4U>NSJ9PWFY-+?K39Y*WX?Y'EAC"* M3!ZH5:2][HE0:W#K@3NMJ7D(DTPG\[*2PN:6E:TCM Y*:"I8@T;5RN'I[+)W MS78$?(5[6U6XP=UL/,P/K,[X)J\T/&4%,2WJW32.Z'$C?6%EV-(R16K- G2U M&S[)G]T>$,"2J#>*9:T$8UF/EM1F%1IU'-+1PD?VHF2E),*!)KZK:N)PO'#& M'X=7(ZJ*\WE_87/M^QA%R\]^$%#65ZG16>DTA[&HFZ"9 K13=QS+^MD(YXJN M-F,=&FV=NB_TSX"75'R@K^]K6U7GM]ED-.J-AL[5<#1;-RV$AD7II@.UVKO2C/3:;-'& MG;]'=NKK5H&JK(\_Z&1>6&/J:!Z-6,.NO'44JTUE*-(2PK'NCA#&V.H%&C@>O' MQ9.W>\_S,*3$9KGKF:]3W]=.FLYPUOO5&=WE=Z.#X=@97P^=$=WWSA>SN_P5 M!HLJMJ-Q/V? BKO95']>!,#J)RBFV4U@V!443H0'] HVIBDK,[XE,3Y6UM\ MQ?JA%G#07_1&D_F\-^W/>O.?G5G?YE+EQJ$?/NYH "Q:PAX6]:LDR)1/0Z$U^YQ^F\39D-B9+/YWYR1]\+:I%T.2Q,^-% M$=R6/YTUZ]\,%[W93!%?@:X9S1OZ^(!0EQ: MCFOWD378U*_*4P=H>^N!;4?8="(K]??7NN V'@.1W2?DSXP.VG\6^D;?UJ)P MYG=7\_Z_[MCKW_U?+7M"JR1 ZB:(>E@.'B]/"A@K+NAB^^U8!2:<:&\I[8CT M11C<+0WR?EL+GY$'>??^MAW.YH/.YQ?O79G=2_%_>&2WLO^)QG #^8(CT?6. M%3?H)ZF_HFNN)/NMVL[V0\W:X/ )-93=S[LJ_>2G3]=T.T.G2&(_8;9P\G 5 MI4^;&^2P''NAUB7VG>X_8_M-9SBL9NC'I)IC\KG$CC@*Z5^](N-+T^#JCV3[ MD6=M]6[*+#2[H6K&01[-Q=__U,,1*YDSO;\5W6WN=\XLA<8J4R >AM8CVW8Q M=)O$TQE;D)D);KZ/S%C4XAL%63\8;,;7E_[3)ND'C^YVGNJ#5_^J:0XRU:N% M0=;2?# HW5>7[S/WGL@R"XJ(5C\E(_^9U.:W7S%MM.E2\'IDN]H5H=Z0IEL?:A%\W+2RC"L$&>5 M7[8W7/6,)WVCKQ[#]M9,.R],GT%HU*^>9B-3OUJ ,"_S"X/^G6(*V$Z(!)AH M:9EZ#-M1]J D,&V>&+J=*$VD&E[A?';CY;8$,DN>*3B8)-EJG1>30=DTMQATR3UY9^N*6KDD\\Q^?8%$6S8>T?3/56L5!+$.SE"KR/F7K M:BUE )#]B6&9/==.]F M;4*VMPMM1,\.>&B6G$H&M&2)>5?+CZGG06-8473-V2;SB6EI([*$S])9NP_TSFS.[D+J'^%R_(J*JSQXU9 M%'^V+53=((W>Q+=L+PB-9:9K=J.Q\Y(\,)G-K^5427,B,9C_KRXYLG0IF%_@ MW/JAO\I6(_8*\39_9Q#%FSB<_,=-+EH;CWT&293=L1B-/> G5LI,03V'2I!> MB<$*7/(LI2S9^TS+1#C,3_98Q.]>O?#]JIIYEYU\R':0I.D\S [1P+9]Y4\[ M-SZ3PAG?Z+ZC[OGMY#NVMZU&),T,&'@%K.>O];3-*;S>,S=W0Y>$S!8/& M)"WJB3%?J)C02K,S?KZ,RQ#]9T9_*M0K)(_,W%2>&;6#,WM:?AI'SSZU$56PP?-^;*ER7EZHQA>T-A6$0T>8ECS\ FS3P!] ]VL?/L!CFQE)@X M?J'SSF^%)(XA6'?;*[])Y+4X:"BHRB3YTOO@0,.I=3A&3.A6E M#:W-+5YI7C?1RO5#R7Z.TQ89%B+YJF[+.)3LCZ!=;KYFY)G$"6RF(Q7&HJ12@6]#O*2R1J ,RV9?:(1$-I<,5+DQ4 MQDC2!0DNW#?%2=X*@OW44+L>W!+Q.:4)9,L M35(W7-)#'0AP3B_;OKHF2 N)1^/TJ=16VWAD^/Z=6KVD>G&U3?]+=35DX8>; M.0Y#.B,W]"16M][2=F"/D>IG(H;@6#>WM"VI14_]1&HU>6UMKXI&,>-P!0=J M-V0=)7YZ^+P]SXX<-+.]KIFJ+LCAA>F2POTOWA.+QAL0[M7P05WW5==?6 '3C,K>-Y MV2K+(X3I9BLF7I')3O\>D$VT2KE*H) T:71#1U^P?1YI*@]=\_CT8S.%)(Y) M$R.8][)] NK<6I1X<>9KNR(BK%;&4[7(XP@%.]OEOFS$I Z*4JL37(6"3AH9+)7KWY3C..@%/)E/<3'KLK M90"8]D X,&\@ZW#0^82C""";TJ-SR I7"L)?MSO-PV:V?18-I;5Z1N71CL.! M5=3H(O$\>D@_4XY4J%3!!>QNV[G0#8Q:O,(!KX1PA7-9W=-V$5V-S2#<@B+T M,4MF6W*-EEV@C5 5CH78!K< 6L&ZTW<22VB7NHE5_1#;\A;B<%[>8H%KZPW? MMU4KB"_V;?7>7+Q;.'28\_C8F,K*XC,)GLEM%*9/S19WT+AG\$!@-ZS%OT.H MT_(;<>/%YZ@KZ=@-9WN?<'RIJ'#R9(6!?E[B'F\\H.V=@B6!*'/S5$5B$&62 M4W_3\6P'^-H1B#(O3U8>2M$%G7 >4A)W+12506T' M(!]?,KA<12\>Q_ D?'^B('\5+@5Y[-G[VD-($M<"BJBSK\[%<-IERCH)A+E4 M+K-=G09OY;*O-C0%@MLE_.02?G(BX2>HXAR0AZN<8)R#T>@B8_Z'LX\NFK&4 M=_G:6&J"PT*"5K[2K'%4T,LGI!+_@T8XN%V3$!ZCMU-&L9)L7K13\;K2S+:I MX0ARP8^0^-//?EWK;WNIKPP9B! [[R]<#DH2IS8N!4_6Q? MR(,A@S$ 32;IU'VA?U)!( MR49B[HHI_NIZQ7,_0&AJ[6VO2(W!$5"."IVY&[BQ#U><6GO;BT]C= 24XT"G MOUH'T0LAFV=*2TN0$BA 5]L!6_J8@?EQ!E?R]4KTTFT'_U7ZGR>CF_YL_I]Y M'9C%;RWW'8+BH,*92K83K".@7YOG'QB@0AA.HEG_N-3.L[8Z7SR,"=> M%A>2Y 8!>\5QTR[9-%01T]GHMO8@0$0.];)3RC%9WI9$2>Z:V@YL;1]D FON MPTUMF=[8^*])[$=+>HZ-TS89?F;LST?VK_T:TJWYV0UN;1]G4+JZY$\W-LJ, MA/2_D-CS$U,R4AK>VLX1MY34 , I)X,H?B ^%>=)?,T>9@A,20SW0];NRG#+ MC@24RXY(-O#O;RU>!J+?$S'N=+(KZH>MJA[H6+*M&9W&OD=VOVQU$ ,/:2UK MH=OCER8+$5L8!262:^J&PP$EX(?CV1)=, $&!,K54SI**6AJ<'Z"C@@4F1_1 MBTQK3K24F@Y>5^Q08AJ=I^!C J7FI[.5&MEQZ93EIN7YJLGH8*?@V0H3[/QT MJH^](M@9:9RSWAS1^6QABE9_AH%=)C M3U]FE),*U37]<=LY0'I&X3A0G+'LW?C/_I*$2PN2=_AIVWLMNW+'@^$,I6[F M)W\,8L+*51&*;WI$J>-_VO9VTX[4R6! )'7W:G+O=91L0>*59/ME\INV"]WH MR9E1QJ,I"2&\,-W?#!][DP;7^84ER>ROK@<)6!+E)E9""Y5.5. ML69,@ B-L%VVJF4/@M@(W27L-'!#=A(JRQ V73KCL!^29A-/8?Z9;&CH!+]^62.\-=0:P[4WC MRTSY^E"?'88R&!TO(W1QV[KLI! (VMKV-JFY+272$&,/$6:/4Z6$8IS=![XW M>7@@L1\^:@B\? #;CA==@8>PPQ N._5RZ&DB'1#QW2UK+FQMV^F@YKB"4$/L MG61IXB_)-3TY9D%*01WXL?C^D'61]K#]=I&:S0""<;AC3C$D1'L'>0D/N82' M7 J&'XWEEX+AQV;Y/+NGRXWOQB]S-R"3A]P!*K?JDBXX;(VVE9=05-KIVD1I M/RVV>Y@\+"AEB>LQOJH<"9"^.'!3RF(5-@!E*):2X72BLFFE)M;J%&BPE8M' MC4P<)HYK#M@V.Z6'1[K!UG14'_2T'"T'\\!#_-0_K/TX9_F-FQ)*&;^$4I2R7[-O>!SY@]Z=/XKWD4_P[O^2+&V=\S4#<4F6MIW,>DF6OB1+7Y*E+\G2 MQTZ6-G;5>X;)TCL+L]DR0WRJXBXX=$EO-:U3@>/VK#POE97CM46&A4B^^'Z M TK,V*$Y82\N.==1^$SBE#W]-]WZ#O*OEWXAM5,-QK'M-16+5MER-680$LM6 M3/]PSBK7MK23M5J98-@@5'2#D:Q2I7,7^HIP.DX[L-O)KE8(*33)T2L@1Z\: M<=38!;\&1WD4XK CFV?>IFZE$4<:9.&XG"[/ M2[6IXK7% 8Z^2$J 0W7[?$5"\N![OAM,/H>R[I .4U<9NB]2L5I& :;%9T ],'DKIJO)U1= < MAY4"+2$""DJAAS;=COMI)4ZX'$>AN_])V?"J[)3V0#@0E$ICU9VH2Z*94_V8 M?+Z.5JLHS#>=TRSVGMR$.(\Q4:=9 ?M:-WD-Q;)L#[789&@=:H!0-\"8\P^W M!\8B'GL8@HQ6'*G.729VQS@ZGK+X?AYM"FW&++N]D.:M0!",0!4^[FO7#0-1.4 M&B_O F6\78" 5;Y97)3]]?DI^^RN0G@3D;3B=OI<:KW "ZB"/* M9JJ2@,E*&H>KH1X MWSY&SZ^7Q&=(O6=_80"]+P%$?_3[B#RZ03],?>'-,6U5:X3$^DM7:MZ\2_%, M1^-P\7WAFDN;'+:PS%L>VVJ,/9RQF173(8]^LCEQ7$?Q6GXS*&ALSYC7N,2Y M"Y12:*HD5D2_EH=J)TZ6/D6Q_Y?P05Y!6_2O74CFCFEA+)WS (#4G2:-D4'P M@H6:='083=UX$N<4+O/ZS-N4!Q!6XLZV'4)-,%.QPF8>=$<51P]"5N'JJ>IG M.W,$C#:, 3B4]'"N^GH*[6^[3E5#\,Y?6PO7ZBVAXKD?+7 ME&"/X?0HD0&-(6S7S@*+@39;3)7[W'UH\E!:1>3E9/+RF8".MJM3PK:CG3P60$((!ZVLXD@J&@P00<*UNQ[@Z3))-M.@Y; M :'XT;IYXA&'A.U,$HJ)W62L*C)57S\J5L\Q^9S_1AK- NIN.XT+#I0..TY_ M-S&-(X^09<*2W1EM;N@1E:'<;;R47<%G=.NP@_F L.S5F*1-8"Q"4B%=K:=V MP%8\'3Z8"J\MSHXL:C%?>!_])"7Q,%0C >II/0H:!H0&%XX:YKS)H%ZM_#05 M.H)A7:V'/0.1T. #ZNU(>?\TB.(YB9]]K\&^1#@.%%#[#H]F'$*-;KZ[:@^N M:!@HMO:]&(WX@Q_:2?HD+0"A[@J%T*+K TZ,T:5OO^UAGM&,5;WDI(*U>@$$G,=$N(+/L4FO %A\:5 MPYDS%G](_U$Z-0_#4GBSY+2B-8KU>F#P@TL#[B#!E4U3M.$H7\!I[B\0^ -J ME)W^E9/4?]7\QK'6'XHR6I>!@".G+P$G]62/P>P:<#2JE7=Z4A(;N:[DO[Y' MXI5@$R5I#X70LMM$23&.9518=+B\#;A;1V'1,)'NDAH-!L73?IA("UXA!YO) M)7O-J0W&G#' P>!XH15RQF058DVSKV-#E4-!,;,<]]&&3SB4<>#Z<7Y!Y"S_ M)]M$+C](O-J;?HIN4/CLNWQ ])NZ+RO\%KH0Y)=.H*Y0&"R[=73X@$-K]C-, M%I&@?D_)F-^0^_23GS[M[?> N&DF2Y;I[@M0(;#O!NJ:JX;4]L9_]I(F]4&VW73DY^V>@FL64 (:%8H[6>:3' M/]2B4!RINI<%\+A08;#O*>J&@Z9,-DF\V%^GI0FPR$?T?O:)^BUD>2\,A8E/ M\F5D"!B7=Y*/A\>IOY.\DZ>KEUOB,G%B\QS$Y,^,A)[B$2E0YQ/""40/CO>' M=U/E3515UQ/4&0=N&O(I E-&)(I"W[R9)C.V\62;5%6)1%AOVP6A-.05@*.( M.SA.:B69W?WU9Y_$=%Y/+R/R3 *P697VQZ&ANI952A*.AXZY(E>?=Q,S*QD& M!YQZP@O153'%N*SO,%QG:9*3^ 9L='F=;!=R:R2^(B3%7$%F;$L3%1?8EE"G M6W3;V(V4*?A0EN3F3?1=$_C>:<)G["[)%'SO,,+G) E) =Z@:COTE6,%\\;' M>Q7/[6_]!3SD,1H7@T>^>^\'N?-?+>'>C*)9GW5N M.>2$G+0-ZWY)!C'+I!5;%U?NJ1NG!K(GMA%9^X#71 6.O(NUH[PN4!#*S6K! M-J98% ]:;V9M=]10"VH4&@NZ]6)Z=B0WI/AS& (-#:2CM>V3+M/A7$!8=;+A MRO#[6XM%Q=NN#6SRG:P._7")8I<[)NF(_F9;)5\:W?-C=5,[[B]ZH\E\WIOV M9[WYS\ZLCR*8I^_&H1\^[HA2[U[%/2P>S2DTU#Y$*\( FLK& UK>*:OPK)SS6_+-5#$1>FR,66O%>873SK9SJRU#(REU MF+QA!Y0"%>1^DQY*"^5.E=H(+0<'GC!QF_0OMFP*;C M67M 2852U EY]IT%9HYP8+E0=K3V=I.> 9T+%1QN2#$-RL_:3AA+![D78F M;HBY]T26&:L,Z(2IOV3RYS^7<@;[7[P@HY"S4I!TY5IGA6A,'JK4J'*1.OX. MCE!33=]%UTQ D@?5DIB1.GNJNR_@D!LS6E<-2.J,:4@RO5H2=/7"'T">RF#T MHQ=I[(:/.#+:^#, $WKP&@"OWF-+5] M!0 57%XU"A[12)P2Q>VN"H]*,]NI+PVQX!*+ X>=.WI3R"\7&_FB*^F"PQ > M927:SZ@I.4B)/" %X6^'&&EK](OA%:.#=1@ M'.L/8(IEZ^ !S*8(=.U>Z/9@S M_LUPT9L-Y[_L/;*[46UZ9AF5B1,N[R@'8CJO$);^I.AFW\S#V?,6AVQ!D)6!A7 M_KAQ[FRX9TS8FF:UIK8=%T5]FTV1#B?W7@)#DEJ M_0D1(%S]"V'!N','6N@+RG;UMR"DE++,U(MSJDL0 5, \[+O/B#)@^-O>0& MYN$/&"-0&F_#MTF+^RHU+J MD!,NAWFLJO],V,?ED>SJ?OA]3&#B<1P19FR#*3:V7:]L%3I)DJWRE2EB<^" F9!BFA(*0SJB%->#B@7_:MJ,' M^C+-T5 X_<)@^^.QG%7W$%:QB#:OJ%NY>J.05$/?M+T7U9-1HXP_$^'L2H^W M/-J6;CVB->5_VO;>QHXYE<%PD5@NJWZ- CH,>R[!@LQ6/VY[>VA7:OE0G,7[ M;-(;H/TS'07FZ <-T -563PIV6E*KGSJ(@&$0Q^Z4!(Z7XGN6S MB9FK**/8G/B)N4YC<>U^%-';?LKZ<<.LA!@3QT.H;+\,B$.2/^8O\ W#:4[4 MQUCZ9(J1CUD_D9R2-$O@.@_+2MGW0'R6H;RCTIP\OTGR5J MRQQZ?O.+RDQ'D&7NQVP';Y^4+$O@NLBRS1VOU<=&3U&2N1SL9-=;?_'T!&5Y M\SPR"QDQ+Q[A('W<$1W,7@N0 7Y\6OU)6N">A[>$"#]UB49 M++X_G8!]UY4T*R+_E7FQA65)N'Y10[K2Y23 =S@7A>D>^Z\@Y$?%-([CUI+6 M:,\$JCJG%N(_IR]9\$(S]R I8^^50CKL2<#%6&TU]4P:>LH.;@][.Y;P'X>3!)^ M+&[;#Q$R)..;8 \;4@[[-%3.N[_@/3>0#T.EO/O;V7.3 M=YV?YV*20N.P>DSNR[MQE%[R*;CN.%KWX3J0/<7I5AU MP"BX9Z,"W<=>E)CG/#[&>=&*8RT3+:8$5:#NKVFQ*I!-T>A:F>P..UQ0&.ODA*@#/\4)[G4WK\!]]S MEL]^$L7RY_%$K6T7$1'+S8'?3TXLCDORK_'13W>S&EHC?G:2-OVOZ M\&:YK^T*Y*T>WZPS 8?%F6?W"?DSHQ/M/S/MI=^3&Q]A!QP* =O1BF@HE5G& MA8G*.DFZ(,%%+F=J@#HR7]T@Y 3YX&3)]W\Q9U:82,[OT/ZG\@RA'C^06+XN MPGI.X1$#)"\ FF'UF5RR)S^3@&X8^JMU$+T04MI(L,W#/$MR!2J:*J1,;RCK M#V%HR5 3-IVXM2F*KDX>"J*<9]1^%S?@UW2+6Y\ 3A!ZV_'&'\25L8RW'(U<[*DOC9]PA?F7:4Y.0E>3A< M^??LTF</ MQ890%4G5V5>LOZ)@?.&3,)--X';A) M,GGXQ/9683J)9RSZN!2.+,9(W=/V/8EB-:V !>7$Z?NVIW'D$;),!I1C&W*W M=15E\2W27LA44P4VA 6(%?2@#.;NE\GFMXGDZ-UP..L7$AWH,I1IB''?.2:) ME\5^ZI/DV@T"LKQZJ5*C*0$Z UN_:.A %O09J>5HV?R&_8\YF^E/_C]02P$" M% ,4 " !RB@Y+YBM:=5^T "\L0D $0 @ $ 871O M&UL4$L! A0#% @ &UL4$L%!@ & 8 B@$ ' )J- 0 $! end